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GLOBAL TUBERCULOSIS AND ITS CONTROL
This thesis describes and investigates the management of tuberculosis (TB) in Benin, with 
an emphasis on types other than new pulmonary bacteriologically confirmed TB cases, 
childhood TB, drug susceptibility testing among those with retreatment TB as well as 
determinants of a successful treatment outcome during follow-up. The findings from the 
studies in the thesis should contribute to meeting the 2030 Substainable Development Goal 
of ensuring good health and well being for populations.  
Since prehistoric times, tuberculosis (TB) has been a serious burden to mankind, affecting 
and killing many people over generations.1 With major advances made and considerable 
resources allocated to controlling this disease, a significant reduction in the number of new 
cases and TB-related deaths each year might have been expected. However, TB remains a 
major global health concern, especially in developing countries. In the last four decades, 
the situation has been worsened by the arrival of the human immunodeficiency virus (HIV) 
and the development of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-
TB) tuberculosis.2
In 2015, according to the World Health Organization (WHO), one third of the world’s population 
was thought to be infected by the bacillus, Mycobacterium tuberculosis. The number of new 
TB cases was estimated at 10.4 million worldwide, of which 56% were men, 34% were women 
and 10% were children.3 The number is considerably higher than the estimated number of 
new cases in 2014, which was reported at 9.6 million in the WHO 2015 Global TB Report.4 
However, this does not necessarily reflect deteriorating TB epidemiology because the 
estimates of TB incidence for the period 2000-2015 were revised upwards in 2016 compared 
with those published in the 2015 Global TB Report.3 This follows accumulating evidence that 
the burden of disease in India is considerably higher than previously estimated and there 
have been minor upward revisions for the Democratic People’s Republic of Korea and the 
Philippines. In 2016, there were 1.7 million estimated TB deaths, 400,000 of which occurred 
amongst people living with HIV, making it one of the ten top causes of deaths worldwide, 
more than malaria and HIV.5
Sub-Saharan African countries are amongst the most affected by TB in the world in terms of 
numbers affected per 100,000 people. In 2015, the WHO African region had 26% of estimated 
TB cases globally and ranked second after Asia which had 61% of estimated cases.3 Poverty 
has always been an important driver of the TB epidemic in Africa. However, the advent of HIV 
infection in the 1980s dramatically increased the number of people progressing from latent 
infection to active disease, the number with active disease who had unfavourable outcomes 
on treatment and the number developing recurrent TB after treatment had been completed. 2, 6
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Figure 1: Lorem ipsum dolor sit amet.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. 
Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, 
ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim.
Table 1: Lorem ipsum dolor sit amet.
Variable table
Variable 1 Variable 2 Pearson’s r P-value N
Histone H3 LDH activity 0.873 0.000 0
APACHE III score SOFA score 0.748 0.000 0
CAT: ETP CAT: peak height 0.738 0.000 0
Lactate PT 0.597 0.000 0
APACHE III score Lactate 0.567 0.000 0
SOFA score Lactate 0.547 0.003 0
SOFA score Platelet count -0.510 0.008 0
Lactate Platelet count -0.435 0.006 0
LDH activity Antithrombin -0.408 0.007 0
SOFA score Antithrombin -0.420 0.010 0
Histone H3 Lactate 0.403 0.016 0
Histone H3 Platelet count -0.377 0.018 0
LDH activity Platelet count -0.376 0.030 0
Antithrombin Platelet count 0.372 0.005 0
Antithrombin Lactate -0.382 0.019 0
APACHE III score PT 0.363 0.013 0
APACHE III score Prothrombin -0.357 0.010 0
Histone H3 SOFA score 0.373 0.122 0
Histone H3 Antithrombin -0.347 0.040 0
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. 
Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, 
During this time, many policies and strategies were developed by the WHO and other 
international organizations such as the International Union Against Tuberculosis and Lung 
Disease (The Union) to help these countries cope with the situation, resulting in effective 
treatment for many patients within National Tuberculosis Programmes (NTPs) on the 
continent.  The introduction of the Directly Observed Therapy Strategy (DOTS) in 1995 (which 
later became the “Stop-TB Strategy”) was an important game-changer, supplemented 
later by “DOTS-Plus” to confront the developing emergency of drug resistant strains of the 
bacillus. 7,8 In 2014, the World Health Assembly approved a new WHO “End TB Strategy” of 
ending the global TB epidemic by 2035.  The targets set for this new strategy are to reduce by 
95% and 90% respectively, the number of TB-related deaths and incident cases compared 
to 2015, and to ensure that no families bear any catastrophic costs due to TB.9 Within this 
End TB strategy, is embedded the Sustainable Development Goal of ending the global TB 
epidemic by 2030, which has interim targets of reducing TB deaths and TB incidence by 90% 
and 80% respectively.9 The battleground for achieving these ambitious targets will be the 
countries themselves, including Benin, where a good understanding will be needed on the 
epidemiology of the disease and the essential factors for implementing good TB control 
measures.
BENIN – GENERAL FEATURES
Benin is a country located in West Africa which shares borders with Niger and Burkina Faso 
in the north, Nigeria in the east and Togo in the west. It covers an area of 114,763 km² for 
a population of 10,008,749 inhabitants according to the last 2013 general census of the 
population.10 The country is divided into twelve regions from the north to the south: Alibori, 
Atacora, Donga, Borgou, Collines, Couffo, Zou, Plateau, Atlantique, Oueme and Littoral 
(Figure 1).11 Overall, there are 77 communes and 5,288 villages and city districts (subdivisions 
of a city). Porto-Novo, the official capital city, and Cotonou, the largest city, are both located 
in the southern regions of the country.10
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Figure 1. Administrative map of Benin11
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Geographically, the country is generally rugged. There is in the south a low coastal plain 
dotted with swamps, lakes and lagoons that communicate with the ocean. This is followed 
by a variety of forest and savannas plateaus, split by the Couffo, Zou and Oueme rivers. 
The central region also comprises some rocky hills. In the Atacora region, there is a range 
of mountains, with the highest point being Mount Sokbaro at 2,159 feet. The climate is hot 
(average temperature between 22°C and 34°C), humid, with seasonal and geographical 
variations. There is rainfall of between 900 mm and 1,300 mm each year, with a humidity 
that ranges from 65% to 95%. From April to November, the ocean monsoon blows from the 
southwest to the north bringing high humidity. From November to March, the “harmattan”, 
a continental and dry wind from the Sahel, blows in the opposite direction spreading large 
amounts of orange-ochre dust throughout the country which is responsible for many 
respiratory diseases.12
Independence came in 1960, following which there were twelve years of political instability 
marked by several coups. From 1972 until the late 1980s, a military regime was in power 
and adopted a Marxist-Leninist ideology. Following this, there was a national economic 
crisis which ushered in the present period characterised by multi-party democracy. To date, 
there have been regular, peaceful and well organised elections, fixed-term appointments of 
the Head-of-State, which have not been disputed, and a good functioning constitution and 
political system. The country is cited as an example of good governance and democracy in 
sub-Saharan Africa.12
Benin is a low-income country with a  Gross National Income (GNI) per capita of US$ 840.13 
According to the United Nations Development Programme (UNDP) report and based on 
the human development index, the country ranks 167th out of 188.14 The port of Cotonou 
is the pivot of the economy in Benin. Unfortunately, 80% of the imports are re-exported to 
Nigeria, making the country highly dependent on its large African neighbour. Cotton is the 
main export crop. Food crops are mainly developed for local use and include yams, cassava, 
corn, sorghum, rice, fruits and vegetables. Stock farming is carried out, mainly focused on 
cattle, and fishing is mostly of an artisan nature. The country still lags far behind many others. 
Urbanization, road infrastructure and electrification remain inadequate and the cities suffer 
from frequent power-outages, although there have been improvements in the last few years. 
Access to safe drinking water is provided for 78% of the population.10
Overall, the population is young and predominantly female and rural, although the proportion 
of urban dwellers in the country has steadily increased. The majority of the population live 
in the southern region of the country. In 2013, women accounted for 51% and under-fifteens, 
47% of the population.10 Several ethnic groups are represented, dominated by the “fons” 
at 39%. Approximately 50 languages are spoken in the country with “fon” being the most 
important.
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Despite limited and constrained resources, education has received a high priority from 
the government in comparison with other countries in the region, and this has important 
implications for the functioning of both the public and the private sectors.
In terms of health, in 2013, the birth and death rates were 36.4 and 9.6 per 1,000 
inhabitants respectively.15 By 2015, the maternal mortality rate was 405 cases per 100,000 
live births and neonatal mortality stood at 31.8 per 1000 live births. In 2012, life expectancy 
at birth was 59 years.15 Communicable diseases remain the main causes of morbidity and 
mortality. Malaria and acute respiratory infections are the two leading causes for medical 
consultation, accounting for 39.6% and 14.9% of cases respectively in 2008.15 Malnutrition 
amongst children is of great concern since one in three Beninese children is malnourished. 
Despite the increasing emergence of non-communicable diseases, such as high blood 
pressure, diabetes or obesity, malaria, HIV infection and TB remain the three major diseases 
and are given the topmost priority from the government.15
THE HISTORY OF TUBERCULOSIS CONTROL IN BENIN
1966 TO 1984:
Before 1966, TB control activities mainly consisted of mass BCG vaccination of neonates, 
with little interest paid to diagnosis and treatment of TB cases. From 1966, a TB section was 
created in the Ministry of Health, with two specialized anti-tuberculosis centres in Porto-
Novo and Cotonou to serve the whole country. Attempts to diagnose and treat TB cases were 
started, but in a haphazard way and with no formal monitoring or recording. There was also 
no consistent or regular supply of anti-tuberculosis drugs.
From 1972 to 1984, there was an improvement in TB case management in line with WHO and 
Union recommendations, characterised by: i) the establishment of Basic TB Management 
Units (BMU) integrated into the general health services, with the aim of providing better 
national coverage and bringing diagnosis and care closer to the patient; ii) the adoption 
of 12-month standardised treatment regimens for new and retreatment (recurrent) cases, 
although these were not always administered as they should have been to patients; iii) 
the establishment of a National TB Programme with the appointment of the first manager; 
and iv) the introduction in 1983 of shorter 8-month regimens for the treatment of new and 
retreatment (recurrent) cases.
FROM 1984 TO THE PRESENT:
After the NTP was created, many activities were carried out to improve TB case finding and 
treatment. Technical documents and NTP management tools were developed and regularly 
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updated. Human resources were strengthened in all departments. The NTP was structured 
into three levels: the central unit (or headquarters of the Programme located in Cotonou) 
being responsible for the development of TB policies and recommendations as well as 
funding for the implementation of the different TB control activities; the intermediate level 
representing the central unit in the region; and the peripheral level being essentially the BMUs 
integrated in the general health services. The BMUs, as they currently operate, are managed 
by the doctor of the health centre assisted by a nurse who is the TB focal point. Currently, 
there are 67 BMUs that serve the whole country. Most of the BMUs are located in the southern 
part of the country where the population is the highest compared to the other regions (Figure 
2). The NTP receives external technical support from the Union and WHO.
Figure 2. Distribution of basic management units in Benin in 2017
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Figure 3. Millennium Developments Goals 2000-2015 16
GOAL AND OBJECTIVES OF THE NTP FROM 2012 AND THEIR RELATIONSHIP WITH 
INTERNATIONAL GOALS AND TARGETS 
The goals and objectives of the NTP were formulated and launched in 2012 and under-pin TB 
control activities up to the present time. At the time that the operational research programme 
was initiated, the goal was to reduce the spread of the disease amongst the population so 
that TB would no longer be a public health concern. The overall objective was to ensure 
universal access to prevention, diagnosis and high quality treatment.
The goals and objectives of the TB Programme were initially in line with the 
Millennium Development Goals (MDGs), which were launched by the United Nations in 2000 
and which formally came to an end by December 2015 (Figure 3). The MDGs comprised a 
set of eight international development goals and 21 concrete targets and measurements 
of relevant health indicators, with the purpose of ensuring for each individual, the right to 
freedom, equality and a basic standard of living that included good health. TB was one of 
the diseases that received a special focus during these fifteen years. Under MDG 6, Target 
6C, the recommendation was for countries to have halted by 2015 and begun to reverse 
the incidence of malaria and other major diseases that included TB. Indicators 6.9 and 6.10 
articulated that special attention be paid to incidence, prevalence, and death rates due to 
TB and proportions of TB cases detected and cured under directly observed treatment short 
course (DOTS).7, 16
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In 2015, the MDGs were replaced by the Sustainable Development Goals (SDGs) (see Figure 4). 
Although the SDGs are much broader in ambition with 17 goals and 169 targets, the third 
SDG focuses on ensuring healthy lives and promoting well being for all people at all ages. 
The SDG, target 3.3 states that by the end of 2030 the epidemics of AIDS, TB, malaria, and 
neglected tropical diseases will be ended and hepatitis, water-borne diseases and other 
communicable diseases will be combatted.17 The SDG for TB is aligned to the WHO End TB 
Strategy, which was endorsed by the WHO’s 194 member states in 2014.9 The goal of the 
WHO strategy is also to end the global TB epidemic with specific targets being to achieve 
90% reduction in TB deaths and an 80% reduction in TB incidence by 2030 compared with 
2015: these targets being met with no TB-affected families facing catastrophic costs. With the 
advent of the SDGs, Benin’s national goal and objectives for TB control were aligned to meet 
the SDG and the WHO End TB strategy goal of ending the TB epidemic by 2030.9
Figure 4. Sustainable Development Goals: Goal 3: Good health and Well-being 9,17
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TB CONTROL ACTIVITIES IN BENIN
TUBERCULOSIS SCREENING AND DIAGNOSIS
Although all patients suspected of TB are screened, those with pulmonary smear-positive 
TB, who are the main source of transmission, have absolute priority in the programme.18 
Definitions of TB cases are standardised and used everywhere throughout the country.18,19 
(Table 1).
Case-finding is essentially passive, meaning the patient presents to the health services, 
and anyone who has a chronic cough is regarded as a “presumptive case of TB”. However, 
depending on available financial resources, “semi-active” screening is sometimes organized, 
whereby health workers set up tents near to a locality in order to screen symptomatic 
patients. 
All patients with presumptive pulmonary TB submit two sputum specimens for acid-fast 
bacilli and if these are positive the patient is diagnosed with bacteriologically confirmed 
PTB. If the smears are negative, patients are treated with broad spectrum antibiotics for ten 
days to two weeks. After this treatment, if their condition has not improved, two additional 
sputum specimens are collected for acid-fast bacilli and chest radiography is carried out 
for a clinical diagnosis of the disease. EPTB is diagnosed according to clinical, radiographic 
and laboratory-based criteria, and dependent on resources being available at the locality 
where the patient presents. All patients with a previous history of TB, who are once again 
experiencing presumptive symptoms of the disease, are systematically requested to provide 
two sputum specimens for both Xpert MTB/RIF assay and culture with drug-sensitivity testing. 
Any resistance to rifampicin on Xpert MTB/RIF assay testing is regarded as synonymous for 
MDR-TB. In regions of the country where Xpert MTB/RIF instruments are available, the MTB/
RIF assay is recommended as the first examination to be performed, over and above smear 
microscopy. All diagnosis and treatment for TB are provided free of charge to patients.
Despite these processes, not all TB cases are diagnosed and registered for treatment. 
According to WHO, the most recent estimated incident TB case rate was 60 per 100,000 
inhabitants while the notified incident TB case rate was 39 per 100,000 population.20
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Table 1: Current operational definitions of TB cases used in the programme.18,19
Designation Definitions criteria
Presumptive TB 
case
All patients with unexplained cough lasting two weeks or more
Bacteriologically 
confirmed TB 
case
A biological specimen from a presumptive TB patient is positive by smear microscopy 
for acid-fast bacilli, mycobacterial culture or one of the WHO-approved Rapid 
Diagnostic tests such as Xpert MTB/RIF
Clinically 
diagnosed TB case
The patient does not fulfil the criteria for bacteriological confirmation but has 
been diagnosed with active TB by a clinician or another medical practitioner 
who has decided to give the patient a full course of TB treatment. These include 
those diagnosed on the basis of radiographic abnormalities, suggestive histology or 
extra-pulmonary features without laboratory confirmation. Clinically diagnosed 
cases subsequently found to be bacteriologically positive (before or after starting 
treatment) should be reclassified as bacteriologically confirmed
Pulmonary TB 
case
Any patient diagnosed with TB disease involving the lung parenchyma or the 
tracheobronchial tree. Miliary TB is also classified as pulmonary TB
Extrapulmonary 
TB case
Any patient diagnosed with TB disease involving organs other than the lungs, e.g. 
pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges
New case A patient diagnosed with TB but who has never been treated for TB or who has 
taken anti-TB drugs for less than one month
Retreatment case The patient has already received one month or more of anti-TB drugs in the past. 
Bacteriological confirmation of specimens is mandatory for the diagnosis. These 
patients are classified according to their most recent course of treatment into relapse, 
treatment after failure, treatment after loss to follow-up and other previously treated 
patients (see below) 
Relapse case The patient has been previously treated for TB, was declared cured or treatment 
completed at the end of his most recent course of treatment, and is now diagnosed 
with a recurrent episode of TB
Treatment after 
failure case
The patient has previously been treated for TB but failed at the end of his most 
recent course of treatment
Treatment after 
loss to follow-up 
case
The patient has previously been treated for TB but was declared lost to follow-up at 
the end of his most recent course of treatment
Other previously 
treated case
The patient has previously been treated for TB but his outcome after their most 
recent course of treatment is unknown or undocumented
RR TB case A patient who is detected resistant to rifampicin using phenotypic or genotypic 
methods, with or without resistance to other anti-TB drugs.
MDR TB case A patient with resistance to at least both isoniazid and rifampicin
XDR TB case A MDR TB case with resistance to any fluoroquinolone and to at least one of the 
three second-line injectable drugs (capreomycin, kanamycin and amikacin)
Legend: TB: Tuberculosis; WHO: World Health Organization; MDR: Multi Drug Resistance; XDR: Extensively 
Drug Resistance; RR: Rifampicin Resistance
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INITIATION AND FOLLOW UP OF TREATMENT OF TUBERCULOSIS CASES
Once diagnosed and before starting treatment, an interview is organised with the patient 
by a nurse; and information is provided on the disease, the treatment and follow-up. This 
interview also helps to identify and address any at-risk situations that could later lead to 
loss-to-follow up of the patient. The optimum place to receive treatment is identified, and 
this can be either the BMU at which the interview is conducted or another BMU. Occasionally, 
treatment is provided at a non-BMU health centre that may be closer to the patient’s home. 
HIV testing and counselling is then offered. Any family contacts with symptoms suspicious 
of TB are contacted and properly investigated, and any children under-five years of age who 
are healthy are prescribed Isoniazid Preventive Chemoprophylaxis (IPT). Other non-family 
contacts of the index case of TB are also requested to come to the health centre for further 
investigations. The anti-tuberculosis treatment regimens used in Benin are shown in Table 2.
Table 2: Principal regimens used in Benin 21, 22
Type of treatment Regimen
New case 2 months intensive phase of rifampicin, isoniazid, pyrazinamide, ethambutol 
followed by 4 months continuation phase of rifampicin and isoniazid 
Retreatment case 3 months intensive phase of streptomycin, rifampicin, isoniazid, pyrazinamide, 
ethambutol (2 months) followed by rifampicin, isoniazid, pyrazinamide, 
ethambutol (1 month) and 5 months continuation phase of rifampicin, isoniazid, 
and ethambutol
MDR case 4 months intensive phase of kanamycin, moxifloxacin, prothionamide, ethambutol, 
clofazimine, pyrazinamide and isoniazid followed by four months continuation 
phase of moxifloxacin, prothionamide, ethambutol, clofazimine, pyrazinamide
Since 2006, the six-month short-course anti-tuberculosis treatment regimen has been used 
for treating all new diagnosed cases.21 At the time of the implementation of the operational 
research studies, retreatment patients with fully sensitive bacilli were treated with an 8-month 
retreatment regimen. Since this year, all retreatment TB patients with fully susceptible anti-TB 
drugs have been treated with the six months regimen according to the new recommendations 
of WHO.23 MDR-TB has always been treated differently requiring second-line anti-tuberculosis 
drugs. In 2009, the NTP adopted The Union recommended short-term standardized regimen 
for MDRTB cases (TB patients whose Mycobacterium tuberculosis isolates are at least 
resistant to isoniazid and rifampicin).22
Treatment of all bacteriologically confirmed pulmonary TB cases is directly observed and 
supervised during the intensive phase. In the continuation phase, patients are regularly 
supplied with drugs for self-administration. Clinically diagnosed pulmonary TB and EPTB 
patients are also given drugs on a regular basis for self-administration. Generally, treatment is 
provided on an outpatient basis, although some patients require in-patient care. Patients also 
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receive nutritional support during their treatment. Bacteriologically confirmed pulmonary 
TB patients are monitored with sputum smear examination at set months according to 
international guidelines.18 If needed, further support and more intensive monitoring for non-
adherent patients are carried out by BMU workers.
MULTIDRUG RESISTANT TB (MDR-TB)
According to the current recommendations, all previously treated TB patients and a 
representative sample of new TB cases are investigated with Xpert MTB/RIF and culture 
with drug-sensitivity testing to determine the presence or absence of MDR-TB. The last drug 
resistant survey carried out among patients diagnosed in 2009 showed that the proportion 
of MDR-TB was 0.5% among new cases and 13.3% in retreatment patients.24 According to 
the WHO, MDR-TB was estimated at 1.2% (0–2.6%) among new cases and at 8.1% (4.6–13%) 
among retreatment TB cases.20
MYCOBACTERIUM LABORATORY NETWORK
A Mycobacterial Reference Laboratory (LRM) in the NTP headquarters has responsibility for 
supervising an integrated laboratory network throughout the country and ensures good 
quality control. Direct examination of sputum by smear microscopy of acid-fast bacilli is 
carried out at the peripheral BMU levels. Xpert MTB/RIF devices (cartridge based automated 
nucleic acid amplification tests that use a common platform to diagnose both TB and 
rifampicin resistance) are functional at the regional levels. Conventional mycobacterial 
culture using Löwenstein-Jensen medium and drug sensitivity testing using the proportional 
method is performed at the LRM.25
SUPPLY OF ANTI-TUBERCULOSIS DRUGS
A functioning mechanism for the regular supply of anti-TB drugs, materials and laboratory 
reagents is in place. A stock-reserve of six months minimum is always constituted at the 
national level and for three months at the peripheral and regional levels; and the programme 
has never had interrupted supplies of drugs. Fixed-dose combination drugs are used 
wherever possible and paediatric formulations are available. 
MONITORING AND TRAINING
All BMUs are supervised on a quarterly basis by the central level, assisted by the regional 
TB work force. Quarterly reports are issued on case finding and treatment outcomes and 
an annual report is published. TB Programme staff officers also receive periodic training, 
particularly in relation to new guidance and recommendations. Two annual meetings are 
held to discuss performance and share experience, one between the central unit and all the 
regional levels at the headquarters and the other between both the regional and peripheral 
levels in each region of the country. 
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FUNDING
NTP activities are funded by the national budget along with external donor support. External 
donor support includes: the Global Fund against AIDS, TB and Malaria (GFATM), the French 
Development Agency through The Union, the Swiss Lung League, and the WHO. Since 
2013, most of the improvements within the programme have been accomplished thanks 
to the GFATM. For example, in 2015, of the €2,147,221 spent for the programme’s activities, 
€1,730,992 (81%) was covered by the GFATM. This strong dependence on the GFATM is also 
one of the most important weaknesses of the Programme.
COLLABORATIONS – INTERNAL AND EXTERNAL
Relations between the different actors within the Program are good, with regular 
communication facilitated by a functioning phone call network. There are also good relations 
between the NTP and other national programmes in Benin as well as between the NTP 
and other TB programmes of other countries in the region. In 2015, a West African regional 
network was created in Cotonou, which facilitates the sharing of experiences and the solving 
of TB management related trans-borders issues.
CHALLENGES FOR TB CONTROL IN BENIN
There are a number of challenges for TB control. The studies conducted as part of this thesis 
address four important challenges for the national TB Control Programme. 
First, many factors affect the epidemiology and development of TB which include the social 
determinants of the disease. These may have changed over the last 10-20 years and may 
change subsequently going forward. During this period, the country has based its main case 
detection strategy on passive case finding – namely waiting for patients to present to the 
health sector with symptoms. It is important therefore that the NTP has good information 
about its estimated and notified TB cases during the MDG period. Going forward, it also 
needs to narrow the gap between estimated and notified cases, reduce those who are 
missing and rapidly diagnose and treat those that are identified, as this will greatly assist in 
reducing TB incidence. Whether the passive case finding strategy is sufficient or whether the 
country should embark on a more ambitious active case finding strategy must be decided. 
Second, there are three groups of patients that historically have caused problems for NTPs 
in resource-constrained settings: those with smear-negative pulmonary TB, with extra-
pulmonary TB and childhood TB. In all three groups, it is difficult to get bacteriological 
confirmation of TB, and thus the diagnoses are prone to error and treatment outcomes may 
be adversely affected. The NTP needs better information about the profiles of patients with 
these types of TB and their specific treatment outcomes, data on which were not readily 
available in national aggregate reports. 
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Third, there is the spectrum of multidrug-resistant TB (MDR-TB) which has grown hugely at 
the global level over the last two decades. Patients registered with retreatment TB (namely, 
those who have been previously treated) are at high risk of acquiring or developing drug 
resistance because of factors such as poorly administered first line treatment, delayed 
diagnosis of drug resistance or contact with other cases of MDR-TB. Such patients may 
therefore have poor treatment outcomes that threaten the overall treatment success of the 
NTP. More information is needed about this high-risk group of patients and especially about 
the optimum time for starting empirical MDR-TB treatment in those with retreatment TB 
while waiting for culture and drug susceptibility tests. 
Finally, the treatment outcome category of lost to follow-up, defined as failing to attend 
scheduled appointments for two months or longer, can be large and can reduce treatment 
success. Tracing patients at their homes before they are declared lost to follow up might 
reduce this adverse treatment outcome, but whether costly tracing activities produce the 
desired benefit or whether better patient education is more effective is not known.
 
PROVIDING SOLUTIONS FOR IDENTIFIED TB PROGRAMME CHALLENGES THROUGH 
OPERATIONAL RESEARCH
The discipline of operational research (OR) was first developed to improve industrial and 
military production processes, 26 but has gained increasing importance and recognition in 
health sciences during the last several years. There are several overlapping and sometimes 
contradictory definitions of OR, 27-29, of which the most relevant one in our view is “research 
into interventions, strategies or tools that can enhance the quality, effectiveness, coverage 
or performance of disease control programmes or health systems in which the research is 
being conducted”. 26 This kind of research is mainly understood as undertaking secondary 
analysis of already collected data that originate within programme settings. However, both 
quantitative and qualitative research constitute OR and prospective data collection is also 
considered as part of the discipline provided the study design is pragmatic and routine care is 
not altered substantially. An important goal of OR is to improve programme implementation 
and performance with the ultimate aim of improving health outcomes for the people and 
communities in need. In summary, Operational research projects aim to identify constraints 
that prevent objectives being met with the purpose of finding solutions and achieving those 
objectives.
For the NTP, implementation of programmatic operational research projects should help to 
solve some of the recognized challenges. 9,30 As such, an operational research unit was created 
within the Benin NTP in 2010 with a view to scaling up programmatic operational research. 
Initially, the unit held monthly meetings at which research projects or research topics were 
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discussed, but there was little in the way of implementation. In 2012, an operational research 
fellow (SA) from the Centre for Operational Research, The International Union Against 
Tuberculosis and Lung Disease, Paris, France, was appointed within the NTP to promote and 
lead a TB-specific operational research agenda. Since then, and following a formal training 
at the Union-MSF run SORT IT Course, 31 he has been working with NTP colleagues to develop 
and implement a TB-specific operational research agenda in Benin and this thesis stems 
from that work. The studies which constitute this thesis address the four important technical 
challenges discussed earlier in the Introduction. 
AIM AND OBJECTIVES AND RATIONALE OF THE THESIS
The aim of this thesis is to assess TB case management practices in Benin, particularly in 
relation to the four important technical challenges of TB Control outlined above. 
Specific objectives are to document: 
1. the epidemiology of TB in Benin between 2000 and 2014 and the forecasted numbers of TB cases 
in the subsequent five years  
2. the diagnosis and management of smear negative pulmonary TB, extrapulmonary TB and 
childhood TB 
3. the diagnosis and management of retreatment TB patients, the association with drug-resistance 
and whether empirical treatment for MDR-TB amongst those who fail treatment is justified 
4. in patients who have missed their scheduled appointments and are therefore at risk of being 
lost-to follow-up, the reasons for not making the appointments and the contribution of tracing 
activities towards improving treatment success
The rationale and justification of the studies: The first study in the thesis is to determine the 
epidemiology of TB in Benin over the last fifteen years between 2000 and 2015 and use this 
data to forecast what might happen to TB cases in the following five years. Benin uses a 
passive case finding approach. This may not be sufficient to identify all missing cases and 
ultimately reduce TB incidence. The WHO has promoted active case finding32 and the country 
therefore needs to know whether to take on this approach or not.
The following three studies in the thesis address problematic groups of patients – those with 
smear-negative pulmonary TB, EPTB and childhood TB. The NTP needs to know more about 
the profile of these three types of TB, the proportion if any with bacteriological confirmation, 
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co-morbidities such as HIV infection and finally their treatment outcomes and case fatality 
and how these compare with patients diagnosed with bacteriologically confirmed TB. This 
detail is important to reassure the country that the cases are as genuine as possible and that 
they are being appropriately diagnosed and treated. The last point relates particularly to the 
mortality target of the SDGs.17
The next two studies focus on retreatment TB and drug-resistance. The NTP needs to know 
what proportion of all its registered TB cases have been previously treated, what is the 
profile of these patients, whether or not they have been appropriately investigated for drug-
resistance by either Xpert MTB/RIF or culture and drug susceptibility testing and what are 
their treatment outcomes. Importantly, WHO recommends that patients who have failed 
treatment should be considered for empirical MDR-TB treatment while awaiting definitive 
culture and drug susceptibility testing, but whether this universal recommendation is 
appropriate for Benin is not known.21 These are all important questions not only for the Benin 
NTP, but also in the wider context of accurate reporting to WHO about drug resistance and 
treatment outcomes and in relation to meeting the treatment outcome targets set by the 
SDGs and the WHO End TB Strategy. 9,17
The final study addresses the important issue of lost to follow-up by determining the number 
and profile of those who missed their scheduled appointments and whether tracing patients 
was a worthwhile activity in terms of improving treatment success. All NTPs suffer from 
programmatic losses to follow-up and any sustainable method to pre-empt this adverse 
outcome and reduce its occurrence is worthwhile. Tracing patients is a time consuming and 
costly exercise, so if its contribution to overall treatment success is low, then more focus needs 
to be paid to other activities such as good education given by health workers to patients at 
the start and during the course of treatment. 
Overall, the studies conducted as part of this thesis, which are related to the four thematic 
areas using already collected data without any additional financing, should be helpful to 
the Benin NTP to improve its performance and meet the SDGs targets of ending by 2030 the 
epidemic of TB.9,17
OUTLINE OF THE THESIS
This thesis consists of seven operational research studies that have focused on case finding 
and treatment outcomes within the NTP of Benin. These studies were integrated within 
program activities and required minimal additional resources for their implementation. 
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First, in order to suggest relevant actions especially for moving forward, the programme 
undertook an analytic overview of TB control activities carried out in the previous ten years. 
This body of work is presented in Chapter 2. 
Second, smear-negative TB cases have received less attention in previous years from the 
programme and external technical advisors, due to the fact that they are less infectious than 
their smear-positive counterparts. However, paying less attention to these cases may lead 
to delayed diagnosis and more severe forms of disease which can lead in turn to increased 
morbidity and mortality. Better diagnosis would also increase the number of TB cases 
detected in the community. The issue of smear-negative TB is discussed in Chapter 3.
Third, extrapulmonary TB (EPTB) has always been a difficult area for the NTP because of 
the limitations of diagnosis within resource-constrained settings. The challenge of EPTB 
is presented and discussed in Chapter 4, with a focus on burden, presenting types and 
treatment outcomes.
Fourth, TB in children has been another difficult area with poor routine information 
collected and analysed within the TB programme. Assessing how well TB control activities 
are undertaken in this vulnerable group is thus a challenge. The problems of diagnosis and 
treatment of Paediatric TB are presented in Chapter 5.
Fifth, recurrent or retreatment TB is an important component of TB control because a repeat 
episode of TB is devastating for the patient, causes loss of credibility of the programme in the 
eyes of patients and communities and is a risk factor for the development of drug resistant 
TB. The diagnosis and treatment of retreatment TB patients is reviewed in Chapter 6. 
Sixth, and linked to retreatment TB, is the concern about how much MDR-TB is generated as 
a result of recurrent disease. This aspect was reviewed over a nine-year period in Chapter 7. 
Finally, it is important to understand why patients fail to attend scheduled appointments 
and to know whether tracing them and bringing them back to care is a useful activity in 
terms of the programme maintaining a high treatment success rate. The tracing system that 
was developed and implemented by the NTP in Cotonou was therefore assessed with the 
findings and lessons learnt presented in Chapter 8. 
The linkage of these projects with the SDGs and WHO End TB Strategy9,17 are summarized 
below (Figure 5).  The thesis finishes with a Discussion and Conclusion of the findings of these 
studies and lists the recommendations made to the Benin NTP to improve TB control in the 
country.
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Figure 5. Conceptual framework
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ABSTRACT
Objective: To determine any changes in tuberculosis epidemiology in the last 15 years in 
Benin, seasonal variations and forecasted numbers of tuberculosis cases in the next five 
years.
Materials and Methods: A retrospective cohort and time series study of all tuberculosis 
cases notified between 2000 and 2014 in Benin. The “R” software version 3.2.1 (Institute for 
Statistics and Mathematics, Vienna, Austria) and the Box-Jenkins (1976) modeling approach 
were used for time series analysis.
Results: Of 246943 presumptive cases presenting between 2000 and 2014, 54303 (22%) were 
diagnosed with tuberculosis. There was an increase in annual notified case numbers, with the 
highest reported in 2011. New pulmonary bacteriologically confirmed tuberculosis (NPBCT) 
constituted the majority of cases (average=78%±SD 2%). Retreatment cases decreased from 
10% to 6% and new pulmonary clinically diagnosed cases increased from 2% to 8%. There 
was a decrease in NPBCT notification rates in males from 2012, in young people aged 15-34 
years-old and in Borgou-Alibori region. There was a seasonal pattern in tuberculosis cases. 
More than 90% of NPBCT cases were HIV-tested with a stable HIV-prevalence of 13%. The 
ARIMA best fit model predicted a decrease in tuberculosis case finding in the next five years.
Conclusion: Tuberculosis case notifications are predicted to decrease in the next five years if 
current passive case finding is used. Additional strategies are therefore needed in the country.
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INTRODUCTION
Despite the discovery of the causative agent more than one century ago, a vaccine, highly 
effective medications and recent improvements in biological molecular field and genetic 
engineering, tuberculosis (TB) remains a major public health concern in the world. In 2014, 
globally, there were estimated 9.6 million incident cases, of which 1.5 million were estimated 
to have died. The burden of the disease is particularly immense in Africa from where the case 
rate was reported to be 281 per 100000 people [1].
The year 2016 is an important turn for the TB world, with the World Health Organization 
(WHO) launching the “End TB strategy” with ambitious new targets of reducing by 2035 the 
incidence and the mortality of the disease by 90% and 95% respectively, compared with 2015 
[2]. Success in this new strategy requires additional and relevant actions/strategies at both 
international and national levels. In countries, such actions/strategies cannot be properly 
planned without a clear understanding of the past and current local epidemiology of the 
disease.
Benin is a small country in West Africa with an area of 114763 km² for a population of 
10008749 inhabitants in 2013 [3]. With activities just restricted to a mass BCG vaccination 
before 1966, TB care activities in the country significantly improved from 1972 with the 
establishment of the National TB Programme (NTP). An epidemiological review of TB 
patients diagnosed in the country between 1995 and 2007 showed an average of new notified 
pulmonary bacteriologically confirmed TB cases (NPBCT) of 35 per 100000 inhabitants, 
with a slight increase of 1% per annum. Large variations were observed in notifications of 
TB cases between the north and the south of the country, in line with population densities. 
The male-female sex ratio was 1.8 and no change in the age structure was reported. Human 
Immunodeficiency Virus (HIV) prevalence of the 97% of TB patients that were tested was 14% 
[4].
As implementation of the “End TB Strategy” commences, it is important to better understand 
the new challenges and to determine whether the local TB epidemiology has changed 
over time. There is also no information available within the national tuberculosis control 
programme on the relationship between seasons and TB case finding. This information may 
be useful in forecasting the number of TB cases expected in Benin in the coming years.
The current study was therefore undertaken i) to assess whether there were any changes in 
the local TB epidemiology the last fifteen years and ii) to determine the forecasted number 
of TB cases in next five years. Specific objectives were to determine between 2000 and 2014 
in Benin: i) the trend of presumptive and notified TB cases; ii) the trend of the different types 
and categories of TB cases; iii) any changes in baseline characteristics and HIV-status of 
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notified NPBCT; iv) any seasonality in TB case finding in the country; and     v) the forecasted 
number of TB cases that might be diagnosed within the programme in the next five years.
MATERIALS AND METHODS
STUDY DESIGN 
This was a retrospective cohort and time series study of notified TB patients, using routinely 
collected data.
GENERAL SETTING AND STUDY SITES
Country: Benin shares borders with Burkina Faso and Niger in the north, Togo in the west, 
Nigeria in the east and the Atlantic Ocean in the south. The country is low-income with a 
Gross National Income per capita estimated at US$ 810 in 2014. The under-five and maternal 
mortality rates were 85 per 1000 live births and 340 per 100 000 live births respectively in 2013 
[5]. HIV prevalence among adults aged between 15 and 49 years was 1.1% in 2012 [6]. For 
decades, BCG vaccination has been implemented in public and also some appointed health 
facilities in the country. BCG vaccination is recommended within the first two weeks after 
birth. In 2014, the coverage rate was 96% [7]. BCG vaccination is free of charge.
Administratively, the country is divided into six functional departments: Atacora-Donga 
and Borgou Alibori in the north, Zou-Collines in the centre, Mono-Couffo, Oueme-Plateau 
and Atlantique-Littoral in the south. Cotonou the economic capital is located in Atlantique-
Littoral. The density of the population gradually increases from the north to the south, 
with the highest population density reported from Cotonou. Overall in Benin, the climate 
is hot and humid. There were two rainy seasons (a principal season from April - July and a 
shorter season from September - November) and two dry seasons (a principal season from 
December - April and a shorter season from July - September).
THE NATIONAL TUBERCULOSIS CONTROL PROGRAMME (NTP)
Organization and function: The NTP is under the Ministry of Health and has a pyramidal 
organizational structure with three (central, intermediate and peripheral) levels, based on 
that of the general health system. Diagnosis, registration and treatment are decentralized 
to 57 BMUs (48 public and 9 confessional health facilities) at peripheral levels. Attempts had 
been made previously to include private clinics but with no success, because the private 
sector is benefits-oriented, contrary to the Programme’s objective of making free of charge 
all related-TB activities (consultations and/or examination charges for diagnosis, treatment 
and follow-up). However, these private clinics are not completely excluded from TB activities. 
Their workers are regularly trained to identify and refer to the closest BMU patients with 
presumptive symptoms of TB. This system functions well. There is supervision of all the 57 
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BMUs organized by the central and intermediate levels of the TB Programme on a quarterly 
basis.
Diagnosis, Treatment and Case Notification: Diagnosis and treatment are provided in line 
with the WHO and the Union recommendations [8, 9]. Overall, a passive screening strategy is 
routinely performed, although in 2011, there was some experimentation with a semi-active 
case finding strategy named “TB Reach” funded by the WHO. The laboratory network is 
made up of 57 laboratories in BMUs with 10 additional Centres for microscopic diagnosis. 
In these laboratories, specimens from all presumptive TB cases (regardless of their public, 
confessional or private sector origin) are analysed mainly using Ziehl-Neelsen staining and/
or fluorescence auramine microscopy. Fluorescent microscopy was first introduced into the 
largest BMU of the country twenty years ago. Since then, this technology has been scaled up 
to six regional laboratories in 2010 and to 10 other laboratories with the highest workloads 
in 2014. With the new Global Fund against AIDS, Tuberculosis and Malaria (GFATM) grant, the 
rest of the laboratories in the network will be equipped with fluorescent microscopy by 2017.
In addition to microscopy, phenotypic culture on solid medium (Löwenstein-Jensen) 
followed by identification and drug susceptibility testing is routinely carried out at the 
mycobacteria national laboratory. Since 2012, Xpert® MTB/RIF (Cepheid Inc, Sunnyvale, CA, 
USA) has also been available in this laboratory. This technology is not part of the routine 
diagnosis strategy of all TB cases but is mainly used for 1) detecting patients earlier with 
resistance to rifampicin, almost synonymous with multidrug-resistant TB and 2) diagnosing 
HIV-infected patients with presumptive symptoms of TB. On the first targeted population, in 
Benin, rifampicin resistant patients are mostly found among retreatment TB cases. Thus, all 
previously treated patients positive on smear microscopy are tested. In 2016, Xpert® MTB/
RIF (Cepheid Inc, Sunnyvale, CA, USA) was scaled up in the six regional laboratories. In the 
short term, decentralization of these machines at peripheral levels is not possible because of 
various technological and other constraints (for example, cost, environmental temperatures, 
shelf-life of cartridges, electricity supplies in a country where electricity is neither stable nor 
permanent, and the need for annual calibration of the machine [10].
Once the diagnosis is confirmed, patients are registered in the “TB registers” which are only 
available in the 57 BMUs. Those, who reside far from the place of diagnosis, are sent to the 
BMU closest to their domicile and registered in that new BMU.
Treatment is then started and is in line with WHO recommendations. All consultations, 
bacteriological examinations, treatment and follow-up are provided free of charge. Anti-TB 
drugs are not available in private pharmacies but only in BMUs. This presents an advantage 
for TB notification completeness since patients have to be sent to one of the 57 BMUs and be 
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registered before starting treatment. For all pulmonary TB bacteriologically confirmed cases 
through microscopy, treatment is directly observed during the intensive phase.
Within the first two weeks after the end of each quarter, a report on TB cases diagnosed 
during these three months and (also outcomes of the cohort of patients put on treatment 
one year earlier) is made by the nurse under the responsibility of the medical doctor. A visit 
is then made by the supervision team; and the report is checked (and corrected if necessary) 
before being brought back to the coordinator for national statistics. To date, the notification 
system is paper based, but the programme is about to move to an electronic notification 
system (District Health Information System 2 developed by University of Oslow).
TB/HIV coinfection management: Since 2006, all TB cases in the country have been 
systematically offered HIV testing. Those who are found co-infected with TB and HIV receive 
cotrimoxazole (CTX) for opportunistic infections prevention. Since 2010, antiretroviral therapy 
(ART) has been initiated for all co-infected TB/HIV patients, regardless of their CD4 cell counts 
[11].
Financing: TB activities are funded by the government. However, similar to many other 
developing countries, an important component of the funding is provided by the International 
Institutions, especially the Global Fund against AIDS, Tuberculosis and Malaria (GFATM). In 
2014, 48% of the national programme needs were internationally funded [12].
STUDY POPULATION
All TB patients registered in the NTP between 2000 and 2014 were included in the study. 
DATA VARIABLES, DATA SOURCES, DATA VALIDATION AND DEFINITIONS
Aggregate data were collected for this study and included: number of presumptive TB cases, 
number of notified TB cases (all types), number of NPBCT (Patients never treated or treated 
with anti-TB drugs for less than 1 month, whose TB diagnosis was bacteriologically confirmed 
on sputa by smear microscopy, culture or WHO-approved rapid diagnostics such as Xpert 
MTB/RIF), new pulmonary clinically diagnosed TB (patients with pulmonary disease never 
treated or treated with anti-TB drugs for less than 1 month who did not fulfil the criteria for 
bacteriological confirmation but were diagnosed with active TB by a clinician who decided 
to give the patient a full course of TB treatment), new extrapulmonary TB (Patients never 
treated or treated with anti-TB drugs for less than 1 month with a bacteriological or a clinical 
diagnosis of TB involving anatomical sites other than the lungs) and retreatment TB (or 
previously treated patients who received 1 month or more of TB treatment in the past. They 
included relapse, treatment after failure and treatment after loss to follow-up cases) [13], 
demographical characteristics of NPBCT cases (sex, age group, department), HIV-status of 
NPBCT (positive, negative, unknown). These data were collected into paper-based quarterly 
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reports and validated during quarterly supervisions. They were then entered into a Microsoft 
Excel file.
ANALYSIS AND STATISTICS
Baseline characteristics, types of TB and HIV-status were described using frequencies and 
percentages. The notified NPBCT rates in males, females, age groups and departments 
were calculated from the general population. For the time series analysis, the number of 
TB cases notified half-yearly between 2000 and 2014 was derived. The “R” software version 
3.2.1 (Institute for Statistics and Mathematics, Vienna, Austria) and the Box-Jenkins (1976) 
modeling approach were used to analyse the time series and to determine the best suitable 
model for the time series data. The Ljung–Box–Pierce test was performed to check whether 
the model was correctly specified. Levels of significance were set at 5%.
ETHICAL CONSIDERATIONS
Permission for the study was obtained from the NTP management staff. Approval from the 
local Ethics Committee (“Comité National d’Ethique pour la Recherche en Santé” (http://
www.ethique-sante.org/index.htm) was not required because of the retrospective nature of 
this study according to the country’s recommendation. Approval was also not required from 
the Ethics Advisory Board of the International Union against Tuberculosis and Lung Disease 
(The Union) because of the use of aggregate not individual data. The study used already 
collected data. Therefore, written informed consent given by participants was not possible 
to obtain. Since aggregate data were used for the study, there was no way to recognize 
participants.
RESULTS
CASES DETECTION AND TYPES OF TB
Between 2000 and 2014, of the 246943 TB presumptive patients, 54303 (22%) were diagnosed 
with TB. The numbers / trends of presumptive and diagnosed TB patients seen respectively 
over these fifteen years are shown in Figure 1. There was a progressive increase in the number 
of patients being investigated for TB. In the same manner, the number of diagnosed TB cases 
also increased. The maximum number of presumptive and diagnosed TB cases was reported 
in 2011 and this was followed by a decrease the year after. 
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Figure 1. Trend of presumptive and notified tuberculosis cases in Benin, 2000-2014
Figure 2. Different types of tuberculosis diagnosed in Benin, 2000-2014
Figure 2 shows the different types of TB diagnosed over the study period. NPBCT through 
microscopy represented the large majority of TB cases diagnosed (average = 78% [±SD 2%]). 
Retreatment TB patients declined from at least 10% in the first five years to about 6% in the 
last few years while new pulmonary clinically diagnosed TB cases slightly increased  from 2% 
to 8%.
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Figure 3A. 
Figure 3B. 
BASELINE CHARACTERISTICS AND HIV-STATUS VARIATION
Baseline characteristics and HIV-status of patients are shown in Figure 3 (3A, 3B, 3C and 3D). 
Among NPBCT, the notification rate was 1.5 times higher in males compared to females. 
However, from 2012 onwards there was a decrease in male case numbers (Figure 3A). TB case 
notification rates decreased among young people aged from 15 to 34 years-old compared 
with older people (Figure 3B). The Atlantique-Littoral region continuously reported the 
highest rate of TB during the last ten years while a decrease in cases was noticed in Borgou-
Alibori (Figure 3C). The proportion of TB patients tested for HIV was high (>90%) while the 
prevalence of HIV-positive status among NPBCT tested was quite constant each year at 13% 
(Figure 3D).
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Figure 3C. Cases per 100.000
Figure 3D. 
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SEASONALITY OF TB CASE DETECTION AND FORECASTED NUMBERS OVER THE NEXT FIVE 
YEARS
The time series analysis of TB cases diagnosed between 2000 and 2014 in Benin is shown in 
Figure 4 (4A, 4B, 4C). The raw graph of all cases diagnosed each semester showed an overall 
gradual increase of these cases over the study period, with several peaks suggesting a cyclical 
seasonal pattern in TB case finding (Figure 4A). This assumed that the TB case finding time 
series was composed of a trend (gradual increase over time), seasonal variations (several 
peaks at regular intervals) and a residual component. After a profiles method, the additive 
model was the most appropriate to decompose this time series. The decomposition into 
trend, seasonality and residual components is shown in Figure 4B. Trend analysis showed an 
upward-sloping but not linear curve, and the seasonality curve, an alternative and regular 
fluctuation in the interval (52.009; -52.009) over the study period. Overall, in each year, except 
2004, 2005 and 2008, the number of TB cases notified for the first semester was higher than 
that reported for the second semester. The residual component was on average generally 
constant over the period. The Dickey-Fuller test confirmed that this time series was effectively 
stationary (Dickey-Fuller = -5.781, Lag order = 3, P-value = 0.01). The Autocorrelation Function 
(ACF) and the Partial Autocorrelation Function (PACF) suggested an Autoregressive Integrated 
Moving Average - ARIMA (2,0,3) model (Figure 4C). 
Figure 4: Time series analysis of all tuberculosis cases diagnosed, 2000 – 2014, Benin.
4A= Tuberculosis cases diagnosed per semester; 4B= Decomposition of tuberculosis cases 
diagnosed with an additive model; 4C= Autocorrelation and Partial autocorrelation functions 
of tuberculosis time series.
Figure 4A. 
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Figure 4B. 
Figure 4C. 
The coefficients of the autoregressive and moving average parts of the best fit model were 
determined and are presented in Table 1. The best fit model for this time series was therefore 
ARIMA (0,0,1) (1,0,0) with a constant. This model was validated using the Ljung–Box–Pierce 
test (chi-squared=11.939, df=1, P<0.001), confirming thereby that the residual components in 
this time series were white noises (ie independent and identically distributed).
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Table 1: Estimation of the coefficient of the best fit model for the TB case finding time series.
MA1 AR1 Intercept
0.6037 0.865 1759.7924
Standard error 0.2232 0.092 163.3689
Best fit model ARIMA (0,0,1)(1,0,0) with constant
Convergence criteria Log Likelihood=-182.67 ; AIC=373.33 ; BIC=378.94
Note: MA: Moving Average; AR: AutoRegressive.
Finally, the forecasted number of TB cases per semester between 2015 and 2019 was 
calculated and is presented in Table 2.
Table 2: Forecasted number tuberculosis patients predicted to be diagnosed between 2015 and 
2018 in Benin.
2015 2016 2017 2018 2019
S1 S2 S1 S2 S1 S2 S1 S2 S1 S2
Prevision 1989 1917 1958 1896 1931 1877 1908 1861 1888 1848
[IC95%] [1788
-
2189]
1683
-
2152]
[1666
-
2250]
[1586
-
2206]
[1587
-
2275]
[1522   
-
2234]
[1529
-
2287]
[1475
-
2249]
[1485
-
2291]
[1439
-
2257]
Note: S: Semester; IC95%: 95% forecasting interval.
The numbers of TB cases are predicted to decrease during these next five years (Figure 5).
Figure 5. Trend of TB cases in Benin between 2000 and 2014 and forecasted number of TB cases from 2015 
to 2019
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DISCUSSION
This study aimed to describe in Benin, at the start of the new Global End TB strategy, 
changes that occurred in the epidemiology of TB patients during the previous fifteen years 
and the predicted trend in TB case finding in following five years. We found that between 
2000 and 2014, the number of presumptive and notified TB cases slightly increased. In 
contrast to new pulmonary clinically diagnosed TB cases that increased during this time 
period, the proportion of retreatment TB cases decreased. Those found NPBCT positive on 
microscopy regularly comprised at least three quarters of all notified TB cases. With respect 
to demographic characteristics, the burden of the disease was consistently higher among 
males compared to females. However, from 2012 onwards, there was a striking decrease in 
males being notified with TB. The burden of disease also decreased among younger adults 
aged less than 34 years, who also constituted a large proportion of the TB population. The 
Atlantique-Littoral region continued to drive the epidemic in the country, while there was a 
drop in notified cases in Borgou-Alibori.
HIV testing in TB patients was excellent, with each year over 90% of patients tested. Of 
those who were tested, one in seven was annually found to be co-infected, with no change 
observed in this proportion over these fifteen years. The findings showed a seasonal variation 
in TB case finding and notification, with a higher number of TB cases reported at the end of 
the first semester of each year. Finally, the forecasted number of TB cases to be diagnosed 
and notified in next five years was predicted to decrease if only the current passive screening 
strategy in the country is applied.
The strengths of this study were that it involved all TB patients in the country who were notified 
to the NTP and therefore there was no need for any sampling framework. Data used were also 
previously validated during regular quarterly supervisions which contributed to minimizing 
errors. The study followed the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines [14]. Limitations were related to the retrospective nature 
of the study.
One of the major questions that came from our findings was the decrease of TB cases in men, 
young adults and also the decline in the forecasted numbers that will be notified in next five 
years. Taking into account the most important achievement within the Programme, that is a 
treatment success rate of 90% or more among NPBCT in these last six years [12], it is possible 
that the programme has significantly cut down transmission of infection from index smear-
positive cases leading to a reduction in the burden of TB in the country. However, this belief 
should be interpreted with caution for several reasons. 
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First, the Programme routinely uses a passive strategy for TB screening. The decrease reported 
in the study is therefore related to TB cases that reached health facilities. Unfortunately, 
the utilization of the national health services remains low, estimated at 51.4% in 2013 
[15]. In other words, TB cases that occurred in those not accessing TB services will not be 
diagnosed and notified. The increase in notified TB cases reported in the year of the “TB 
Reach” experience followed by a decrease after this adds weight to this theory. Advantages of 
a semi-active case finding strategy have also been reported elsewhere [16, 17]. The high cost-
efficacy of a semi-active case finding strategy does not allow it to be routinely performed in 
a resource-constrained setting, although this should always be considered. In 2015 and with 
the positive impact of the “TB Reach” experience on TB case finding, the GFATM authorized 
the implementation of other active case finding strategies in the country. An additional 
measure to be taken into account for reaching those who do not use health facilities could 
be to strengthen sensitization especially among traditional practitioners who most of time, 
are at the front line for providing care.
Second, it is possible that patients of some vulnerable groups such as HIV-infected patients, 
those with diabetes mellitus, and pregnant women were not diagnosed, since they were 
not systematically screened by practitioners for TB at each visit, unless they complained 
themselves of presumptive TB symptoms. Actions to address this shortfall and also 
implementation of some semi-active case finding sessions have been planned in the next 
three years national strategic plan, mainly with the new GFATM grant. All these new activities 
are expected to increase TB case finding as follows: 5093 cases by 2016, 5449 by 2017, 5613 
by 2018 and 5781 by 2019. 
Third, because of the strong relationship between TB and poverty, TB reduction/elimination 
undoubtedly will not be achieved without real improvements in population life conditions. 
Although, the GDP per capital in Benin grew from US$ 339 in 2000 to US$810 in 2014, the 
country remains one of the poorest in the world, with a poverty headcount ratio of 36% in 
the general population [18, 19]. A significant improvement in population life-conditions is 
probably needed to effectively reverse the TB trend in the country and to achieve the 2035 
TB goal of ending TB epidemic.
The high predominance of NPBCT positive cases on microscopy with no apparent decrease 
over the 15 years confirms the laboratory network efficacy but also raises the question 
about early diagnosis of TB in the country. A positive result on smear microscopy requires an 
average concentration of 10000 bacilli per millilitre in sputum specimens [20]. There is a need 
to advocate for earlier screening and diagnosis through more education, communication 
and effective screening of close contacts of smear-positive TB patients [17]. The progressive 
reduction in the proportion of retreatment TB patients is, however, a favourable observation 
and is likely to be due to improvements in treatment outcomes of new cases.
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We are not surprised that the Atlantique-Littoral region which houses the economic capital 
and is burdened with rural migrations and promiscuity issues, remains the one most affected 
by the disease; but reasons why the trend of TB notifications is declining in Borgou should 
be sought and addressed. In the same way, reasons for the apparent seasonality in notified 
TB cases in the country are not clear. One suggested hypothesis is the variation in health 
facilities utilization in relation to seasons. Access to health facilities in the rainy season is a 
problem in many countries, and it might be expected that a decrease in TB case notifications 
occurs at this time. However, this hypothesis is not supported by our data, since in contrast 
a higher number of notified TB cases was often reported during the first semester which is 
when the main rainy season occurs. There may be other determinants contributing to TB case 
finding and notification seasonality in the country. Seasonality in TB cases finding has also 
been reported from elsewhere [21-23]. One hypothesis found in the literature, that attempted 
to explain such seasonality has been a variation in Vitamin D, important substance in host 
defence, which is produced by the body in association with sunshine exposure may be a 
factor [24].
With respect to HIV infection, the proportion of patients with HIV-infection has not increased. 
HIV is an important driver of the TB epidemic in many countries. Benin is a mixed epidemic 
country. Between 2000 and 2013, there has been a decrease of HIV prevalence in the 
population aged between 15 and 49 years from 2% to 1.1%. Furthermore, the coverage rate 
of ART intake that started in 2002 has progressively improved. The proportion of HIV-infected 
patients on ART increased from 12080 in 2008 to 28850 in 2014 [6, 25]. All of these factors have 
probably helped in preventing an increase in HIV-associated TB in Benin during the last 15 
years. 
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CONCLUSION
The number of TB cases over the last 15 years in Benin has decreased among males and 
young adults, and the number of forecasted TB cases predicted to be diagnosed in next 
five years will also decrease if only a passive screening strategy is continued. Benin needs 
to decide whether it needs alternative case finding strategies to meet the END TB Targets by 
2035. 
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ABSTRACT
Background: In Benin, patients with smear-negative pulmonary TB (SNPTB) are of low 
priority in the National Tuberculosis Programme (NTP) and little is known about their profile 
or treatment outcomes.
Methods: A retrospective cohort study was carried out to determine characteristics and 
treatment outcomes in all adults registered with SNPTB in 2009. Findings were compared 
with patients with new smear-positive pulmonary tuberculosis (PTB) diagnosed in the same 
period.
Results: Of 3140 patients with PTB, 273 (8.7%) had SNPTB, with higher rates in northern 
and southwestern regions. SNPTB was associated with female gender, older age and HIV-
positive status (p<0.01). Patients with SNPTB had a higher proportion of unsuccessful 
treatment outcomes compared with smear-positive PTB owing to death and loss to follow-
up (LFU) (p<0.01). The region with the capital city had the highest rate of LFU. Differences 
in unsuccessful outcomes between SNPTB and smear-positive PTB were more apparent in 
persons who were HIV-negative, and among HIV-positives not on antiretroviral treatment.
Conclusion: In Benin, treatment outcomes of SNPTB patients were inferior to those with 
smear-positive PTB, with LFU being a major problem. The Benin NTP needs to better 
address the problem of patients with SNPTB in terms of monitoring and reporting, treatment 
management including that associated with HIV care, and reducing LFU.
NATIONAL PROFILE AND TREATMENT OUTCOMES OF 
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INTRODUCTION
Adult patients with sputum smear-negative pulmonary TB (SNPTB) are diagnosed according 
to international standards if they have a cough for more than 2–3 weeks, negative sputum 
smears, chest radiographic findings consistent with active TB, and lack of response to a 
trial of broad-spectrum antimicrobials.1 Such patients receive lower priority from National 
Tuberculosis Programmes (NTPs) in terms of follow-up, recording and reporting because 
they are perceived to be less contagious and therefore less of a risk to the community than 
smear-positive pulmonary TB (PTB) patients.
In high HIV prevalence countries, especially in sub-Saharan Africa, the number of patients 
with SNPTB has increased significantly and their outcomes are reported to be worse than 
those of patients with smear-positive PTB.2–6 The reasons for this include HIV-related 
immunosuppression, misdiagnosis and stigma, the latter causing delays in presentation, 
diagnosis and treatment. In contrast, in countries with a low prevalence of HIV and TB, 
outcomes in patients with SNPTB are reported to be no different to those of other patients.7,8 
Benin is a low-income country in West Africa with an intermediate HIV prevalence.9 Benin has 
a functional NTP that is responsible for the management of all TB patients. The NTP registers 
in total approximately 3500–4000 TB patients per year, of whom only 7–10% are recorded 
as SNPTB. Although the NTP reports quarterly on cases and outcomes, these reports are 
focused on smear-positive patients and there is no information on demographic and clinical 
characteristics, HIV status or treatment outcomes of those with SNPTB. In addition, these 
patients do not receive directly observed treatment, short course (DOTS).
It is therefore important to obtain more information about SNPTB in Benin because of the 
need to provide optimum individual case management for all TB cases and because the 
WHO now reports on treatment success for new smear-positive and all newly diagnosed TB 
patients.10 The aim of this study was therefore to describe the epidemiological characteristics 
and treatment outcomes of patients registered with SNPTB in Benin and to compare these 
with patients who were diagnosed as having smear-positive PTB. Specific objectives were 
to determine among adults (age ≥15 years) with PTB in the whole population of Benin in 
2009: (i) the number and proportion registered as SNPTB; (ii) demographic and HIV-related 
characteristics of SNPTB and smear-positive PTB; and (iii) treatment outcomes of patients 
with SNPTB and new smear-positive PTB, stratified by gender, age, region, HIV status and HIV 
treatment.
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MATERIALS AND METHODS
STUDY DESIGN
This was a retrospective cohort study of all adult patients recorded as SNPTB and smear-
positive PTB in Benin between 1 January and 31 December 2009.
SETTING: GENERAL AND STUDY SITE
COUNTRY
Benin is a West African country with a population of 9 million inhabitants. The country shares 
borders with Togo in the west, Nigeria in the east, and Burkina Faso and Niger in the north. 
In this part of Africa, it is notable that the notified TB incidence rate largely varies according 
to countries. In 2011, it ranged from 57 per 100 000 population in Burkina Faso to 118 per 
100 000 population in Nigeria, and was 70 per 100 000 population in Benin. In comparison 
with its neighbouring countries, Benin has reported the highest treatment success rate 
among new smear positive and/or culture-positive cases (91% vs ≤84% for the others).10 
The TB programme follows the DOTS strategy and uses recognised international criteria for 
the diagnosis and treatment of patients with TB.11,12 Diagnosis, registration and care of TB 
patients are decentralised to 57 basic management units in the country.
TB CONTROL 
An adult patient is suspected of having TB when he/she coughs for more than 3 weeks and 
is then asked to provide two sputum samples for acid-fast bacilli (AFB) microscopy. Sputum 
samples are examined using either auramine phenol staining and fluorescence microscopy, 
or using Ziehl-Neelsen staining with light microscopy. Patients with at least one sputum 
smear-positive for AFB, are registered as smear-positive PTB. Patients with smear-negative 
sputum, provided another diagnosis is unlikely, are given a trial of broad-spectrum antibiotics 
for 2 weeks. If symptoms persist, new sputum samples are taken for smear microscopy and if 
they are again negative for AFB, chest radiography is done. The presence of radiological signs 
of TB allows a doctor to consider the patient as having SNPTB and to start TB treatment. No 
further investigations are routinely undertaken, and culture of sputum for Mycobacterium 
tuberculosis is not done. A similar routine is followed for HIV co-infected patients, with an 
exception being for those with severe disease in whom there is a lower threshold for starting 
TB treatment.1 Almost 100% of adults with suspected PTB submit sputum specimens for 
smear microscopy.
All SNPTB patients are classified as new cases in the Benin NTP. A positive smear or culture 
is mandatory for the diagnosis of re-treatment TB. Bacteriological proof is required for these 
retreatment cases to avoid TB treatment wrongly given to patients who may have other 
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respiratory diseases. All new smear-positive PTB and SNPTB patients are treated using the 
same standardised regimen, consisting of daily rifampicin, pyrazinamide, isoniazid and 
ethambutol for 2 months (initial phase) followed by daily rifampicin and isoniazid for 4 months 
(continuation phase). Treatment of smear-positive PTB is directly observed by a healthcare 
worker during the initial phase, but this does not apply for patients with SNPTB. Treatment is 
free of charge and is only provided by the NTP. Treatment outcomes are monitored through 
the use of treatment cards and registers, and cases and their standardised outcomes are 
reported through quarterly reports. The NTP also has a department with responsibility for 
looking for patients with smear-positive PTB who discontinue during treatment, but this 
does not apply to SNPTB.
MANAGEMENT OF TB/HIV CO-INFECTION
All registered TB patients are systematically offered an HIV test, and 99% of them have 
known HIV status.13,14 Those who are HIV-positive (17% in the last national report) are 
offered trimethoprim/sulfamethoxazole (SXT) to prevent other opportunistic infections. 
For HIV treatment, since 2011 the country follows the 2010 WHO recommendations for the 
administration of antiretroviral therapy (ART). The regimen usually prescribed is efavirenz, 
zidovudine and lamivudine, and all co-infected patients can receive ART regardless of their 
CD4 counts.15
PATIENTS
All adult patients in Benin aged≥15 years registered with new pulmonary PTB (SNPTB or new 
smear-positive PTB) between 1 January and 31 December 2009 were included in the study.
DATA VARIABLES, SOURCES OF DATA, AND DATA COLLECTION TOOL
Data variables that were collected included epidemiological characteristics, HIV serological 
status, sputum smear result, standardised treatment outcomes, TB treatment regimen, and 
SXT and ART administration. Sources of data were TB registers, co-infection registers and 
quarterly reports. Data were collected into paper-based study questionnaires.
ANALYSIS AND STATISTICS
Data from the questionnaires were double-entered into an EpiData file (EpiData Software, 
CDC, Atlanta, GA, USA). Data were analysed by frequencies and percentages for demographic 
and HIV-associated characteristics and treatment outcomes. Findings in patients with SNPTB 
were compared with patients who had smear-positive PTB using the x2 test, with RR and 95% 
CI as appropriate. Levels of significance were set at 5%.
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RESULTS
EPIDEMIOLOGICAL CHARACTERISTICS AND HIV STATUS
There were 19 782 patients suspected of TB who provided sputum for smear microscopy 
in 2009. Of these, 3140 were diagnosed and registered with new PTB. The number and 
proportion of these patients with new SNPTB and smear-positive PTB for the whole country 
and in the different regions are shown in Table 1. Of these, 273 adults (8.7%) had SNPTB 
(mean age 42.4 years). None reported a previous history of TB. A higher proportion of SNPTB 
was found in the regions of Borgou, Atacora and Mono in the northern and southwestern 
parts of the country. 
Table 1: Patients with new smear-negative and smear-positive pulmonary tuberculosis 
registered nationally and in the different regions of Benin in 2009.
Regions Total SNPTB (%*) Smear-positive PTB (%*)
Benin 3140 273 (8.7) 2867 (91.3)
Regions
Northern 
regions
Atacora / Donga
Borgou / Alibori
200
241
24 (12)
33 (13.7)
176 (88)
208 (86.3)
Central region Zou / Collines 310 20 (6.5) 290 (93.5)
Southern 
regions
Atlantique / Littoral
Mono / Couffo
Ouémé / Plateau
1256
482
651
107 (8.5)
55 (11.4)
34 (5.2)
1149 (91.5)
427 (88.6)
617 (94.8)
Note: TB=Tuberculosis; SNPTB = Smear-negative pulmonary tuberculosis; PTB = Pulmonary tuberculosis
*The percentage is calculated from the total number of newly diagnosed pulmonary TB cases in each region.
Demographic characteristics and HIV status of patients with new SNPTB and smear-positive 
PTB are shown in Table 2. There were higher proportions of females, persons aged ≥65 
years and persons with HIV-positive status among those with SNPTB compared with smear-
positive PTB.
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Table 2: Demographic characteristics and HIV status of patients with new smear-negative and 
smear-positive pulmonary tuberculosis in Benin in 2009.
Total SNPTB (%*) Smear-positive PTB (%*) P value
All 3140 273 2867
Sex Male 2016 147 (53.8) 1869 (65.2) <0.001
Female 1124 126 (46.2) 998 (34.8) <0.001
Age in 
years
15 – 24 582 36 (13.2) 546 (19) 0.01
25 – 34 1021 59 (21.6) 962 (33.6) <0.001
35 – 44  693 67 (24.5) 626 (21.8) NS
45 – 54 449 49 (17.9) 400 (14) NS
55 – 64 221 26 (9.5) 195 (6.8) NS
≥ 65 174 36 (13.2) 138 (4.8) <0.001
HIV status Positive 500 113 (41.4) 387 (13.5) <0.001
Negative 2570 149 (54.6) 2421 (84.4) <0.001
Indeterminate 19 1 (0.4) 18 (0.6) NS
Not recorded 51 10 (3.7) 41 (1.4) <0.01
Note: TB=Tuberculosis; HIV=Human Immunodeficiency Virus; SNPTB=Smear-negative pulmonary tuberculosis; 
PTB=Pulmonary tuberculosis
*Percentage is calculated among new smear-negative and smear-positive TB patients respectively.
TREATMENT OUTCOMES
Treatment outcomes are shown in Table 3. There was a significantly higher rate of unsuccessful 
outcome in patients with SNPTB, in whom loss to follow-up (LFU) and death were significantly 
more frequent compared with patients who had smear-positive PTB. Failure rates were just 
above 2% for new smear-positive PTB: these are not determined for patients with SNPTB in 
whom follow-up smears in the continuation phase are not carried out. With regard to the 
high LFU and death in patients with SNPTB, there were no significant differences in relation 
to gender or age. However, in the Atlantique region, 35 (32.7%) of 107 patients with SNPTB 
were lost to follow-up, which was significantly higher than that observed in the other regions 
where there was one patient lost to follow-up (p<0.001).
CHAPTER 3
62
Table 3: Treatment outcomes in patients with new smear-negative and smear-positive 
pulmonary tuberculosis in Benin in 2009.
SNPTB (%)
Smear-positive 
PTB (%)
P value
Total enrolled 
for treatment
273 2867
Successful 
Outcome
204 (74.7) 2588 (90.3) * <0.001
Unsuccessful 
outcome 
69 (25.3) 279 (9.7) <0.001
Failure 0 67 (2.3)
Death 30 (11) 163 (5.7) <0.001
Loss-to-follow up 36 (13.2) 35 (1.2) <0.001
Transfer out 3 (1.1) 14 (0.5) NS
Note: TB=Tuberculosis; SNPTB=Smear-negative pulmonary tuberculosis; PTB=Pulmonary tuberculosis
* There were 2351 (82%) patients who were cured with negative sputum smears at the end of treatment.
Treatment outcomes of patients with SNPTB and smear-positive PTB stratified by HIV status 
are shown in Table 4. In those who were HIV-positive, there was no difference in overall 
unsuccessful outcome between patients with SNPTB and smear-positive PTB, although there 
were more patients with SNPTB who were lost to follow-up (p<0.001). In those who were 
HIV-negative, significantly more patients with SNPTB had an overall unsuccessful outcome 
compared with smear-positive PTB patients (p<0.001), with the main outcomes significantly 
different being death (11.4% vs 3.8%; p<0.001) and LFU (10.1% vs 1.3%; p<0.001). For those 
with indeterminate HIV status (n=19) and HIV status not recorded (n=51), there were no 
differences in outcomes between the two types of TB.
There were 500 HIV/TB co-infected patients, of whom 494 (98.8%) received SXT (99.7% of 
smear-positive PTB and 95.6% of SNPTB). Altogether 216 HIV-infected patients (43.2%) were 
treated with ART, which included 52.2% of HIV-positive SNPTB patients and 40.6% of HIV-
positive smear-positive PTB patients. 
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Table 4: Treatment outcomes of new smear-negative and smear-positive pulmonary TB 
patients stratified by positive or negative HIV status in Benin in 2009.
HIV status HIV-Positive HIV-Negative
SNPTB 
(%)
Smear-positive 
PTB (%)
SNPTB 
(%)
Smear-positive 
PTB (%)
Patients evaluated 113 387 149 2421
Successful outcome 82 (72.6) 310 (80.1) 117 (78.5) 2233(92.2)
Unsuccessful  
outcome
31 (27.4) 77 (20) 32 (21.5) 188 (7.8)
Failure 0 12 (3.1) 0 55 (2.3)
Death 10 (8.8) 57 (14.7) 17 (11.4) 92 (3.8)
Loss-to-follow up 18 (15.9) 4 (1) 15 (10.1) 31 (1.3)
Transfer out 3 (2.7) 4 (1) 0 10 (0.4)
Note: TB=Tuberculosis; HIV=Human Immunodeficiency Virus; SNPTB=New smear-negative pulmonary 
tuberculosis; PTB=Pulmonary tuberculosis.
Treatment outcomes of HIV-infected patients with and without ART are shown in Table 5. 
Among those on ART, there was no difference overall in unsuccessful outcomes between 
SNPTB and smear-positive PTB. In those not on ART, there was a higher proportion of SNPTB 
patients overall with unsuccessful outcomes (p<0.01), and this was principally due to a higher 
LFU (p<0.001). 
Table 5: Treatment outcomes in HIV-infected patients with new smear-negative and new 
smear-positive pulmonary tuberculosis stratified by antiretroviral treatment, in Benin in 
2009.
On antiretroviral treatment No antiretroviral treatment
Type of TB SNPTB (%) Smear-positive PTB (%) SNPTB (%)
Smear-positive 
PTB (%)
Patients evaluated 59 157 54 230
Successful outcome 82 (72.6) 310 (80.1) 117 (78.5) 2233(92.2)
Unsuccessful outcome 9 (15.3) 23 (14.6) 22 (40.6) 54 (21.7)
Failure 0 6 (3.8) 0 6 (2.6)
Death 3 (5.1) 16 (10.2) 7 (13) 41 (17.8)
Loss to follow up 6 (10.2) 1 (0.6) 12 (22) 3 (1.3)
Transfer out 0 0 3 (5.6) 4 (1.7)
Note: TB=Tuberculosis; HIV = Human Immunodeficiency Virus; SNPTB = New smear-negative pulmonary 
tuberculosis; PTB = Pulmonary tuberculosis.
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DISCUSSION
This is the first national study in Benin that has assessed the burden of SNPTB and its 
treatment outcomes in relation to baseline characteristics, HIV status, and HIV care and 
treatment. The main findings were that almost 10% of patients with pulmonary disease had 
SNPTB, with higher rates seen in the northern and southwestern regions of the country. Being 
female, age ≥65 years and being HIV-positive were associated with SNPTB.
In terms of treatment outcomes, patients with SNPTB experienced a higher overall rate of 
unsuccessful outcome compared with patients who had smear-positive PTB, and this was 
mainly due to a higher rate of death and LFU. There was no influence of age and gender on 
these findings. However, the majority of patients lost to follow-up resided in the Atlantique 
region, which houses the economic capital city of the country, Cotonou. Differences in 
unsuccessful outcome between SNPTB and smear-positive PTB patients were more apparent 
in persons who were HIV-negative and in persons who were HIV-positive but not on ART, with 
LFU being the major problem.
The strengths of this study are that it covered the whole population and it was therefore 
nationally representative of the epidemiology of TB in Benin. All adults suspected of PTB 
submitted sputum specimens and all registered patients were included, thus there was no 
need for any sampling framework. The study report also followed Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) guidelines.16 Limitations include the 
operational nature of the study, the use of routine data from registers and quarterly reports 
which may be inaccurate, and lack of M. tuberculosis culture facilities to confirm whether or 
not patients truly had SNPTB.
There has been concern that Benin under-reports the number of patients with SNPTB. 
However, a study in 2006 and 2007 in the largest basic management unit found a small 
proportion of patients with smear-negative culture-positive TB, indicating that there may 
not be a high prevalence of true smear-negative disease in the country.17 The current study 
found higher rates of SNPTB in the northern and southwestern regions of the country where 
the incidence of TB is much lower than in the south.18 It is possible that doctors are under less 
pressure of work in the north and southwestern regions of the country and therefore have 
more time to consider and follow the correct algorithms and procedures for the investigation 
of SNPTB.19 There were higher rates of SNPTB in females and in those who were HIV-positive, 
and this is in agreement with other findings in Africa showing that HIV infection targets young 
women who then are at increased risk of TB.2,3
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The finding of SNPTB is older persons also makes sense. Older people may be at risk of 
chronic pulmonary disease due to fibrosis or occupational exposure and it is possible, as has 
been shown in other studies,5,19 that SNPTB is wrongly diagnosed.
There were generally poor treatment outcomes in patients with SNPTB, especially in those 
who were HIV-negative and in those who were HIV-positive but not on ART. Treatment 
outcomes in HIV-positive patients with TB in programme settings before the advent of ART 
were very poor in sub-Saharan Africa, largely owing to HIV-related opportunistic infections 
as well as delays in diagnosis and treatment due to stigma and other factors causing an 
increase in mortality.19,20 In HIV-negative patients, poor treatment outcomes were probably 
related to misdiagnosis or poor compliance with treatment.19,20 In the current study, there 
were high rates of LFU, which compromised treatment outcomes especially in the Atlantique 
region. Previous research in Africa has identified death, transfer-out and discontinuation 
of treatment due to side effects or poor reception at health facilities as being responsible 
for LFU.21 The reasons for LFU in SNPTB patients in Benin are not known, but it was more 
common in the region housing the capital city and probably relates to the challenges of urban 
TB control, a mobile urban population, lack of attention paid by the NTP to this category of 
patient, and death.
This study has important implications for the Benin NTP, whose outcome data reported from 
the treatment of new smear-positive PTB are excellent, with a success rate of 91% in 2010.13 
First, there is a need for SNPTB to assume a higher status within the programme and for 
treatment outcomes to be monitored, recorded and reported. Second, more attention needs 
to be paid to improving treatment outcomes of SNPTB. DOTS should be administrated for 
SNPTB, and an active search made for those who discontinue therapy during treatment. 
Third, although there is good uptake of HIV testing and SXT, more patients need to access 
ART as this therapy improved TB treatment outcomes both in SNPTB and smear-positive PTB 
patients. This is not easy to do and may require better integration of HIV and TB services as 
well as improvement in ART accessibility in the country.
Finally, the programme must reduce the number of patients who are lost to follow-up and 
focus efforts around the Atlantique region and the capital city of Cotonou.
CONCLUSION
This national study in Benin found that almost 10% of patients with pulmonary disease 
had SNPTB, with higher rates seen in the northern and southwestern regions of the country. 
Certain characteristics such as being female, age ≥65 years and being HIV-positive were 
associated with SNPTB, and treatment outcomes of these patients were in general inferior to 
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those of patients with smear-positive PTB. LFU was a major cause of unsuccessful treatment 
outcome. The Benin NTP needs to pay more attention to the problem of SNPTB in terms 
of monitoring, recording and reporting, better treatment management including that 
associated with HIV care, and reducing LFU.
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ABSTRACT
Background: In sub-Saharan Africa, there is a dearth of published literature on extrapulmonary 
tuberculosis (EPTB).
Objective: To describe demographic, diagnostic and HIV-status characteristics of patients 
with EPTB in Benin, their treatment outcomes, and among those who completed their 
treatment in the Centre National Hospitalier de Pneumo-Phtisiologie (CNHP-P), the 
proportion whose bodyweight increased during treatment.
Material and Findings: This was a retrospective cohort study with comparisons made 
between EPTB and new smear-positive pulmonary tuberculosis (NPTB) patients diagnosed 
in the country from January to December 2011. There were 383 EPTB patients (9% of all TB 
cases) with a mean age of 35 years, male/female ratio of 1.3 and important regional variation.
There were significantly more females (p=0.001), children <15years (p<0.001) and HIV-positive 
patients (p=0.005) with EPTB compared with NPTB. Pleural effusion, spinal and lymph node 
tuberculosis accounted for 66% of all EPTB. Children<15 years represented 16% of cases, 
with lymph node disease being most common among them (p=0.001). Of 130 EPTB patients 
registered in CNHP-P, 7% had a confirmed bacteriological/histological diagnosis. There were 
331 (86%) patients who successfully completed treatment. More patients with EPTB were 
lost-to-follow-up compared with NPTB (p=0.001) with all these patients from one region. 
The best treatment completion rates were in children <15 years (OR: 3.5, 95%CI: 1.0–14.8) 
while patients with pleural effusion and ascites had the worst outcomes. Of 72 HIV-coinfected 
patients, 88% were on antiretroviral therapy (ART). HIV-positive status was associated 
with poor outcomes while those on ART fared better. In the CNHP-P, more than 80% who 
completed their treatment showed an increase in bodyweight and this was more evident in 
HIV-positive compared with HIV-negative patients (p = 0.03).
Conclusion: Patients with EPTB generally do well in Benin, although the TB Programme 
would benefit through more attention to accurate diagnosis and earlier start of ART in HIV-
infected patients.
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INTRODUCTION
Patients with extrapulmonary tuberculosis (EPTB), i.e., tuberculosis (TB) without associated 
lung involvement, usually receive less priority in national TB Programmes. However, in 
many countries, their numbers remain either stable or are increasing while numbers of 
patients with pulmonary disease are decreasing [1]. In populations with a low prevalence 
of HIV infection, these patients usually represent 15% to 20% of all TB cases. However, this 
proportion is thought to be higher in populations with a high prevalence of HIV infection [2], 
the latter mostly occurring in sub-Saharan Africa.
Confirmation of the diagnosis of EPTB, as recommended by the World Health Organization 
(WHO) [3], is not easy. Diagnosis in many low income countries is often based on presumptive 
and circumstantial evidence, with the consequence of a possible misdiagnosis [4].
In Bénin, information is limited about this type of TB, especially with regard to epidemiological 
characteristics and the most predominant forms of EPTB. Furthermore, the treatment 
outcomes of patients with EPTB are analyzed in the routine programme together with those 
of patients with smear-negative pulmonary tuberculosis, the latter in a recent study showing 
higher rates of unsuccessful treatment compared with new smear-positive pulmonary 
tuberculosis (NPTB) [5]. These treatment outcomes are usually reported quarterly, using 
standard classifications; and a “treatment completion” is considered a successful outcome 
[3]. 
However, treatment can be completed without improvement of the patient’s health condition, 
particularly if the diagnosis of EPTB is wrong. The disappearance of initial symptoms along 
with weight gain in patients who have completed treatment might be a better gauge of 
successful treatment.
In this study, we aimed to describe the pattern of disease in patients registered as EPTB, 
their treatment outcomes and among those who completed their treatment in the Centre 
National Hospitalier de Pneumo-Phtisiologie (CNHP-P), the proportion whose weight 
increased during the course of treatment.  Specific objectives were to determine in Bénin 
for 2011: i) the number (and proportion) of patients recorded as EPTB and NPTB among all 
TB cases, ii) demographic, clinical characteristics and HIV-status of patients with EPTB and 
NPTB, iii) treatment outcomes of patients with EPTB and NPTB and the influence of HIV-
infection and antiretroviral therapy and iv) the proportion who increased in weight among 
those who completed their treatment in the CNHP-P.
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MATERIALS AND METHODS
ETHICS STATEMENTS
This study was approved by “Ethics Advisory Group” of the International Union against 
Tuberculosis and Lung Disease, Paris, France and “Bénin TB Control Programme 
Coordination”. Because of its retrospective nature, the local Ethics Committee approval 
(“Comité National d’Ethique pour la Recherche en Santé”) was not required according to the 
country’s recommendations.
This study uses already collected data, and written informed consent -given by participants 
was not possible to obtain. Patient records/Information was collected anonymously. Each 
participant of this study was attributed a unique identifier number, in order to compare data 
files that have been double entered. After checking and cleaning the database, the unique 
identifier numbers have been removed and participants were de-identified prior to analysis. 
There was no way to recognize them. All databases were kept confidential and have been 
protected with a password, with only access by authorized persons.
STUDY DESIGN
This was a retrospective cohort study of all patients recorded as EPTB and NPTB between 1st 
January and 31st December 2011 in Bénin.
SETTING – GENERAL AND STUDY SITE, INCLUDING TB PROGRAMME
Bénin is a West-African country with a population of 9 million and a HIV prevalence rate of 
1.1% [6].  Seven to 10% of the 4000 TB patients registered each year have EPTB. There is a 
national TB Programme which follows the DOTS strategy and uses recognised international 
criteria for the diagnosis and treatment of TB patients [7]. Diagnosis, registration and care 
are decentralised to 57 Basic Management Units in the country. Of them, the largest is the 
CNHP-P of Cotonou, the economic capital. It houses the Mycobacteria Reference Laboratory 
where culture and molecular diagnostics can be performed for the whole the country.
DIAGNOSIS AND MANAGEMENT OF NPTB AND EPTB IN THE BÉNIN TB CONTROL 
PROGRAMME:
Pulmonary TB diagnosis is made with respect of WHO recommandations [2]. A person who 
coughs more than 3 weeks is regarded as having presumptive pulmonary tuberculosis. He/
she is requested to provide two sputum samples for acid-fast bacilli microscopy. Sputum 
samples are examined using either auramine-phenol staining and fluorescence microscopy 
or Ziehl-Neelsen staining with light microscopy. Patients with at least one sputum smear 
positive for acid-fast bacilli and who have never been previously treated for TB (or less than 
one month) are registered as NPTB.
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A patient is considered as having presumptive EPTB if he/she has symptoms suggestive of 
TB related to an extrapulmonary site, with a decision then made by a medical doctor to treat 
with a full course of anti-tuberculosis treatment. Usually, because of difficulties in accessing 
and obtaining specimens from different biological sites, TB treatment is started based on 
symptoms and other circumstantial evidence that includes laboratory investigations and 
radiographic abnormalities. Whenever possible, specimens collected should be submitted 
for bacteriological investigation (direct microscopy examination or standard culture, or 
molecular tests). Rarely, these specimens are also analysed in histology laboratories. In terms 
of registration, for patients who have TB in both pulmonary and extrapulmonary sites, they 
are classified as having “pulmonary TB”. For patients with TB in several extrapulmonary sites 
(e.g., lymph nodes and pleural effusion), they are registered according to the most severe 
form of disease.
All NPTB and EPTB cases are treated with the same standardized first-line anti-tuberculosis 
regimen. Patients receive daily rifampicin, pyrazinamide, isoniazid and ethambutol for 2 
months (initial phase) followed by daily rifampicin and isoniazid for 4 months (continuation 
phase). Contrary to the treatment of NPTB, EPTB treatment is not directly observed during the 
intensive phase and anti-tuberculosis drugs are given every two weeks for self-administration. 
Treatment is free and is only provided by the Programme for all TB patients. TB drugs are not 
available in private pharmacies in the city or country. While sputum microscopy examination 
is performed during follow-up of NPTB patients, those with EPTB are monitored clinically and 
in particular body weight is measured and recorded during treatment on personal treatment 
cards (at two, five and six months).
Standardized treatment outcomes are monitored through the use of treatment cards and 
registers, and number of cases and outcomes are quarterly reported.
TB/HIV CO-INFECTION MANAGEMENT:
Every patient who is diagnosed with TB (including EPTB) is systematically offered an HIV test 
using rapid tests and following national guidelines [8]. Those who are found to be HIV positive 
receive in addition cotrimoxazole. Since 2011 and according to recent WHO guidelines, all 
TB cases (including EPTB) are eligible for antiretroviral therapy (ART) [9]. The first line ART 
regimen is efavirenz and two other drugs, zidovudine and lamivudine. If there is anemia 
(Haemoglobin<7g/dl) or a low platelet count (<75000/l) zidovudine is replaced by stavudine. 
Cotrimoxazole and ART are provided free of charge. 
STUDY PATIENTS
All patients recorded as EPTB and NPTB between 1st January and 31st December 2011 in 
Bénin were included in the study.
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DATA VARIABLES, SOURCES OF DATA AND DATA COLLECTION
Variables for NPTB and EPTB patients included: sex, age, residence by region, HIV-status 
(positive, negative, unknown), cotrimoxazole and ART administration, treatment outcomes 
(completion, death, loss-to-follow-up, not evaluated). Variables for EPTB patients included in 
addition:- sites of disease (pleural effusion, spinal, lymph node, bone or joint, ascites, other 
and not recorded) and weight change during treatment for patients managed in the CNHP-P. 
Individual data for EPTB patients were collected from TB registers, laboratory TB registers, 
treatment cards and TB medical personal files into a standardized paper-based study 
questionnaire. For NPTB patients, data were collected from quarterly and annual reports.
ANALYSIS AND STATISTICS
Data were double entered into an electronic file (EpiData3.1, EpiData Association, Odense, 
Denmark). Data were analyzed by frequencies and percentages. Comparisons were made 
between groups using the chi-square test, odds ratios (OR) and 95% confidence intervals 
(95% CI) as appropriate. Levels of significance were set at 5%.
RESULTS
NUMBERS, EPIDEMIOLOGICAL AND DIAGNOSTIC CHARACTERISTICS OF TB PATIENTS
The number and proportion of patients with EPTB and NPTB diagnosed in the same time 
period are shown in Table 1. Overall, EPTB patients represented 9% of all TB cases (mean 
age: 34.5 years, male / female ratio: 1.3), with a large variation between regions from 23% in 
Borgou (North of the country) to 5% in Ouémé (South of the country). All patients were new 
cases.
Table 1: Patients with extrapulmonary tuberculosis and new smear-positive pulmonary 
tuberculosis registered in Bénin and the different regions of the country in 2011.
Regions All TB** EPTB (%*) NPTB (%)
Benin 4320 383 (8.9) 3331 (77.1)
Atacora 251 18 (7.2) 189 (75.3)
Borgou 367 58 (23.1) 255 (69.5)
Zou 567 70 (12.3) 442 (78)
Atlantique 1646 146 (8.9) 1226 (74.5)
Mono 664 51 (7.7) 534 (80.4)
Ouémé 825 40 (4.8) 685 (83)
Note: EPTB=Extrapulmonary tuberculosis; NPTB=New smear-positive pulmonary tuberculosis; 
TB=Tuberculosis
* The percentage is calculated from the total number of TB cases diagnosed in each region
** All TB cases include all patients with new and retreatment TB, irrespective of the site of tuberculosis.
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Demographic characteristics and HIV-status of patients with EPTB and NPTB are shown in 
Table 2. There were significantly more females (p=0.001), children under 15 years (p<0.001) 
and HIV-positive patients (p=0.005) diagnosed with EPTB compared with NPTB.
Table 2: Demographic characteristics and HIV-status in patients with extrapulmonary 
tuberculosis and new smear-positive pulmonary tuberculosis, Bénin, 2011.
EPTB (%) NPTB (%) p value
All 383 3331
Sex Male 216 (56.4) 2158 (64.8) 0.001
Female 167 (43.6) 1173 (35.2) 0.001
Age (years) 00 – 14 62 (16.2) 62 (1.9) <0.001
15 – 24 62 (16.2) 608 (18.3) NS
25 – 34 75 (19.6) 1035 (31.1) <0.001
35 – 44  64 (16.7) 743 (22.3) 0.01
45 – 54 58 (15.1) 472 (14.2) NS
55 – 64 36 (9.4) 252 (7.6) NS
≥ 65 26 (6.8) 159 (4.8) NS
HIV-status Positive 72 (18.8) 449 (13.5) 0.005
Negative or unknown 312 (81.5) 2882 (86.5) 0.005
Note: EPTB=Extrapulmonary tuberculosis, NPTB=New smear positive pulmonary tuberculosis; 
TB=Tuberculosis.
The different sites of EPTB are presented in Table 3. Pleural effusion, spinal disease and 
lymph node disease accounted for 66% of all EPTB cases.
Table 3: Different sites of extrapulmonary tuberculosis in Bénin, 2011.
n (%)
All sites 383
Pleural effusion 94 (24.5)
Spine 82 (21.4)
Lymph node 77 (20.1)
Bone and Joint 29 (7.6)
Ascites 15 (3.9)
Other * 17 (4.4)
Not recorded 69 (18)
Note: * Others include pericardial TB (n=10), cerebral TB (n=1), meningeal TB (n=1), female genital TB (n=1), 
male genital TB (n=3), skin TB (n=1). TB=Tuberculosis.
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Demographic characteristics and HIV-status in relation to the different sites of EPTB are shown 
in Table 4. There was no association between gender and different types of EPTB. Children 
(under 15 years) represented 16% (62/383) of all EPTB cases diagnosed. Lymph node TB was 
more common in children than adults (p<0.001) while TB pleural effusion was more common 
in adults (p<0.001). Otherwise, there were no significant associations between age and other 
sites of EPTB. Compared with other regions, there was significantly more lymph node TB (OR: 
2.6, 95%CI: 1.4-4.7, p=0.001) and bone or joint TB (OR: 4.9, 95%CI: 2.1-11.6, p<0.001) in Zou 
while there was significantly more TB pleural effusion in the Atlantique region. TB pleural 
effusion was significantly more common in HIV-positive patients compared with HIV-negative 
patients (p<0.001).
The only health facility where confirmation of diagnostic has been assessed was CNHP-P. Of 
130 EPTB patients registered and followed-up in this centre, the diagnosis was confirmed 
for 9 cases (7%): 2 with positive Mycobacterium tuberculosis culture and direct smear 
examination, 1 with positive culture alone, 1 with positive direct smear  examination alone 
and 5 with histology showing tuberculous granuloma. For aspirates of pleural or peritoneal 
fluid, measurements of protein concentration and cytological analysis were performed for 
all cases.
Table 4: Epidemiological characteristics and HIV-status in relation to the different sites of 
extrapulmonary tuberculosis, Bénin, 2011.
Total Pleural 
effusion
Spine Lymph 
node
Bone
/Joint
Ascites Other * Not 
recorded 
383 94 82 77 29 15 17 69
Sex Male 
Female 
216
167
58(26.9)
36(21.6)
39(18.1)
43(25.7)
42(19.4)
35(21)
16 (7.4)
13 (7.8)
8(3.7)
7(4.2)
12(5.6)
5(3)
41(19)
28(16.8)
Age
(years)
< 15 62 3(4.8) 12(19.4) 24(38.7) 8 (12.9) 2(3.2) 1(1.6) 12(19.4)
≥ 15 321 91(28.3) 70(21.8) 53(16.5) 21 (6.5) 13(4) 16(5) 57(17.8)
Region Atacora
Borgou
Zou
Mono
Atlantique
Ouémé
18
58
70
51
146
40
1(5.6)
10(17.2)
8(11.4)
3(5.9)
69(47.3)
3(7.5)
3(16.7)
19(32.8)
18(25.7)
9(17.6)
27(18.5)
6(15)
5(27.8)
10(17.2)
24(34.3)
3(5.9)
23(15.8)
12(30)
0 (0)
8 (13.8)
14 (20)
3 (5.9)
1 (0.7)
3 (7.5)
1(5.6)
2(3.4)
1(1.4)
2(3.9)
8(5.5)
1(2.5)
1(5.6)
2(3.4)
0(0)
1(2)
12(8.2)
1(2.5)
7(38.9)
7(12.1)
5(7.1)
30(58.8)
6(4.1)
14(35)
HIV Positive
Negative
Unknown
72
306
5
29(40.3)
65(21.2)
0(0)
4(5.6)
74(24.2)
4(80)
15(20.8)
61(19.9)
1(20)
0(0)
29(100)
0(0)
5(6.9)
10(3.3)
0(0)
3(4.2)
14(4.6)
0(0)
16(22.2)
53(17.3)
0(0)
Note: * Others include pericardial TB (n=10), cerebral TB (n=1), meningeal TB (n=1), female genital track TB 
(n=1), male genital track TB (n=3), skin TB (n=1). TB=Tuberculosis.
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TREATMENT OUTCOMES
Treatment outcomes of patients with EPTB and NPTB are presented in Table 5. Overall, 86% 
of patients successfully completed treatment. There were significantly more patients with 
EPTB who were lost-to-follow-up compared with NPTB (p<0.001). 
Table 5: Treatment outcomes of patients with extrapulmonary tuberculosis and new 
smear-positive pulmonary tuberculosis in Bénin, 2011.
EPTB (%) NPTB (%) p value
Total evaluated 383 3324 *
Successful completion 331 (86.4) 2988 (89.9) ** 0.03
Failure
Death
Loss-to-follow up 
Not evaluated
0 (0)
32 (8.4)
15 (3.9)
5 (1.3)
99 (3)
196 (5.9)
27 (0.9)
14 (0.4)
<0.001
NS
<0.001
0.04
Note: EPTB=Extrapulmonary tuberculosis; NPTB=New smear positive pulmonary tuberculosis
* 7 patients of the 3331 were wrongly registered as new smear-positive TB and were removed from the cohort 
analysis one year later.
** 2800 of the 2988 patients were cured with negative sputum smear examination for acid-fast bacilli.
Treatment outcomes in relation to demographic characteristics, sites of disease, HIV-status 
and ART administration to co-infected patients are shown in Table 6. No association was 
found between gender and treatment outcomes. However, treatment success was higher 
in children aged < 15 years (OR: 3.5, 95%CI: 1.0 - 14.8, p: 0.02). All patients who were lost-
to-follow-up during treatment were from the Atlantique region and patients with pleural 
effusion or ascites had the worst completion rates.
Finally, of 72 HIV-TB co-infected patients, 99% received cotrimoxazole and 88% were given 
ART. HIV-positive patients were at higher risk of death than HIV-negative patients during 
treatment (OR: 2.5, 95%CI: 1.0 - 5.7, p: 0.02). In HIV-positive patients, those on ART had much 
better outcomes than those not on ART (82.5% versus 44.4%, p=0.03). The concomitant 
administration of ART was also associated with a lower loss-to-follow-up rate (OR: 31, 95%CI: 
2.2 – 922, p: 0.005). There were no other significant differences. 
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Table 6: Treatment outcomes of patients with extrapulmonary tuberculosis in relation to 
demographic characteristics, regions, HIV status and ART administration in those with HIV 
coinfection, Bénin, 2011.
Total Completion Death Loss to 
follow-up 
Not 
evaluated
383 331 32 15 5
Sex Male 
Female 
216
167
evaluated
183 (84.7)
148 (88.6)
17 (7.9)
15 (9)
11 (5.1)
4 (2.4)
5 (2.3)
0 (0)
Age
(years)
< 15 
≥ 15
62
321
59 (95.2)
272 (84.7)
2 (3.2)
30 (9.3)
1 (1.6)
14 (4.4)
0 (0)
5 (1.6)
Region Atacora
Borgou 
Zou 
Mono
Atlantique 
Ouémé
18
58
70
51
146
40
17 (94.4)
47 (81)
67 (95.7)
47 (92.2)
114 (78.1)
39 (97.5)
1 (5.6)
10 (17.2)
2 (2.9)
4 (7.8)
14 (9.6)
1 (2.5)
0 (0)
0 (0)
0 (0)
0 (0)
15 (10.3)
0 (0)
0
1 (1.7)
1 (1.4)
0 (0)
3 (2.1)
0 (0)
Site Pleurisy
Spine
Lymph node
Bone and Joints
Ascites 
Other* 
Not recorded
94
82
77
29
15
17
69
73 (77.7)
75 (91.5)
70 (90.9)
27 (93.1)
10 (66.7)
14 (82.4)
62 (89.9)
11 (11.7)
4 (4.9)
4 (5.2)
2 (6.9)
4 (26.7)
1 (5.9)
6 (8.7)
7 (7.4)
1 (1.2)
3 (3.9)
0 (0)
1 (6.7)
2 (11.8)
1 (1.4)
3 (3.2)
2 (2.4)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
HIV 
status
Negative
HIV positive on ART
HIV positive not on ART
Unknown
306
63
9
5
270 (88.2)
52 (82.5)
4 (44.4)
5 (100)
21 (6.9)
9 (14.3)
2 (22.2)
0 (0)
11 (3.6)
1 (1.6)
3 (33.3)
0 (0)
4 (1.3)
1 (1.6)
0 (0)
0 (0)
Note: * Others include pericardial TB (n=10), cerebral TB (n=1), meningeal TB (n=1), female genital track TB 
(n=1), male genital track TB (n=3), skin TB (n=1).
TB=Tuberculosis; ART = antiretroviral therapy.
WEIGHT VARIATION DURING TREATMENT
The change in body weight among patients who completed their treatment in relation to HIV-
status in the CNHP-P, the largest basic management unit in Bénin, is shown in Table 7. Up to 
80% of patients who successfully completed treatment showed an increase in body weight, 
and this was more apparent among HIV-positive than HIV-negative patients (p=0.03).
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Table 7: Treatment completion and change in weight in HIV-positive and HIV-negative 
patients with extrapulmonary tuberculosis treated in the Centre National Hospitalier de 
Pneumo-Phtisiologie, Bénin.
All patients HIV-negative HIV-positive p (value)
Extrapulmonary tuberculosis
Treatment Completion N (%*)
Increase in Weight  N (%**)
Mean increase in weight (Kg)
[95%CI]
129
101 (78.3)
82 (81.2)
5.8
[4.9 – 6.6]
95
74 (77.9)
60 (81.1)
5.21
[4.2 – 6.2]
34
26 (76.5)
21 (80.8)
7.3
[5.7 – 8.9]
0.86
0.83
0.03
Note: * The percentage was calculated from the EPTB cases diagnosed. ** The percentage is calculated from 
the total number of patients who completed their treatment.
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DISCUSSION
This is the first study in Bénin to describe the epidemiological and diagnostic characteristics 
and treatment outcomes of EPTB patients. Patients with EPTB constituted less than 10% of 
all notifications, with some parts of the country showing higher prevalence than others. EPTB 
appeared to be more common in females, children under the age of 15 years and in those 
who were HIV-positive. Predominant sites of disease were pleural, spinal and lymph node, 
with TB lymph node disease being more common in children and pleural effusion being 
more common in adults, especially those HIV-positive. Diagnostic confirmation was rare 
even in the largest basic management unit in the country.
Successful treatment completion was good especially in children, although there was a 
higher rate of loss-to-follow-up when compared with patients who had NPTB. Interestingly, 
all patients lost to follow-up were from a specific region of Bénin. Patients with pleural 
effusion and ascites had the worst treatment completion rates. Patients with HIV-associated 
TB remained at higher risk of death compared with those who did not have HIV-infection, 
although those on ART fared much better. Finally, in CNHP-P where weight during the 
treatment has been collected, there was a significant weight gain amongst those who 
completed treatment, with the change in weight being more evident in patients who were 
HIV-positive compared with those who were not HIV-infected.
The strengths of this study were that it involved the whole population and it was therefore 
nationally representative of the epidemiology of EPTB in Bénin. There was no need for any 
sampling framework. In addition, basic management units are regularly supervised every 
three months by the TB control Programme coordination, and during these supervisory visits, 
quarterly reports and patients’ personal data are systematically reviewed and if necessary, 
corrections are made. Limitations related to the operational nature of the study which used 
already collected data from registers, medical files and quarterly reports which are difficult to 
validate when conducting a retrospective record review. In spite of regular supervision, some 
errors could also remain in the consulted documents.
There were important variations in the proportion of EPTB patients in the different regions of 
the country; and this could be related to the implication of medical doctors in the diagnosis 
of this form of TB. In Borgou region, where the highest proportion of EPTB cases was reported 
from, the large majority of these patients were diagnosed in two well frequented hospitals 
because of their good reputation (a confessional centre and a teaching hospital). 
The proportion of patients diagnosed with EPTB in Bénin was lower than that reported from 
other parts of world [1,10-15], and few diagnoses were confirmed. Lack of appropriate and 
specific diagnosis in EPTB in sub-Saharan Africa remains a continuing source of debate [4]. 
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There are recommendations that the diagnosis of EPTB should be based on at least one 
specimen with confirmed Mycobacterium tuberculosis (using microscopy examination, 
culture or rapid molecular testing), histological or strong clinical evidence consistent with 
active EPTB, followed by a clinician decision to treat with a full course of tuberculosis 
chemotherapy [3].
However, in resource-poor countries like Bénin, following these recommendations is 
difficult. Obtaining the diagnosis is difficult for several reasons, such as lack of specialised 
physicians, microbiologists and pathologists, weak laboratory infrastructure and poor access 
to radiography and other more sophisticated imaging technologies such as ultrasound and 
computerised tomography scans.
The finding of females, children and HIV-positive patients having a higher prevalence of EPTB 
is in line with reports from other countries [1,12,16,17]. For children, the predominant site of 
TB reported in the literature is usually lymph node disease [1], although in adults a wide variety 
of patterns is reported from other countries which may depend to a large extent on resources 
available for diagnosis [16,18-25]. In Bénin, we found few patients with TB meningitis, while 
the proportion diagnosed in others studies has been higher [23,24]. This may be due to good 
coverage of BCG immunization in Bénin and also the difficulties in establishing the diagnosis 
in this type of disease [22,26,27].
Although successful treatment completion was reasonable, this could be improved by 
reducing the losses-to-follow-up, especially in Atlantique region, where Cotonou, the 
economic capital city of the country, is located. One of the reasons for patients being lost-
to-follow-up may be misdiagnosis, and this has been found in other parts of Africa. Patients 
with other pathology such as lung cancer, mesothelioma or systemic disease may be 
wrongly treated with anti-tuberculosis drugs without improvement, persuading them to seek 
alternative opinions and stopping treatment. Another reason is that some patients reported 
as lost-to-follow-up may have died, and this has also been found in other studies [28]. Finally 
more attention needs to be paid to accurate diagnosis of patients with pleural effusion and 
ascites, the latter especially having a wide differential diagnosis that includes chronic liver 
disease.
HIV-positive patients with EPTB were at higher risk of death than HIV-negative patients, 
despite good coverage with ART. Often, HIV-infected patients with EPTB present with 
advanced immune suppression with CD4 counts <200 cells /µl, and hence their classification 
as a WHO Stage 4 AIDS defining disease. As a result, patients can also be affected by other 
opportunistic diseases that can result in death [29,30]. The time of start of ART in relation to 
start of anti-TB treatment is an important factor that determines mortality, and late initiation 
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of ART is associated with increased case fatality [9]. A weakness of this study was the lack of 
information about when ART was started.
Finally, we assessed whether patients who completed treatment increased their weight, 
the latter adding to the evidence to support a successful treatment completion. The large 
majority of patients who completed their treatment showed an increase in body weight, 
especially in HIV-positive patients, and this has been found elsewhere. As recommended in 
guidelines, weight should be regularly measured during the course of treatment [4,31].
The findings of this study have several implications for the Bénin TB control Programme. First, 
there is a need to improve the diagnosis of EPTB in the country and to perform appropriate 
examinations when needed such as mycobacterial culture on tissue and other specimens. 
The introduction of rapid molecular tests such as Xpert MTB/RIF should be considered 
especially for the more difficult-to-diagnose cases of EPTB [32,33]. Second, the follow-up 
of patients during treatment must improve especially in the Atlantique region where there 
was high loss-to-follow-up. Third, more attention needs to be paid to getting HIV-infected 
patients on to ART as soon as possible and to ensure that the time of start of ART in relation 
to start of anti-TB treatment is well documented. 
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CONCLUSION
The study has shown that the proportion of patients diagnosed and registered with EPTB 
was low and below 10%. Treatment outcomes of EPTB cases were satisfactory, although the 
high loss-to-follow-up in the Atlantique region of the country needs to be rectified. The TB 
control Programme in Bénin would benefit through more attention to accurate diagnosis of 
EPTB and earlier start of ART in HIV-infected patients. 
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ABSTRACT:
Setting: The National Tuberculosis Programme (NTP) and the paediatric ward of the General 
Hospital (GH), Cotonou, Benin.
Objective: To describe the burden of tuberculosis (TB), characteristics and outcomes among 
children treated in Cotonou from 2009 to 2011.
Design: Cross-sectional cohort study consisting of a retrospective record review of all children 
with TB aged <15 years.
Results: From 2009 to 2011, 182 children with TB were diagnosed and treated (4.5% of total 
cases), 153 (84%) by the NTP and 29 (16%) by the GH; the latter were not notified to the 
NTP. The incidence rate of notified TB cases was between 8 and 13 per 100 000 population, 
and was higher in children aged >5 years. Of 167 children tested, 29% were HIV-positive. 
Treatment success was 72% overall, with success rates of 86%, 62% and 74%, respectively, 
among sputum smear-positive, sputum smear-negative and extra-pulmonary patients. 
Treatment success rates were lower in children with sputum smear-negative TB (62%) and 
those with HIV infection (58%).
Conclusion: The number of children being treated for TB is low, and younger children in 
particular are underdiagnosed. There is a need to improve the diagnosis of childhood TB, 
especially among younger children, and to improve treatment outcomes among HIV-TB 
infected children, with better follow-up and monitoring.
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INTRODUCTION
Globally, childhood Tuberculosis (TB) has received limited priority by National TB programmes 
due to the fact that many children are smear-negative and therefore are perceived to have 
limited infectiousness, and the numbers are often thought to be few. Numbers of children 
reported with TB may also be inaccurate due to difficulties in diagnosis of both pulmonary 
and extrapulmonary tuberculosis. 
Of the estimated 9 million TB cases, children under the age of 15 years constitute about 11% 
of total cases worldwide [1]. Although this proportion may seem small, TB in children under 
5 years of age, especially those under 2 years of age, has been shown to cause high mortality 
and morbidity [2]. Globally TB has been reported to be one of the important causes of death 
among children [1], and treatment outcomes among children with TB were also found to be 
poor [3].
In Benin, there is limited information about the burden of TB in children. While children 
with TB are normally registered and have their outcomes recorded in registers, they are not 
specifically identified in the quarterly reports, except for the notification of sputum smear 
positive pulmonary cases (all grouped together in a 0-14 age group). Furthermore, in the 
general hospital in Cotonou, the economic capital city, children are diagnosed and treated 
with information recorded in their personal medical files, but never notified to the NTP. 
Therefore, NTP data on children are incomplete and cannot be used to estimate the true 
burden of the disease among children in the country.
The aim of this study was to describe the burden of tuberculosis, characteristics and outcomes 
of children treated in Cotonou, Benin. Specific objectives were to determine over three years 
from 2009 - 2011: i) the total number of TB cases recorded in the TB registers and of these the 
number of children under the age of 15, ii) the incidence rate of notified tuberculosis cases 
among children aged less than 15, iii) the number of children registered with TB in the TB 
register and the number of children recorded in medical files in the general hospital (who are 
not in the TB register), and in each of these groups stratification by sex, age, type of TB and 
HIV status, and iv) treatment outcomes of children stratified by place of treatment, sex, age, 
type of TB and HIV status.
STUDY POPULATION, DESIGN AND METHODS
STUDY DESIGN
This was a cross-sectional and retrospective cohort study of children with TB in Cotonou 
using reviews of TB registers and medical files of the general hospital.
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SETTING – GENERAL AND STUDY SITE
Country: Benin is a small country in West Africa with a population of 9 million people and 
a gross national income of USD$ 780 per capita (http://data.worldbank.org/about/country-
classifications). The National TB Control Programme (NTP) registers about 3,500 TB cases 
each year. The national incidence rate of notified new TB cases is quite stable between 
41 and 46 / 100,000 inhabitants these ten last years. The TB programme follows the DOTS 
strategy and uses recognised criteria for diagnosing and treating patients with TB [4,5]. 
The programme has a central unit that is responsible for policy and strategy; diagnosis, 
registration and care are decentralised to 57 basic management units (BMUs) in the country. 
These BMUs are either public or private.
TB Control:  Children are suspected as having TB if they have chronic symptoms such as 
cough more than three weeks, persistent fever, malnutrition, weight loss and/or failure to 
thrive. The presence of an adult with sputum smear positive TB living in the same household 
than the child is a strong argument but is not always found. Children suspected of TB are 
investigated through sputum smear microscopy (if they can produce sputum or if gastric 
lavage is feasible), chest radiography (interpreted by radiologists and chest physicians), 
tuberculin skin testing. Culture of Mycobacterium tuberculosis from sputum or other 
specimens is occasionally used. Lack of response to non-specific antibiotics is also a 
strong argument for TB diagnosis. The child’s condition is determinant to start treatment. 
Diagnosed children are classified into pulmonary (smear-positive and smear-negative) 
and extra-pulmonary TB, and into new and previously treated cases according to national 
and international guidelines [4, 5]. All diagnosed children are supposed to be registered in 
a BMU close to their homes, and they receive standardized treatment. In children under 8 
years of age, they receive rifampicin, pyrazinamide and isoniazid for 2 months (initial phase) 
followed by rifampicin and isoniazid for 4 months (continuation phase). In children 8 years 
and above, treatment is similar except that ethambutol is added in the initial phase to make 
a total of four drugs. In the GH in Cotonou, regimens are sometimes different, and not always 
standardized. For diagnosis, less than USD$1 is usually, but not necessarily, required for 
payment for sputum smear examination. Treatment is free and TB drugs are only provided by 
the NTP (they are not available in private pharmacies). Treatment outcomes are monitored 
through the use of treatment cards and paper registers, and cases and their outcomes are 
reported through quarterly reports.
For healthy children aged less than 5 years and living in the same household than an adult 
with sputum smear positive TB, they are given Isoniazid preventive therapy for 9 months.
Cotonou: The study took place in Cotonou, the economic capital of Benin and its suburbs. 
The population of the city was about 1 million habitants. As with all large cities of the region, 
it has expanded far beyond its administrative boundaries. There are five BMUs in Cotonou, 
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and all have a TB register and use TB treatment cards. In the general hospital there are a 
pediatric department and a pediatric surgery department where children are also diagnosed 
and treated for TB.
PATIENTS 
All children, aged from 0 to 14 years, who were diagnosed and treated for TB in Cotonou 
and its suburbs between 1st January 2009 and 31st December 2011 were included in the 
study.  Children who received TB preventive treatment with isoniazid during this time were 
not included.
DATA VARIABLES, SOURCE OF DATA AND DATA COLLECTION TOOL
Sources of data were the TB registers in the NTP and the medical files in the general 
hospital. Diagnosis is made by general practitioners and chest physicians in the NTPs and by 
pediatricians in the GH. Data from each individual patient were collected on a standardized 
paper-based study questionnaire. Each data variable was collected by two different 
investigators in order to avoid errors.
Data variables collected were: the epidemiological characteristics of the child (sex, age), the 
type and category of TB, HIV status (positive, negative, indeterminate and unknown) and 
standardized treatment outcomes. For these variables, standardized definitions of the Union 
and the World Health Organization were used [6]. In case that the treatment outcome was not 
known, it was classified as “unknown”. Treatment outcomes were “successful” if the children 
were cured or had completed treatment, and were “unsuccessful” if the children died, were 
lost-to-follow-up, failed, were transferred out or unknown. Finally, a child was classified as 
“still on treatment” if treatment had not yet finished.
ANALYSIS AND STATISTICS:
Data from the questionnaire were double entered into an electronic file (EpiData). We used 
frequency analysis and analysed demographic, clinical characteristics and site of diagnosis 
and care in relation to TB treatment outcomes using the chi-squared test, relative risks (RR) 
and 95% confidence intervals (95% CI). Comparisons are made in Epi info version 6.04dfr. 
Levels of significance were set at 5%.
ETHICS:
This study was approved by the Ethics Advisory Board of the Union and the NTP staff of Benin.
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RESULTS
EPIDEMIOLOGICAL CHARACTERISTICS
The number of children, all forms, treated for TB in Cotonou from 2009 to 2011 was 182 (67, 
42 and 73 cases respectively in 2009, 2010 and 2011). This represented 4.5% of all notified TB 
cases per year (Table 1). 
Table 1: Tuberculosis cases, all forms and childhood, in Cotonou, Benin, 2009-11.
Total Number of TB 
cases notified
Total number of pediatric 
TB cases
Proportion of pediatric 
TB among total TB (%)
2009 1503 67 4.5
2010 1383 42 3.1
2011 1495 73 4.9
Note: TB= Tuberculosis.
The incidence rate of notified TB cases among children in Cotonou was between 8 and 13 
per 100,000, much lower than what was observed in adults group in this city (p<0.01). These 
reported cases were higher among children over 5 years-old (Table 2). One hundred and fifty-
three children (84%) were treated in the NTP facilities, and 29 children (16%) were followed 
up in the GH and not registered. Thus, during these three years, at the NTP level, 16% of all 
TB cases notified among children were missed because not registered. The sex ratio (male 
/ female) was 0.94. Fifty-eight (32%) children were aged less than 5 years while 124 children 
(68%) were between 5 and 14 years old.
Table 2: Estimated population, notified TB cases and incidence of TB in childhood, Cotonou, 
Benin, 2009-11.
Estimated children 
population*
Notified cases Incidence Incidence of
notified cases
(/100,000 
adults)
Age 
(Year)
Total < 5 5-14 Total <5 5-14 Total <5 5-14 p ≥ 15 p **
2009
2010
2011
506728
517046
527267
194709
199850
204404
312019
317196
322863
67
42
73
17
16
25
50
26
48
13.2
8.1
13.8
8.7
8.0
12.2
16.0
8.2
14.9
<0.01
0.01
<0.01
177.7
160.5
165.5
<0.01
<0.01
<0.01
* Source: From statistical yearbook of Health Ministry of Benin, 2009, 2010 and 2011; ** Comparison is made 
between the incidence rate of notified cases among children and adults; TB = tuberculosis.
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DIAGNOSIS OF TB 
Table 3 shows TB case notifications by place of treatment (NTP facilities, GH or all sites) 
stratified by age, sex, type of TB and HIV status. There were 5 times more patients in the 
NTP facilities than in the GH. In comparing the type of TB diagnosed between the NTP 
facilities and the GH, there were significantly more new sputum smear positive TB (SS+) 
patients diagnosed in NTP facilities (p<0.01), and in contrast there were significantly more 
extrapulmonary tuberculosis (EPTB) cases diagnosed in the GH (p<0.01). The result of HIV test 
was known for 167 (92%) children, and was positive for 49 (29%). Significantly more children 
in the GH did not have their HIV status assessed compared with NTP facilities (p<0.01).
Table 3: TB cases in children stratified by age, sex, type of TB and HIV status, Cotonou, Benin, 
2009-11.
Place NTP facilities
N (%)
General Hospital
N (%)
All sites
N (%)
p value
Number 
evaluated
153 29 182 
Age in 
years
0 – 4
5 – 14
45 (29)
108 (71)
13 (45)
16 (55)
58 (32)
124 (68)
0.08
0.08
Sex Male
Female
73 (48)
80 (52)
15 (52)
14 (48)
88 (48)
94 (52)
0.69
0.69
Type of 
TB
New SS+
New SS-
New EPTB
53 (35)
69 (45)
31 (20)
03 (10)
12 (41)
14 (49)
56 (31)
81 (44)
45 (25)
<0.01
0.71
<0.01
HIV status Positive
Negative
Unknown
43 (28)
106 (69)
04 (3)
06 (21)
12 (41)
11 (38)
49 (27*)
118 (65)
15 (8)
0.41
<0.01
<0.01
Note: SS+: Sputum Smear Positive TB; SS-: Sputum Smear Negative TB; EPTB: Extra Pulmonary TB; 
TB: Tuberculosis; NTP = National TB Programme; GH: General Hospital.
* HIV positive was 27% among the overall 182 cases but was 29% when taking only the 167 tested patients 
into account.
Table 4 shows the number of children with different types of EPTB. There were 45 children 
with just EPTB in one site, 34 children with pulmonary TB and EPTB (who were in fact 
registered as having pulmonary TB) and 3 children with EPTB in 2 sites. The most common 
sites for EPTB were lymph node, vertebral and pleural.
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Table 4: Number of patients with extrapulmonary tuberculosis according to site of disease, 
Cotonou, Benin 2009-11.
N %
Lymph node 
Vertebral
Pleural
Miliary 
Peritoneal 
Bone (except vertebral)
Neuro-meningeal
Pericardial
Cutaneous
Renal
22
20
17
9
4
3
2
2
2
1
27
24
21
11
5
4
2
2
2
1
Total 82 100
Note: TB= Tuberculosis.
TREATMENT OUTCOMES 
Of the 182 patients diagnosed, 163 children ended their treatment, and 19 children were 
still under treatment. Treatment outcomes stratified by place, age, sex, type of TB and 
HIV status are shown in Table 5. The cure rate was higher among children in NTP facilities 
compared with those from the GH (p<0.01), where the rate of unknown outcome was higher. 
In comparing successful (cure and/or treatment completed) and unsuccessful (death, loss-
to-follow-up and unknown) treatment outcomes between the different groups, successful 
treatment outcomes were lower in SS- compared with SS+ (RR 0.72, 95% CI 0.58-0.90 p<0.01) 
and were lower in HIV-positive compared with HIV-negative children (RR 0.73, 95% CI 0.56-
0.96, p<0.01). All of these co-infected children were on Cotrimoxazole preventive therapy. 
Unfortunately we didn’t collect information about their antiretroviral treatment during this 
study. Otherwise there were no significant differences between the groups.
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Table 5: Distribution of treatment outcomes stratified by place of treatment, age, sex, type of 
tuberculosis and HIV status, Cotonou, Benin, 2009-11.
Category Total 
number
Cure and/or 
treatment 
complete
N (%)
Death
N (%)
LTFU
N (%)
Unknown
Outcome
N (%)
All cases
Place
All cases
NTP facilities
General 
Hospital
163 *
138
25
118 (72)
109 (79)
9 (36)
14 (9)
12 (9)
2 (8)
12 (7)
10 (7)
2 (8)
19 (12)
7 (5)
12 (48)
Age 0-4 yrs
5-14 yrs
52
111
34 (65)
84 (76)
6 (12)
8 (7)
5 (10)
7 (6)
7 (14)
12 (11)
Sex Male
Female
79
84
60 (76)
58 (69)
5 (6)
9 (11)
4 (5)
8 (10)
10 (13)
9 (11)
Type of 
TB
New SS+
New SS-
New EPTB
49
71
43
42 (86)
44 (62)
32 (74)
3 (6)
9 (13)
2 (5)
0 (0)
9 (13)
3 (7)
4 (16)
9 (13)
6 (14)
HIV 
Status
Positive
Negative
Unknown
45
104
14
26 (58)
82 (79)
0 (0)
6 (13)
8 (8)
10 (71)
5 (11)
5 (5)
2 (14)
8 (18)
9 (9)
2 (14)
Note: SS+: Sputum Smear positive case; SS-: Sputum Smear Negative case; EPTB: Extra Pulmonary case; 
Tuberculosis; TB: Tuberculosis; NTP: National Tuberculosis Programme; LTFU: Loss to follow-up. * = number of 
children who completed follow up for treatment.
DISCUSSION
This study is the first in Benin which describes the burden of TB and treatment outcomes 
among children in the capital city, Cotonou, and this in turn has a direct influence on 
the national results. The main findings were a low rate of children being treated for TB 
(less than WHO estimates) and a higher proportion of these children being in the older 
age group of 5-14 years. About 16% of children were diagnosed and treated in the GH 
and were not notified. They contribute to the underreporting on the true burden of 
childhood TB in Cotonou and Benin. Furthermore, a higher proportion of children at 
the GH was diagnosed with extra-pulmonary disease, so this type of TB is particularly 
underreported. In addition, this situation may also relate to misdiagnosis because of lack 
of training of health care workers on TB in children. Actually, trainings on TB mostly 
emphasize on adults SS+ detection.
There are conflicting reports from elsewhere of TB prevalence being higher in younger 
children [7 - 12]. Although younger children are at greater risk of getting active TB once 
infected with Mycobacterium tuberculosis, they were underrepresented in our study 
because of misdiagnosis [13 - 16]. For example, younger children presenting with acute 
pneumonia or malnutrition are most likely to be missed (because clinical overlap with 
other common child illness) and to die with TB. In addition, collecting adequate sputum 
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specimens in this young age group is very difficult and remains the challenge. There are 
increasing data, advocating for the implementation of other sampling methods such as 
induced sputum in primary level heath care settings. [17,18].
This study took place in an urban setting with a low rate. We assume that this rate is even 
lower in rural settings because of shortage of specialists and difficulties to access health 
care services.
The predominance of lymph node, pleural and spinal sites among EPTB was similar to 
that reported in Malawi [4]. We found TB meningitis to be rare, in contrast to higher 
rates reported elsewhere [19]. Reasons relate to difficulties in confirming the diagnosis 
and to BCG coverage, which is almost 100% in Benin, and which protects children against 
severe forms of TB such as TB meningitis and miliary disease [20, 21]. 
Surprisingly, although Benin is not a high burden country (1.7%), HIV seroprevalence 
among children with TB was high (29%). Moreover, it was much higher than adults’ 
(15%). There is a substantial limitation to our study because of unreported data on 
antiretroviral therapy treatment (ART). However overall, WHO recommendations for 
ART are applied. The number of maternity wards involved in Preventive Mother-To-
Children Treatment is increasing (61% in 2012) and there is a transition to three drugs 
prophylaxis. But efforts are still requiring in obtaining the total coverage of pregnant 
women (51% in 2010).
Treatment outcomes were reasonable. The overall treatment success rate was higher 
than that reported in Malawi [22], but lower than in Djibouti in 2010 at 84% [23]. A 
higher treatment success rate of 86% in SS+ cases was close to that reported for adults 
at 90% [1], and overall better treatment outcomes could be obtained through better 
monitoring systems to reduce the losses to follow-up and unknown outcomes and possibly 
by more accurate diagnosis. For example, unknown outcomes were particularly common 
in children registered and treated at the GH. This may be related to either misdiagnosis 
(with consequently discontinuation) or lack of information on the treatment course 
duration. So, referring children to BMUs (where health care workers use to search for 
patients who loss to follow-up) for their treatment monitoring might be seek. Obviously, 
appointments will be also set with the GH practitioner.
Not surprisingly, worse outcomes were observed in SS- and HIV infected children because 
it could remain a doubtful diagnosis of TB in both cases.
In conclusion, childhood TB makes up a small proportion of all reported TB cases in 
Cotonou, Benin. Similarly, while treatment outcomes are reasonable, especially for SS+ 
THE BURDEN AND OUTCOMES OF CHILDHOOD TUBERCULOSIS IN COTONOU, BENIN
99
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
cases, there needs to be better follow-up and monitoring during treatment to reduce 
the high burden from loss-to-follow-up and unknown outcomes. For case notification 
and treatment outcomes there needs to be better collaboration between the NTP and 
the GH. 
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ABSTRACT
Objective: To determine among retreatment tuberculosis patients in Benin baseline 
characteristics, culture and drug sensitivity testing (DST) results and treatment outcomes.
Materials and Methods: A retrospective national cohort study of all retreatment tuberculosis 
patients in Benin in 2013 using registers and treatment cards.
Results: Of 3957 patents with tuberculosis, 241 (6%) were retreatment cases. Compared 
to New Pulmonary Bacteriologically Confirmed Tuberculosis (NPBCT) patients, there were 
significantly higher numbers of males (P=0.04), patients from “Atantique-Littoral” (P=0.006), 
patients aged 45 - 64 years (P=0.007) and HIV-positive patients (P=0.04) among those 
retreated. Overall, 171 (71%) patients submitted sputum for DST, of whom (163) 95% were 
positive for Mycobacterium tuberculosis on Xpert MTB/RIF and/or culture, 17 (10%) were 
rifampicin resistant (9 with MDR-TB and 8 mono-resistant to rifampicin). For those without 
MDR-TB (n=224), treatment success was 93%. Worse outcomes occurred in those with 
unknown HIV-status (RR: 0.27; 0.05 – 1.45; P<0.01) while better outcomes occurred in those 
who relapsed (RR: 1.06, 95CI: 1.02 - 1.10, P=0.04).
Conclusion: In 2013, a high proportion of retreatment patients received DST. Treatment 
success was good although more needs to be done to systematically increase the final 
follow-up smear examination. Reasons of high losses-to-follow up from “Oueme-Plateau” 
should be investigated.
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INTRODUCTION
Patients with retreatment tuberculosis (TB) represent those who have been treated previously 
for one month or more with anti-TB drugs and who have been diagnosed once again with the 
disease. These patients mainly include relapses, treatment after failure or loss to follow-up on 
a first line treatment regimen [1]. The number of these patients is not negligible. In 2014, of the 
6.3 million TB cases that were notified by National TB Programmes (NTPs) to the World Health 
Organization (WHO), approximately 700,000 patients were already previously treated [2].
Interest in this category of TB comes from the fact that patients are known to have a higher 
risk of drug resistance compared with new cases. Therefore, in addition to recommendations 
that all TB patients be screened for Human Immunodeficiency Virus (HIV) co-infection, NTPs 
have been advised since 2010 by WHO to systematically test at diagnosis all retreatment 
TB patients for culture and drug susceptibility (DST with genotypic and/or phenotypical 
methods), in order to detect resistance to rifampicin which is usually synonymous with 
Multidrug Resistance (MDR, strictly defined as resistance of Mycobaterium tuberculosis to 
both rifampicin and isoniazid) [3, 4]. Unfortunately, there is concern about implementation 
of this recommendation as only 58% of all retreatment TB patients in the world were tested 
for drug resistance in 2014 [2]. Improving this proportion in the future requires an analysis of 
the situation at country levels.
In Benin, a sub-Saharan country that reports approximately 40 incident TB cases per 100,000 
people per year, retreatment patients account for less than 10% of all notified TB cases. 
Unfortunately, there is dearth of information on the epidemiological characteristics and HIV-
status of these patients in annual reports in the country [5]. Two previous studies, which 
were only conducted in Cotonou, the economic capital and which had included retreatment 
patients diagnosed in the periods of 1992-2001 and 2005-2009 respectively, reported a high 
loss to follow-up of 12%, with a treatment success of retreatment cases significantly lower 
than new cases. Moreover, the majority of these patients recorded as “loss to follow-up” 
during the retreatment initially had also defaulted from their first line treatment [6, 7]. DST 
in retreatment cases was also only performed in early 2003 in those patients registered in 
Cotonou that also houses the “Laboratoire de Référence des Mycobactéries (LRM)”.
The current study was therefore undertaken in the whole country to determine the principal 
characteristics of retreatment patients, to assess how well DST was performed in this 
category of patients and whether there was any change in their treatment outcomes. Specific 
objectives were to determine among retreatment TB patients diagnosed and treated in 2013 
in Benin: i) The epidemiological, clinical and geographical characteristics and HIV-status 
of these patients and compared to those registered with New Pulmonary Bacteriologically 
Confirmed TB (NPBCT); ii) The proportion with DST results available along with the proportion 
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showing resistance to rifampicin; iii) Treatment outcomes of these patients compared with 
NPBCT cases; and iv) Factors associated with a successful treatment outcome.
MATERIALS AND METHODS
STUDY DESIGN 
This was a retrospective cohort study using routinely collected data.
GENERAL SETTING AND STUDY SITES
Country: Benin is a small low-income country in West Africa with a population of 10,315,244 
inhabitants in 2015 [8]. The country shares borders with Burkina Faso and Niger in the north, 
Togo in the west, Nigeria in the east. Benin is a low-income country with a gross national 
income per capita of US$1780 in 2013 and an under-five mortality rate of 85 per 1000 live 
births [9].
National TB Programme & Management of patients with a previous history of TB. The 
country follows the WHO DOTS strategy for diagnosis and treatment of TB patients [4]. All 
patients with a previous history of TB and who return to the health facility for presumptive 
symptoms of the disease are requested to provide two sputum samples on two consecutive 
days for acid-fast bacilli microscopy. Sputum samples are routinely examined using 
auramine-phenol staining and fluorescence microscopy. The diagnosis is confirmed by a 
positive result for acid-fast bacilli on sputum smears. Sputa of all confirmed retreatment 
TB cases in the 57 Basic Management Units (BMUs) are then sent by laboratory technicians 
using cetylpyridinium chloride solution to the LRM for both Xpert MTB/RIF and culture on 
Lowenstein-Jensen media. All retreatment TB patients, except those diagnosed in Cotonou, 
start on a standardised regimen of retreatment [3]. When the result of Xpert MTB/RIF is 
available (this usually takes some days or weeks), those who are found sensitive to rifampicin 
continue the standardised regimen. On the other hand, patients with resistance to rifampicin 
are switched to a MDR-TB treatment regimen.
Because of the closeness of the LRM, patients treated in Cotonou do not start TB treatment 
unless their Xpert MTB/RIF is available. This takes approximately 24 hours. The standardised 
retreatment regimen consists of an initial phase of rifampicin, isoniazid, ethambutol and 
pyrazinamide for 3 months (with streptomycin added during the first 2 months) followed by 
a continuation phase using the first three anti-TB drugs for 5 months [3]. The treatment is 
strictly directly observed during the initial phase. Patients with resistance to rifampicin are 
treated with a shortened 9-month regimen recommended by the International Union Against 
Tuberculosis and Lung Disease [10]. During retreatment of rifampicin sensitive patients, 
sputum samples are collected at 3 months, 5 months and at the end of the treatment for 
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microscopy. Treatment is monitored through the use of treatment cards and registers. 
A quarterly supervision of all the 57 BMUs is systematically organized by the TB control 
Programme coordination. All retreatment TB patients are systematically offered HIV testing 
at diagnosis. Those who are found co-infected receive cotrimoxazole, and Antiretroviral 
Therapy (ART) is provided within 2 weeks to 2 months after TB treatment initiation [11].
All molecular tests, culture, DST, TB treatment, cotrimoxazole and ART are provided free of 
charge. Anti-TB and ARV drugs are not available in private pharmacies.
STUDY POPULATION
All retreatment TB patients diagnosed and treated between January and December 2013 
were included in the study.
DATA VARIABLES, SOURCES OF DATA, DATA COLLECTION TOOLS AND DEFINITION OF 
VARIABLES
For each retreatment TB case, data were collected on epidemiological characteristics, region, 
HIV-status, type of retreatment, ART status for HIV-positive patients, Xpert MTB/RIF results, 
culture and DST results, and treatment outcomes. Sources of data were TB registers and TB 
treatment cards. Xpert MTB/RIF, culture and phenotypical DST results were extracted from 
a laboratory Excel file. For comparison, aggregate data of NPBCT patients were collected 
from the annual report. Data on patients were collected into a paper based questionnaire. 
Because of the retrospective nature of this study, data validation was not possible. The 
definitions of the NPBCT, the different types of previously treated patients and the treatment 
and outcomes are explained in the Box.
ANALYSIS AND STATISTICS
Data from the questionnaire were double entered into an electronic file using EpiData 
software and analysed using this software (EpiData version 3.1 for entry and version 
2.2.2.182 for analysis, EpiData Association, Odense, Denmark). Data were analysed by using 
frequencies and percentages. Comparisons between categorical variables were done using 
the chi-square test and risk ratios as appropriate with 95% confidence intervals. Levels of 
significance were set at 5%.
ETHICAL CONSIDERATIONS
The study was approved by the Benin NTP Coordination and the ‘‘Ethics Advisory Group’’ of the 
International Union against Tuberculosis and Lung Disease, Paris. Because of its retrospective 
nature, approval from the national ethics committee (‘‘Comité National d’Ethique pour la 
Recherche en Santé’’) was not required according to the country’s recommendations.
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RESULTS
In 2013, 241 retreatment TB patients were diagnosed and treated in Benin on the basis of 
a positive result for acid-fast bacilli using sputum smear microscopy. They represented 6% 
of the 3957 total TB cases notified in the country in the same time-period. Demographic 
characteristics and HIV-Status of these patients were compared to those reported from 
NPBCT and are shown in Table 1. There were significantly more males (P=0.04), patients from 
the “Atantique-Littoral” (P=0.006), patients aged between 45 and 64 years-old (P=0.007) and 
HIV-positive patients (P=0.04) among retreatment TB cases compared to NPBCT patients. 
On the other hand, patients younger than 24 years were significantly less common among 
previously treated patients (P<0.001). 
Table 1: Demographic characteristics and HIV-status of new pulmonary bacteriologically 
confirmed and retreatment tuberculosis patients, Benin, 2013.
NPBCT * Retreatment TB p value
Total 3129 241
Sex Male
Female
2063 (65.9)
1066 (34.1)
175 (72)
67 (28)
0.04
0.04
Age (years) 00 – 24
25 – 44
45 – 64
65 and above
600 (19.2)
1705 (54.5)
676 (21.6)
148 (4.7)
21 (8.7)
136 (56.6)
70 (28.9)
14 (5.8)
0.00005
0.55
0.007
0.43
Region Atacora-Donga
Borgou-Alibori
Zou-Collines
Mono-Couffo
Oueme-Plateau
Atlantique-Littoral
199 (6.4)
231 (7.4)
416 (13.3)
486 (15.5)
708 (22.6)
1089 (34.8)
14 (5.8)
13 (5.4)
33 (13.7)
29 (12)
47 (19.5)
105 (43.6)
0.72
0.24
0.86
0.14
0.26
0.006
HIV-Status HIV positive
HIV negative
Unknown
396 (13.5*)
-
-
43 (18.2**)
193 (82)
5 (2.4)
0.04
-
-
Note: NPBCT=New Pulmonary Bacteriologically Confirmed Tuberculosis. TB=Tuberculosis. * Of the 2934 new 
pulmonary bacteriologically confirmed tuberculosis patients who underwent the HIV test, 396 were found 
positive.
** Of the 236 retreatment tuberculosis patients who underwent the HIV test, 43 were found positive.
Demographic characteristics and HIV-status of the different types of retreatment TB cases 
are compared in Table 2. “Oueme-Plateau” reported significantly more “treatment after 
loss to follow-up cases” (P<0.001) while “Atlantique-Littoral” reported more “relapse cases” 
(P=0.04). In addition, significantly more males were found in “treatment after loss to follow-
up” (P=0.03). Otherwise, no significant differences were found.
CHARACTERISTICS AND TREATMENT OUTCOMES OF RETREATMENT TUBERCULOSIS PATIENTS IN BENIN
109
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
Table 2: Demographic characteristics and HIV-status of the different types of retreatment 
tuberculosis patients, Benin, 2013.
Relapse Failure Treatment after 
loss to follow-up
p value
Total 147 78 16
Sex Male
Female
102 (69.4)
45 (30.6)
56 (71.8)
22 (28.2)
16 (100)
-
0.03
0.03
Age (years) 00 – 24
25 – 44
45 – 64
65 et +
10 (6.8)
86 (58.5)
42 (28.6)
9 (6.1)
10 (12.8)
42 (53.8)
22 (28.2)
4 (5.1)
1 (6.3)
8 (50)
6 (37.5)
1 (6.3)
0.29
0.69
0.74
-
Region Atacora-Donga
Borgou-Alibori
Zou-Collines
Mono-Couffo
Oueme-Plateau
Atlantique-Littoral
8 (5.4)
7 (4.8)
16 (10.9)
16 (10.9)
27 (18.4)
73 (49.7)
6 (7.7)
6 (7.7)
16 (20.5)
12 (15.4)
10 (12.8)
28 (35.9)
0
0
1 (6.3)
1 (6.3)
10 (62.5)
4 (25)
-
-
0.09
0.46
<0.001
0.04
HIV-Status HIV positive
HIV negative
Unknown
27 (18.4)
116 (78.9)
4 (2.7)
14 (17.9)
63 (80.8)
1 (1.3)
2 (12.5)
14 (87.5)
0
0.84
0.70
-
Note: NPBCT=New Pulmonary Bacteriologically Confirmed Tuberculosis. TB=Tuberculosis. * Of the 2934 new 
pulmonary bacteriologically confirmed tuberculosis patients who underwent the HIV test, 396 were found 
positive.
** Of the 236 retreatment tuberculosis patients who underwent the HIV test, 43 were found positive.
The results of Xpert MTB/RIF and/or Mycobacterium tuberculosis culture among retreatment 
TB patients and rifampicin sensitivity are presented in Table 3. Overall, 71% of the 241 
retreatment TB patients submitted their sputum for DST, and 95% of these patients showed 
a positive result on Xpert MTB/RIF and/or culture for M. tuberculosis. Of these patients, 17 
(10%) were found to have resistance to rifampicin (9 with MDR-TB and 8 with mono-resistance 
to rifampicin) and they were redirected to a MDR-TB treatment regimen.
Table 3: Retreatment Tuberculosis patients, drug susceptibility testing achieved and bacilli 
sensitivity to rifampicin, Benin, 2013.
Total retreatment TB patients 241
Patients whose specimens were sent to the 
LRM for DST tests (*)
171 (71)
MTB identification after culture and or 
Xpert MTB/RIF §
163 (95)
Xpert (+) Culture (+) (§)
Xpert (+) Culture (-) (§)
Xpert (-) Culture (+) (§)
86 (50)
72 (42)
5 (3)
Resistance to rifampicin (§) 17 ¥ (10)
Note: TB=Tuberculosis; LRM=“Laboratoire de Références des Mycobactéries”; DST=Drug Susceptibility Testing
* The percentage was derived from the total tuberculosis patients retreated.
§ The percentage was derived from the total tuberculosis patients whose sputa were sent and analyzed in the LRM.
¥ Of the 17 patients with resistance to rifampicin, there were 9 multidrug resistant and 8 mono-resistant.
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Treatment outcomes of the remaining 224 retreatment TB patients were compared with 
those for NPCBT cases and the results are shown in Table 4. In 2013, the success rate of these 
patients was 93%. There were significantly more patients who completed their treatment 
without achieving the last follow-up examination, but otherwise there were no other 
differences between the groups.
Table 4: Treatment outcomes of new pulmonary bacteriologically confirmed and retreatment 
tuberculosis patients, Benin, 2013.
NPBCT * Retreatment TB p value
Total  3124 § 224 £
Successful 
outcome
2803 (89.7) 208 (92.9) 0.12
Cure
Completion
2587 (82.8)
216 (6.9)
184 (82.1)
24 (10.7)
0.79
0.03
Unsuccessful 
outcome
321 (10.3) 16 (7.1) 0.13
Failure
Death 
Loss to follow-up
Not evaluated
91 (2.9) 
170 (5.4) 
45 (1.4)
15 (0.5)
3 (1.3)
9 (4)
3 (1.3)
1 (0.4)
0.16
0.37
0.83
0.72
Note: TB: Tuberculosis.
* NPBCT: New Pulmonary Bacteriologically Confirmed Tuberculosis 
§ Of the 3129 new smear positive TB patients treated, treatment outcomes were assessed for 3124 patients 
in 2013.
£ Of the 241 retreatment tuberculosis patients treated, 18 were found multi-drug resistant and did not 
continue the retreatment regimen.
Factors associated with a successful outcome are presented in Table 5. Patients with relapse 
TB had a significantly higher chance of successful treatment outcome (RR: 1.06, 95CI: 1.02 
- 1.10, P=0.04) while those with an unknown HIV status had a worse treatment outcome 
(RR: 0.27; 0.05 – 1.45; P<0.01). In this cohort, in which all but one of the HIV positive patients 
were on ART, no significant difference in treatment success was found between HIV positive 
and HIV negative patients.
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Table 5: Factors associated with a successful treatment among retreatment tuberculosis 
patients, 2013, Benin.
Successful 
Outcome
Risk 
Ratio
[95% CI] p value
Sex Female
Male
60/62 (97.8)
148/162 (91.4)
1
0.94 0.88 – 1.01 0.24
Age group 00 – 24
25 – 44
45 – 64
65 et +
19/19 (100)
117/124 (94.4)
60/67 (89.6)
12/14 (85.7)
1
0.94
0.90
0.86
0.90 – 0.99
0.83 – 0.97
0.69 – 1.06 
0.59
0.34
0.17
Type of TB NPBCT
Relapse
Failure
Treatment after Loss to 
Follow-up
2803/3124 (89.7)
133/140 (95)
63/69 (91.3)
12/15 (80)
1
1.06
1.02
0.89
1.02 – 1.10
0.95 – 1.10
0.69 – 1.15
0.04
0.67
0.19
HIV-Status HIV negative 
HIV positive
HIV-status unknown
169/181 (93.4)
38/39 (97)
1/4 (25)
1
1.04
0.27
0.98 – 1.11
0.05 – 1.46
0.47
0.001
Region Atacora-Donga
Borgou-Alibori
Zou-Collines
Mono-Couffo
Oueme-Plateau
Atlantique-Littoral
13/14 (92.9)
9/11 (81.8)
28/30 (93.3)
27/28 (96.4)
40/42 (95.2)
91/99 (91.9)
1.01
0.89
1.02
1.05
1.04
1
0.86 – 1.18
0.67 – 1.10
0.91 – 1.14
0.96 – 1.15
0.95 – 1.13
1
0.26
1
0.68
0.72
Note: NPBCT: New Pulmonary Bacteriologically Confirmed Tuberculosis; TB: Tuberculosis.
DISCUSSION
The main findings of this study were the predominance of males, adults aged between 45 
and 64 years and HIV-positive status among retreatment TB cases compared with NPBCT 
patients. Most of these previously treated TB patients were reported from “Atlantique-
Littoral” where there were also predominately “relapse cases”. The large majority of patients 
who were reported from “Oueme-Plateau” were recorded as “loss to follow-up” prior to 
treatment, which is a department close to “Atlantique-Littoral” in the southern part of the 
country. Rifampicin sensitivity-status was known in nearly three fourths of patients with 
one tenth of those tested having resistance to rifampicin and therefore requiring a MDR-TB 
treatment regimen. Treatment outcomes of patients who were found without resistance to 
rifampicin were excellent, although some did not achieve the last follow-up sputum smear 
examination after treatment completion. Patients who relapsed had a greater chance of a 
successful treatment outcome, while those with unknown HIV status had worse treatment 
outcomes. 
The strengths of this study were the inclusion of all retreatment TB patients diagnosed 
in the country, and therefore there was no need for any sampling framework. The study 
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report also followed Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines [12]. Data used for this study had been checked and validated during 
regular quarterly supervision of the 57 BMUs from the central unit. Limitations include the 
operational nature of the study and the use of routine data from registers and quarterly 
reports. Some information such as time to relapse after a previous treatment is often missed 
and therefore could not be included in the study.
This is the first assessment one year after the NTP coordination decided as a policy to perform 
DST at diagnosis for all retreatment cases countrywide. Benefits from the implementation 
of such a recommendation can be seen from this study. MDR-TB patients can promptly 
start appropriate treatment without having to start and fail a retreatment regimen, which 
has individual benefits as well as preventing further transmission of drug-resistant TB in the 
community. Studies from India have also shown that this approach improves treatment 
outcomes among previously treated patients [13]. According to our study findings, one 
quarter of the patients did not achieve this goal of DST. The proportion of previously treated 
patients in whom DST has been performed largely varies according to the study settings, 
from less than 10% in the mid-west Nepal to 91% in Sri Lanka [14, 15].
One of the major challenges in achieving DST for all patients that arose from discussions 
with health workers, and that has also been reported elsewhere, is related to transportation 
issues of samples from laboratories in BMUs to the LRM. This is a key step for successful 
implementation of culture and DST, particularly in resources-limited countries. 
In Benin, several options of sample transportation have been tried. In the first option, 
sputum specimens once collected were appropriately packaged in specific boxes in BMUs; 
and during quarterly supervisions, national teams had the opportunity to bring them back to 
the LRM for analysis with results communicated later to the TB health workers in the BMUs. 
The consequences of this approach, however, were the high likelihood of having a negative 
culture due to lengthy times between sputum collection and the plating of specimens on 
Lowenstein Jensen culture media and the subsequent delays in diagnosing and treating 
patients requiring MDR-TB treatment. In the second option, laboratory technicians in BMUs 
were requested to bring to the LRM specimens from patients and they were reimbursed for 
transportation. Unfortunately the high cost of this option did not allow it to continue. The 
third option and the current strategy is to send sputum specimens as soon as these are 
collected to the LRM through public transportation with transportation charges immediately 
refunded at receipt in the LRM. This strategy seems to be working well and contributes 
to an increase in the proportion of retreatment TB patients being tested. For example, 
an assessment of the 2014 programme activities of diagnosis and treatment of TB by the 
International Union Against Tuberculosis and Lung Diseases estimated that 85% and 92% of 
retreatment TB patients in that year submitted sputum specimens to the LRM (Unpublished 
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data. V. Schwoebel. Benin TB control Programme, Annual report N°30. International Union 
against Tuberculosis and Lung Diseases). Finally, the forthcoming decentralization of Xpert 
MTB/RIF machines in regional laboratories will undoubtedly increase the proportion of 
patients having sputum specimens tested and this should accelerate the achievement of 
100% DST.
There are a few other points to note. The proportion of patients requiring a MDR-TB treatment 
regimen in the country in 2013 was not higher in comparison with previous years [16, 17]. A 
predominance of males among retreatment TB cases was found in this study and this has also 
been reported from elsewhere, although the reasons for this are not known [18]. “Atlantique-
Littoral”, which houses Cotonou, the economic capital and the city with the highest density 
of population, always reports the highest number of TB cases in the country; and we are not 
surprised that this is also the case for retreatment TB cases. In terms of treatment outcomes, 
and in comparison with previous reports, there have been improvements. 
We noticed that patients who were recorded as “loss to follow-up” are no longer at higher 
risk of defaulting during their retreatment [6, 7]. The treatment success is also higher than 
that observed elsewhere [13]. Furthermore, of the different types of retreatment TB patients, 
the highest success rate was reported from those who relapsed. Possible reasons for better 
outcomes include a) this is a new exogenous infection with drug-susceptible Mycobacterium 
tuberculosis rather than reactivation of a drug-resistant strain, b) more awareness about TB 
symptoms and treatment management from the first experience with the disease resulting 
in earlier diagnosis. A worse treatment outcome was also reported in patients with unknown 
HIV-Status. In this group, it is possible that an HIV-positive status was known but the patient 
attempted to hide it with a consequent lack of appropriate HIV-care delivery.
The study has some implications for the programme. First, since the large majority of “loss 
to follow-up” patients retreated were from a specific region, there is a need to address the 
reasons why these patients stopped their first line treatment. Second, although the treatment 
success was good, we need to be stricter on ensuring that the last follow-up sputum 
examination is performed as these patients are being treated for the second time and are 
potentially at high risk of drug resistance. Third, although the proportion of TB patients with 
known HIV-status is high (96%) in the country [5], it is important to try to screen all TB cases 
because of the poor treatment outcomes in those with unknown HIV status. 
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CONCLUSION
In 2013, the proportion of retreatment TB patients tested for culture and DST in Benin was 
71%. Although the treatment success of these patients was encouraging, there is room for 
improvement. There is a need to increase the proportion of patients having the last follow-up 
sputum examination and to understand why one of the regions of the country has a sizeable 
number of patients recorded as “loss to follow-up”.
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ABSTRACT
Setting: Centre National Hospitalier de Pneumo-Phtisiologie, Cotonou, Benin.
Objective: To determine the proportion of individuals needing treatment for multidrug-
resistant tuberculosis (MDR-TB) among patients previously treated for TB.
Design: A retrospective cross-sectional study of all patients previously treated for TB in 
Cotonou from 2003 to 2011.
Results: Of 956 patients on retreatment, 897 (94%) underwent culture and/or a line-probe 
assay. For different reasons, 594 (66%) underwent drug susceptibility testing for rifampicin 
(RMP), of whom 95 (16%) had RMP resistance (68 multidrug-resistance [MDR] and 27 other 
RMP resistance) and therefore needed treatment for MDR-TB. These represent 39% of 
patients who failed/relapsed after standardised retreatment, and 20% of those who failed, 
19% of defaulters and 11% of relapses after first-line treatment. Residence outside of Benin 
was associated with a higher risk of RMP resistance (RR 3.13, 95%CI 2.19–4.48, P < 0.01). From 
2003 to 2011, the prevalence of RMP resistance decreased from 25% to 5% among patients 
living in Benin. Human immunodeficiency virus (HIV) prevalence was 25%; no association 
was found between HIV and RMP resistance. Of patients failing treatment, 48% were fully 
susceptible, 22% were monoresistant and 8% polyresistant.
Conclusion: The majority of patients who fail retreatment or first-line treatment in Cotonou 
do not require empirical treatment for MDR-TB.
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INTRODUCTION
In the last decade, the fight against tuberculosis (TB) worldwide has been disrupted because 
of associated HIV infection and multidrug-resistant tuberculosis (MDR-TB), the latter strictly 
defined as resistance of the Mycobacterium tuberculosis to at least rifampicin and isoniazid. 
As a result of these threats, National Tuberculosis Programmes (NTPs) have been advised by 
the World Health Organization (WHO) to develop strategies in order to better detect and treat 
the growing number of MDR-TB cases [1]. According to the WHO report in 2011, there were an 
estimated 650,000 patients with MDR-TB in the world. [2]. 
Management of MDR-TB requires local strategies that identify and diagnose affected patients 
as early as possible. In this regard, patients with resistance to rifampicin only have almost the 
same profile of response to the retreatment regimen using first line anti-tuberculosis drugs 
when compared with patients who have MDR-TB, and it is recommended that these patients 
be regarded as MDR-TB and be treated with an MDR-TB treatment regimen [3].
Since 2009, NTPs have been advised by the WHO to obtain and use their country-specific 
drug resistance data on patients who have failed, relapsed or returned to treatment after 
default to determine levels of MDR-TB in their countries. In settings where this information is 
not available, it is further advised that empirical treatment with MDR-TB treatment be started 
among all failure cases [4]. 
Using data from TB patients in Benin, the aim of the current study was to report on the 
spectrum of failure, relapse and treatment after default in patients previously treated for 
tuberculosis, and determine the drug-sensitivity patterns of these patients to assess whether 
it is correct to treat all failure patients with an empirical MDR-TB treatment regimen. The 
specific objectives of the study were to determine over 9 years from 2003 to 2011 in retreatment 
patients (stratified by types of retreatment):- i) the proportions with sputum submitted for 
culture and/or rapid test for resistance, drug sensitivity tests and resistance to rifampicin 
and/or isoniazid, ii) the pattern of drug resistance in relation to country of residence, iii) the 
association of drug resistance with HIV status and iv) other patterns of drug resistance. 
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STUDY POPULATION, DESIGN AND METHODS
STUDY DESIGN
This was a retrospective study involving a review of records.
SETTING – GENERAL AND STUDY SITE
Country: Benin is a country in West Africa with a population of 9 million. The country 
registers about 3,500 TB patients each year, of whom just under 10% have been previously 
treated. The TB programme follows the DOTS strategy and uses recognised international 
criteria for the diagnosis and the treatment of patients with TB [5,6]. Diagnosis, registration 
and care are decentralised to 57 Basic Management Units (BMUs) in the country. Cotonou, 
the main city of the country, is served by 3 BMUs, including the Centre National Hospitalier de 
Pneumo-phtisiologie (CNHPP). This centre is also the largest BMU in the country and houses 
the TB programme staff. Almost all patients under retreatment in Cotonou are registered and 
treated in this centre. Because of its good reputation and its geographic situation, the CNHPP 
also receives patients from other countries, especially Nigeria.
TB Control: In Cotonou, since 2003, smear-positive patients with a previous history of TB 
were requested to provide sputum for culture and DST; such patients are classified into 
failure, relapse and treatment after default according to national and international guidelines 
[5,6]. The “classical” retreatment regimen is prescribed: an initial phase of rifampicin, 
pyrazinamide, isoniazid and ethambutol for 3 months (with streptomycin in addition 
during the first two months) followed by a continuation phase of rifampicin, isoniazid and 
ethambutol for 5 months. All cultures, DST and/or molecular tests and anti-TB drugs are free 
of charge. Patients with MDR and other rifampicin-resistances are treated with a shortened 
9-months regimen recommended by the Union. They daily take under direct observation 
gatifloxacin, prothionamide, ethambutol, clofazimine, pyrazinamide for nine months (with 
in addition kanamycin and isoniazid the first four months). Since February 2013, gatifloxacin 
was replaced by moxifloxacin. MDR Anti-TB drugs are only provided by the NTP and are not 
available in private pharmacies of the city.
Mycobacteria Reference Laboratory (MRL): Standard culture and DST are performed 
in the MRL. After decontamination by the modified Petroff method, sputum is cultured 
on a solid medium (Löwenstein-Jensen) in two tubes. Whenever the culture is positive, 
mycobacteria are identified using thiophene-2-carboxylic acid hydrazide (TCH) medium and 
biochemical tests such as nitrate reductase test, niacin test and catalase at 68°C test. When 
the identification test is positive for Mycobacterium tuberculosis complex, DST is performed 
against rifampicin (RMP), isoniazid (INH), streptomycin (SM) and ethambutol (EMB) using the 
proportion method. The concentrations used are RMP 40 µg/ml, INH 0.2 µg/ml, SM 4 µg/ml 
and EMB 2 µg/ml. Since 2009, the Hain test for rifampicin and Isoniazid has also been used 
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for the rapid detection of resistance to these drugs. The quality of the laboratory is regularly 
assessed by the Mycobacteriology Laboratory of the Institute of Tropical Medicine of Antwerp 
(Belgium), as a supranational laboratory, and control tests show excellent results.
PATIENTS
All patients with sputum smear positive and a previous history of TB (this includes failure after 
new treatment, relapse after new treatment, default after new treatment, and TB patients 
returning after retreatment) and registered in the CNHPP from 2003 to 2011 were included in 
this study.
DATA VARIABLES, SOURCE OF DATA AND COLLECTION TOOL AND DATA VALIDATION
An electronic database has been constructed from the TB register, and all previously treated 
TB patients were systematically entered into this database. DST results were entered later. 
Data variables collected included epidemiological characteristics (sex, age, living in or 
outside of Benin), diagnostic characteristics (type of patient, HIV status), culture results, DST 
results for rifampicin, isoniazid and other antibiotics. In case of discordance between culture 
and molecular test results, the culture is used as the gold standard.
ANALYSIS AND STATISTICS
Data were transferred into an EpiData record file for analysis. We used frequency, percentage 
and proportions to describe the population of patients. Comparisons were made with the 
chi-square test. Levels of significance were set at 5%. 
ETHICS
The study was approved by the NTP Management and the Ethics Advisory Board of the 
International Union against Tuberculosis and Lung Disease. It did not involve direct 
interaction with human subjects and therefore minimal risks.
RESULTS
PATIENT CHARACTERISTICS AND RESULTS OF SPUTUM CULTURE AND DST
There were 956 patients, mean age 36 years, male/female ratio of 3.0, who were started on 
a retreatment regimen. This represented 10% of 9,604 patients with all forms of TB treated 
in the Centre, 97% of 985 previously treated patients in Cotonou and 40% of 2516 previously 
treated patients registered in Benin during the same time period.
The number of retreatment cases and the numbers and proportions with a culture and/or 
Hain test, a DST result for rifampicin and evidence of resistance to rifampicin, stratified by 
different categories of retreatment are shown in Table 1. A high proportion (94%) of patients 
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provided sputum for culture and/or Hain test and 66% of those had a DST for rifampicin. The 
culture contamination rate was low at 2.6%. A total of 68 patients (11% of those with a DST 
for rifampicin) had MDR-TB, with the highest rates being seen in those failing or relapsing 
smear-positive after a retreatment regimen or failing on the first line treatment. In addition, 
27 patients (5%) had resistance to rifampicin without resistance to isoniazid. Altogether, 
there were 95 patients (16% of those with a DST for rifampicin), mean age 34 years, male/
female ratio of 4.6, who were diagnosed as having resistance to rifampicin and required a 
MDR-TB treatment regimen. 
Table 1: Retreatment patients and their culture and DST results in relation to different types of 
retreatment in Cotonou, Benin, 2003-11.
Failure after 
new TTT
Relapse 
after new 
TTT
Default 
after new 
TTT
After re-TTT 
(Failure relapse)
Total
All patients on 
retreatment
175 470 263 48 956
Patients with culture 
and/or Hain test 
performed
165 (94*) 440 (94*) 248 (94*) 44 (92*) 897 (94*)
Patients with a DST 
result for R (culture 
and/or Hain)
94 (100**) 300 (68**) 172 (69**) 28 (64**) 594 (66**)
MDR (%**) 18 (19) 22 (7) 21 (12) 7 (25) 68 (11)
RR (%**) 1 (1) 11 (4) 11 (6) 4 (14) 27 (5)
RR + MDR (%**) 19 (20) 33 (11) 32 (19) 11 (39) 95 (16)
Note: R= Rifampicin; MDR= Multi Drug Resistance; DST = drug sensitivity; R = rifampicin; RR = Resistance to 
Rifampicin (without MDR); TTT = Treatment; Re-TTT = Retreatment.
* Percentage was calculated from all patients under retreatment
** Percentage was calculated from patients who had culture and/or Hain test performed.
Final diagnosis of resistance to rifampicin was established with phenotypic method for 92 
patients and Hain test for 3 (Figure 1).
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r 5Figure 1. Number of patients with rifampicin resistance stratified by the different methods of DST among 
retreatment patients.
Note: MDR: Multi Drug Resistance; RR: Resistance to rifampicin (without MDR)
DISTRIBUTION OF PATIENTS ACCORDING TO THE PLACE OF RESIDENCE AND TRENDS
Place of residence (in or out of Benin) of patients with resistance to rifampicin in relation to 
different types of retreatment is shown in Table 2. Most patients (73%) were living in Benin 
with the remainder having their permanent address outside the country, mostly in Nigeria. 
The proportion of patients having MDR-TB was higher in those with a permanent address out 
of Benin (31% versus 11%, p<0.01), and this difference was maintained when stratified by 
different types of retreatment: results for failures and defaulters being 54% Vs 15% (p<0.01) 
and 27% Vs 7% (p<0.01) respectively. 
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Table 2: Patients with resistance to rifampicin and the relationship between types of 
retreatment and residence inside or outside of Benin, Cotonou, 2003-2011.
Type of retreatment patient
Failure after 
new TTT
Relapse after 
new TTT
Default after 
new TTT
After re-TTT Total
N     n (%)* N     n (%)* N     n (%)* N     n (%)* N     n (%)*
Benin 88 12 (15) 270 26 (10) 71 5 (7) 19 5 (26) 441 48 (11)
Outside Benin 13 7 (54) 30 7 (23) 101 27(27) 9 6 (67) 153 47 (31)
Note: TTT: Treatment; re-TTT: Retreatment ; N: Total number of patients with a result for rifampicin after 
culture and/or Hain test; n: total number of patients with resistance to rifampicin.
* Indicates the proportion of patients with a DST for rifampicin who had resistance to rifampicin.
The annual numbers of retreatment cases with culture, DST and MDR-TB results 
between 2003 and 2011 for those living in and outside of Benin are shown in Table 3 
and Figure 2. The number of retreatment cases living in Benin remained stable during 
the time period, but the proportion with MDR-TB decreased from 25% in 2003 to 5% in 
2011. For patients living outside Benin, the numbers of retreatment cases declined over 
time, but the proportion with MDR-TB remained high at between 30% – 50%.
Table 3: Retreatment cases, culture and DST and MDR-TB, stratified by residence inside or 
outside of Benin and year. Cotonou, 2003-11.
Benin Outside Benin
Re-
TTT
Culture 
and/or 
Hain test 
performed 
n (%*)
Patients 
with DST 
for R after 
Culture or 
Hain test   
n (%**)
MDR or 
RR 
n (%***)
Re-
TTT
Culture 
and/or 
Hain test 
performed 
n (%*)
Patients 
with DST 
for R after 
Culture or 
Hain test   
n (%**)
MDR + 
RR 
n(%***)
2003 88 81 (92) 48 (59) 12 (25) 76 74 (97) 50 (68) 9 (18)
2004 66 58 (88) 38 (66) 6 (16) 48 47 (98) 26 (55) 11 (42)
2005 77 73 (92) 48 (66) 6 (13) 49 49 (100) 27 (55) 10 (37)
2006 82 72 (88) 45 (63) 4 (9) 24 23 (96) 19 (83) 7 (37)
2007 94 86 (91) 55 (64) 8 (15) 21 15 (71) 9 (60) 3 (33)
2008 74 71 (96) 46 (65) 4 (9) 21 20 (95) 12 (60) 4 (33)
2009 78 76 (97) 48 (63) 2 (4) 6 6 (100) 4 (67) 2 (50)
2010 61 60 (98) 51 (85) 3 (6) 4 3 (75) 3 (100) 1 (33)
2011 82 78 (95) 62 (79) 3 (5) 5 5 (100) 3 (60) 0 (0)
Total 702 655 (93) 441 (67) 48 (11) 254 242 (95) 153 (63) 47 ( 31)
Note: Re-TTT = Retreatment; DST = Drug sensitivity test; R = Rifampicin; MDR = Multidrug resistance; 
RR = Resistance to rifampicin (without MDR)
* Indicates percentage of number of patients on retreatment in each year
** Indicates percentage of those with Culture and/or Hain test performed
*** Indicates percentage of those with drug sensitivity test for rifampicin .
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Figure 2. Annual prevalence rates of MDR-TB and other resistance to Rifampicin in patients living inside and 
outside of Benin, Cotonou, 2003-2011
ASSOCIATION BETWEEN HIV INFECTION AND MDR-TB
Since 2007, 99% of TB patients have been tested and systematically reported. Of the 289 
retreatment patients tested, no association was found between HIV infection and rifampicin 
resistance (Table 4) (RR 0.52, 95%CI 0.19-1.44, p = 0.28). 
Table 4: Retreatment patients with MDR-TB and resistance to rifampicin in relation to known 
HIV status, Cotonou, Benin.
Known HIV status Total MDR + RR
HIV positive 68 4 (6%)
HIV negative 221 25 (13%)
Note : MDR= Multidrug-resistance; RR = Resistance to rifampicin (without MDR).
OTHER PATTERNS OF RESISTANCE
Phenotypic DSTs results in retreatment patients are shown in Table 5. Of the 545 patients, 
53% were fully sensitive to all four first line anti-tuberculosis drugs, and in patients who 
had failed treatment (both the first and retreatment regimens) over 40% were fully sensitive 
to these four drugs. Resistance to streptomycin was the most frequent type of resistance 
encountered, regardless of the type of retreatment, followed by isoniazid. Overall, mono-
resistance was found in 22% and poly-resistance in 8% of patients.
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Table 5: Patterns of anti-TB drug resistance in retreatment patients, stratified by type of 
retreatment, 2003–11, Cotonou, Benin.
Failure after 
new TTT 
N (%) 
Relapse 
after new 
TTT 
N (%)
Default 
after new 
TTT 
N (%)
After re-
TTT   N 
(%)
Total 
N (%)
DST performed
Fully sensitive
Any resistance
S
R
H
E
Monoresistance
81
39 (48)
43 (53)
31 (38)
19 (23)
28 (35)
13 (16)
18 (22)
268
155 (58)
113 (42)
84 (31)
31 (11)
50 (19)
24 (9)
56 (21)
170
85 (50)
85 (50)
64 (38)
32 (19)
40 (23)
15 (9)
40 (24)
26
11 (42)
14 (54)
12 (46)
10 (38)
7 (26)
5 (20)
4 (15)
545
290 (53)
255 (47)
191 (35)
92 (17)
125 (23)
57 (10)
118 (22)
E 1 (1) 6 (2) 0 (0) 0 (0) 7 (1)
H
S
Polyresistance
ES
HE
HES
HS
5 (6)
12 (15)
5 (6)
1 (1)
0 (0)
0 (0)
4 (6)
9 (3)
41 (15)
26 (10)
5 (2)
0 (0)
5 (2)
16 (6)
10 (6)
30 (18)
13 (8)
4 (2)
1 (1)
1 (1)
7 (4)
0 (0)
4 (15)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
24 (4)
87 (16)
44 (8)
10 (2)
1 (0.2)
6 (1)
27 (5)
Resistance to Rifampicin 1 (1) 11 (4) 11 (7) 3 (12) 26 (5)
R
RE
RES
RS
Multidrug resistance
RH
RHE
RHS
RHSE
0 (0)
0 (0)
0 (0)
1 (1)
18 (22)
3 (4)
2 (2)
4 (5)
9 (11)
6 (2)
0 (0)
2 (1)
3 (1)
20 (7)
7 (3)
1 (0.4)
7 (3)
5 (2)
5 (3)
0 (0)
1 (1)
5 (3)
21 (12)
5 (3)
0 (0)
8 (5)
8 (5)
0 (0)
1 (4)
0 (0)
2 (8)
7 (27)
0 (0)
1 (4)
3 (12)
3 (12)
11 (2)
1 (0.2)
3 (0.6)
11 (2)
66 (12)
15 (3)
4 (1)
22 (4)
25 (5)
Note: TTT=Treatment; re-TTT=Retreatment; DST=drug sensitivity testing; R=Rifampicin; 
H=Isoniazid; E=Ethambutol; S=Streptomycin. Hain test results not included in this table.
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DISCUSSION 
During the study period, nearly 95% of retreatment patients submitted sputum specimens for 
culture or a rapid line probe assay (Hain test), and two thirds had a DST that assessed whether 
the mycobacteria were sensitive or resistant to rifampicin. Altogether, 16% of patients had 
either MDR-TB or other resistances to rifampicin, both of which require a MDR-TB treatment 
regimen with second line drugs. Higher rates of MDR-TB were found in patients who had 
failed first line treatment, who had failed or relapsed after a retreatment regimen and who 
resided in countries outside of Benin. Interestingly, for those retreatment patients living in 
Benin, there was a decreasing prevalence of MDR-TB over the nine years. Finally, amongst all 
retreatment cases with DST results, the most common pattern was full sensitivity to all four of 
the first line anti-TB drugs, and even amongst those failing the first or retreatment regimens 
between 40 – 50% of patients had fully sensitive mycobacteria. 
The strengths of the study were the large number of patients evaluated, the excellent 
monitoring and recording system and the fact that cultures and DST were performed in a 
reliable laboratory, with contamination rates of 2.6% which are lower than the 5% generally 
reported from other laboratories [7]. Limitations reflect the retrospective nature of the study 
and use of routinely collected data which can be incomplete, unusable results (negative 
culture, inconclusive results). Furthermore, during the first years, HIV and Hain tests were not 
performed because these activities started later, respectively in 2006 and 2009.
Benin is a low burden country for MDR-TB, with about 0.5% cases reported among new 
patients [8, 9]. Overall, the retreatment patients needing a MDR-TB treatment regimen were 
fewer than expected (16%), and thus the majority can still be appropriately treated with first 
line anti-tuberculosis drugs. The highest risk group for MDR-TB included patients who either 
failed or relapsed after a retreatment regimen, and where resources are tight priority must 
be given to these patients for culture and DST. The other high risk group included patients 
failing after a first-line regimen. Currently, WHO recommends an empiric MDR treatment for 
failure patients, if individual or country-specific DST information is not available [4]. The 
results of our study suggest that this recommendation would be inappropriate for Cotonou, 
where 80% of the failure cases do not have MDR-TB and could be treated with a retreatment 
regimen using first line anti-TB drugs. Giving empirical MDR-TB treatment to many patients 
unnecessarily might also promote the emergence of resistance against the second line anti-
tuberculosis drugs, particularly if the administration and monitoring of MDR-TB treatment is 
weak.
The prevalence of MDR-TB among failure patients will vary from country to country. For 
example, 50% and 94% of failure patients from Bangladesh and Peru had MDR-TB, while 
none was found in Malawi [10-12]. A study in Teheran, Iran, found no significant differences 
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in MDR-TB in recurrent and new TB, with the authors suggesting that empirical MDR-TB 
treatment should be avoided and decisions on use of this regimen be made only when DST 
results become available [13]. The recommendation from WHO on empirical treatment in 
failure cases must therefore be adjusted to the country specific situation. 
In contrast to patients who fail treatment, defaulters are usually attributed a lower MDR-TB 
risk varying from 0.4% and 4% [14]. However, in our study, the risk for MDR-TB (when adding 
in the results of mono-resistance to rifampicin) was much higher at nearly 20%, and thus this 
group of patients might also be accorded priority for DST in Cotonou. Patients with relapse 
TB had the lowest risk of MDR-TB, which may be because their recurrent TB arises from re-
infection rather than an endogenous reactivation, although we have no evidence to back up 
this statement.
Our findings might be useful when it comes to the practical application of the new nucleic 
acid amplification test, Xpert MTB/RIF. According to validation studies [15-18], when the 
prevalence of rifampicin resistance exceeds 15% in any group of patients, the positive 
predictive value of a rifampicin-resistant result with Xpert MTB/RIF is more than 90%, but this 
declines to 32% when prevalence of rifampicin- resistance is low at less than 1%. Therefore, 
in our patients who have failed or relapsed after retreatment and failed or returned after 
default with first-line treatment, a rifampicin-resistant result could be accepted without the 
need for a confirmatory culture and DST. For relapse cases, however, confirmation would be 
necessary before treating for MDR-TB. 
In this study, we found no association between HIV and MDR-TB, similar to other studies in 
sub-Saharan Africa [9;19]. 
While the decreasing prevalence of MDR-TB in retreatment patients over nine years in those 
residing in Benin is reassuring to the programme, we are not sure of the reasons. The higher 
numbers during the first years of the surveillance may relate to a backlog of previously 
unknown cases. The decrease in numbers of retreatment cases in those with permanent 
addresses outside of Benin is likely due to a reference to a centre in their residence country 
close to their homes before registration, policy which began in 2009.
In conclusion, patients who failed or relapsed after retreatment or failed and defaulted after 
a first line treatment had a higher risk of needing MDR-TB treatment regimens in Cotonou. 
However, the majority of these patients did not have MDR-TB and could be successfully 
treated with first line anti-tuberculosis drugs.
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ABSTRACT
Background: In the “Centre National Hospitalier de Pneumo-Phtisiologie” of Cotonou, Benin, 
little is known about the characteristics of patients who have not attended their scheduled 
appointment, the results of tracing and the possible benefits on improving treatment 
outcomes. This study aimed to determine the contribution of tracing activities for those who 
missed scheduled appointments towards a successful treatment outcome.
Methods: A retrospective cohort study was carried out among all smear-positive pulmonary 
tuberculosis patients treated between January and September 2013. Data on demographic 
and diagnostic characteristics and treatment outcomes were accessed from tuberculosis 
registers and treatment cards. Information on those who missed their scheduled 
appointments was collected from the tracing tuberculosis register. A univariate analysis was 
performed to explore factors associated with missing a scheduled appointment.
Results: Of 457 patients (410 new smear-positive and 47 retreatment tuberculosis), 37 
(8 %) missed one or more of their appointments with a total of 44 episodes of missed 
appointments. The 3.5th (32 %) and 5th (43 %) month appointments were the ones most 
likely to be missed. Being male was associated with a higher risk of missing appointments 
(RR = 4.2; 95 % CI = 1.5–11.8, p = 0.004) while having HIV infection was associated with a 
lower risk (RR = 0.3, 95 % CI = 0.1–0.9, p = 0.03). Principal reasons for missed appointments 
were travelling outside Cotonou (34 %) and feeling better (21 %). In 24 (55 %) of these 44 
episodes of missed appointments, contact was made with the patient who returned to the 
programme. These follow-up activities increased the treatment success by 4 %.
Conclusion: In Cotonou, Benin, less than 10 % of tuberculosis patients miss at least one of 
their scheduled appointments. Tracing activities increase the treatment success rate by 4 
% and current on-going practices in the Programme need to be endorsed and encouraged.
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BACKGROUND
Although treatment success rates in national tuberculosis control programmes (NTPs) have 
improved globally in the last few years to reach 86% in 2013 [1], compliance with scheduled 
visits at clinics to collect drugs or submit sputum specimens for smear microscopy remains 
a serious concern. Poor attendance for follow-up visits compromises a successful treatment 
outcome and favours the emergence and subsequent transmission of drug resistant bacilli 
[2,3]. Various reasons for poor attendance at clinics include patient-related factors, health 
care system failures and community beliefs [4].
To reduce this problem, NTP officers are encouraged to develop feasible strategies to prevent 
loss to follow-up and bring back to treatment those who have been declared loss-to-follow-
up [2,3,5,6]. The priority is to prevent losses to follow-up as significant efforts are required to 
trace and bring patients back to the programme.
Benin is a low-income country in West Africa. Since 2009, the country has achieved a 
treatment success of 90% among new smear-positive TB cases, with approximately 1% loss-
to-follow-up [7,8]. This excellent outcome is the result of several actions and strategies that 
are routinely implemented such as the quality of counselling before starting treatment, the 
application of Directly Observed Treatment (DOT) by health care workers and nutritional 
support. In addition, the NTP has established a special unit charged with tracing those 
who fail to attend DOT sessions or scheduled appointments (SA) during their ambulatory 
treatment. Currently, there is little reported information about the value of ensuring that SAs 
are kept. 
We therefore examined whether a focus on assisting patients who were irregular with their 
scheduled appointments was associated with improved treatment outcomes in Cotonou, 
the economic capital of Benin. Specific objectives were to determine in new and previously 
treated smear-positive pulmonary tuberculosis (TB) patients diagnosed and treated in the 
“Centre National Hospitalier de Pneumo-Phtisiologie” (CNHP-P) of Cotonou: i) the number 
(and proportion) who were traced for missing SA; ii) factors associated with missing SA; iii) 
results of the tracing; iv) reasons of missing the SA; and v) of those declared successfully 
treated, the number and proportion who were previously traced and the contribution of 
tracing activities to successful treatment outcomes.
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METHODS
STUDY DESIGN 
This was a retrospective cohort study.
SETTING – GENERAL AND STUDY SITE
Country: Benin is a low-income country in West Africa with an estimated population of 10 
million and a gross national income of US $750 per capita
(http://data.worldbank.org/about/countryclassifications). The national incidence rate of 
notified new TB cases has remained stable between 39 and 41 per 100,000 populations over 
the last ten years [1].
NTP control and routine strategies to enhance treatment compliance: The Benin NTP 
follows the Direct Observed Treatment Strategy principles and uses recognised international 
criteria for the diagnosis and the treatment of patients with TB [2,3,9]. After the diagnosis of 
TB has been confirmed and before the start of treatment, the patient attends an education 
session, supervised by a medical practitioner and carried out by nurses in conjunction with 
social workers. Information is provided on the disease and therapy. Any concern that the 
patient may have is systematically sought and addressed as far as possible. In addition, 
patients are strongly recommended to provide one supporter with a complete address to 
help them through their treatment. Those who reside far from the Basic Management Unit 
(BMU) from where TB has been diagnosed are either referred to another BMU closer to the 
patient’s home or registered in the initial BMU and sent to a treatment clinic for DOT to avoid 
poor compliance resulting from poor health facility access.
TB patients are then either hospitalized or managed in an ambulatory fashion. During the 
intensive phase, DOT is strict and carried out daily by a nurse for all smear-positive (new 
and retreatment TB) cases. Every morning and before DOT is administered, patients receive 
an educational talk about some aspect of their disease and they also have the opportunity 
to discuss their concerns with social workers. Twice a month, a meeting is scheduled by the 
social services between the TB patients association and patients with newly diagnosed TB. 
After two months (or three months for retreatment TB cases), patients are once again briefed 
on how the continuation phase will be managed. 
In the continuation phase of treatment, there is no DOT and patients are regularly supplied 
with medications for certain defined periods (between 30 to 45 days). At the time of medication 
collection, the patient is reminded about the next scheduled appointment by the nurse. Each 
patient also receives nutritional support at these visits for the whole duration of treatment.
FOLLOW-UP AND TRACING OF TUBERCULOSIS PATIENTS WHO FAIL TO ATTEND THEIR SCHEDULED 
APPOINTMENTS IN COTONOU, BENIN: A RETROSPECTIVE COHORT STUDY
139
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
In spite of all these measures, some patients may fail to attend their SA. For these patients, 
nurses in charge of the TB clinics can use a motor cycle and receive a monthly petrol 
allocation in order to trace these patients. 
The CNHP-P and the “Service de relance”: The CNHP-P is the largest BMU and is situated 
in Cotonou, the economic capital of the country. This centre diagnoses and treats about 
24% and 90% of notified TB cases in Benin and Cotonou respectively. The strategies that 
have been presented earlier to reduce poor treatment compliance are strictly implemented 
in CNHP-P. Tracing of patients who have not attended their SA is entirely in the hands of a 
unit in the centre (with four workers) named “Service de relance”. At the start of treatment, 
every TB patient is sent to the “Service de relance” in order to share proper contact details 
should there be a need for follow-up. Tracing is carried out about five days after patients miss 
their SA for DOT in the initial phase, for drug collection in the continuation phase and for 
sputum smear follow-up examination. The workers in the “service de relance” are informed 
by nurses about patient failures to attend SA, and tracing is carried out through phone calls 
and/or home visits sometimes with the help of the DOT supporter. A home service (sputum 
specimen collection or treatment delivery) can be carried out if necessary. 
STUDY PARTICIPANTS
All smear-positive TB patients diagnosed and treated in the CNHP-P between 1st January and 
30th September 2013 were included in the study.
DATA VARIABLES, SOURCE OF DATA, DEFINITION OF VARIABLES AND DATA COLLECTION 
TOOL
Data collected from TB registers and treatment cards for each patient by included: TB 
registration number, demographic characteristics (sex, age, place of residence), type of TB 
(new smear-positive and retreatment TB), HIV-status (negative, positive, unknown), anti-
tuberculosis treatment regimen and treatment outcomes.
For those who missed one (or more) of their SA, additional information was collected from 
the tracing TB register that included: timing of the missed SA, reasons and results of the 
tracing activity. The tracing TB register was filled in by workers of the “service de relance”. 
The information obtained was shared weekly and validated with nurses and the appropriate 
decisions were made for patients. These data were cross-checked with data on the treatment 
card to ensure that the patient really did miss a SA and the reason for missing the SA. All these 
data were collected by two investigators into a paper-based study questionnaire.       
Because of the retrospective nature of the study, other methods of validating the data were 
not possible.   
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ANALYSIS AND STATISTICS
Data from the questionnaires were double-entered into an electronic file using EpiData 
version 3.1 (EpiData Association, Odense, Denmark). Categorical variables were analyzed 
using frequencies and percentages. Factors associated with failing to attend the SA were 
identified and compared using the chi-square test, risk ratios (RR) and 95% confidence 
intervals (95% CI) as appropriate. Levels of significance were set at 5%.
ETHICAL CONSIDERATIONS
Ethical approval for the study was obtained from the National TB Programme, Benin and 
the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease, 
Paris, France. Because it was a retrospective review of already collected data, approval of 
the local ethics committee named “Comité National d’Ethique pour la Recherché en Santé” 
(http://www.ethique-sante.org/index.htm) was not required according to the country’s 
recommendations. 
The need for informed consent was waived by the National TB Programme, Benin and the 
Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease, 
Paris, France.
RESULTS
There were 457 patients with smear-positive TB who started treatment at the CNHP-P (410 
with new smear-positive TB and 47 with retreatment TB). The number and proportion of 
patients who failed to attend their SA before treatment completion and the types of SA 
missed are shown in Table 1. In total, there were 37 (8%) patients who missed one or more 
of their SA. Of these, seven patients missed their SA on two occasions, making a total of 44 
episodes of missed SA. In new smear-positive TB cases, the 3.5th and 5th month appointments 
were those most commonly missed in 32% and 43% of the 44 episodes respectively. Two of 
these patients eventually had smear-positive sputum at the 5th month of follow-up and were 
declared failures to the first line treatment regimen, after their sputum had been collected 
during home visits - none was found with resistance to rifampicin.
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Table 1: Scheduled appointments missed by tuberculosis patients diagnosed and treated in the 
CNHP-P, Cotonou, Benin, between January and September 2013.
All smear positive 
TB (%)
New smear 
positive TB (%)
Retreatment    
TB (Fraction)
Total TB patients 457 410  47
Patients who missed at least one SAa
Time at which patients missed their SAb
In Initial phase before 2 months 
At 2 months
At 3 months
At 3.5 months
At 5 months
37 (8)
6 (14)
5 (11)
0
14 (32)
19 (43)
36 (9)
6   (14)
5   (12)
-
14 (33)
18 (42)
1 (0.02)
0
0
0
-
1 
Total appointments missed c 44 43 1
Note:
a The denominator is the total number of TB patients treated. 
b The denominator is the total number of appointments missed.
c Some patients missed more than one scheduled appointment: three new smear-positive tuberculosis patients 
missed their scheduled appointments at 2 and 3.5 months; two missed at 
3.5 and 5 months and two missed at the initial phase and at 5 months .
Baseline characteristics associated with a missed SA during the treatment course are shown 
in Table 2.  Being male was associated with a higher risk of missing a SA while having HIV 
infection was associated with a lower risk.
Table 2: Baseline characteristics associated with missed scheduled appointments in 
tuberculosis patients diagnosed and treated in the CNHP-P, Cotonou, Benin, between January 
and September 2013.
Missed 
scheduled 
appointments 
(%)
RR 95% CI p (value)
Sex Female 
Male
4/153 (2.6)
33/304 (10.9)
1
4.2 1.5 – 11.5 0.004
Age (years) <25
25 – 64
≥ 65
5/82 (6.1)
31/360 (8.6)
1/15 (6.7)
1
1.4 
1.1
0.6 – 3.5
0.1 – 8.7
0.21
1
HIV-Status Negative
Positive
Unknown
34/346 (9.8)
3/108 (2.8)
0/3 (0)
1
0.3 
-
0.1 - 0.9 0.03
-
Type of TB New SS+
Retreatment
36/410 (9.8)
1/47 (4.3)
1
0.2 0.03 - 1.7 0.16
Place of 
treatment
CNHP-P
DOT clinic
21/259 (8.1)
16/198 (8.1)
1
1.0 0.5 - 1.9 0.99
Note: RR = Risk Ratio; CI=Confidence Interval; HIV = Human Immunodeficiency Virus; SS+ = New smear 
positive tuberculosis; DOT = Directly Observed Treatment. 
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All 37 patients with a missed SA were contacted by phone or visits by the “service de relance”. 
Results of further tracing activities are shown in Table 3. For 24 (55%) of the 44 episodes 
of missed SA, the patients were contacted and either immediately returned to the centre 
or benefited from a home visit combined with the collection of their sputum. For the 20 
episodes of missed SA for which there was no contact made with the patient, nine patients 
later returned to the centre on their free own will and completed their treatment. In these 
patients who could not be contacted, the contact address was correct in all but one patient, 
but the patients were not at home at the time of the visit.
Table 3: Results from tracing tuberculosis patients who missed their scheduled appointments 
while on treatment in the CNHP-P, Cotonou, Benin, between January and September 2013.
Number 
Contact made with patient during the tracing 24
Results: Immediate return to the centre
Home service delivery
19
5
No contact made with patient during the tracing 20
Results: Returned at some time to the 
centre on their own 9
Total missed appointments investigated 44
The reasons of missing the SA were known in 29 of the 44 episodes and are shown in 
Table 4. The two principal reasons were travelling outside the city of usual residence and 
feeling better on anti-tuberculosis treatment.
Table 4: Reasons of missing a scheduled appointment in tuberculosis patients diagnosed and 
treated in the CNHP-P, Cotonou, Benin, between January and September 2013.
Known reasons for missing a scheduled appointment Patients
Travel
Improving health condition
Death
Incarceration
Other a
10 (0.34)
6 (0.21)
3 (0.1)
2 (0.07)
8 (0.28)
Total b 29
Note:
a Other includes: Financial issues (1), Worsening conditions (1), lapse of memory (1), Hospitalization for 
comorbidity (1), psychiatric troubles (1), accident (1) attending a professional training course (1) and 
treatment resumption in another centre (1).
b Reasons of failing to attend the scheduled appointment were known for 29 out of 44 episodes. 
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Of the 37 patients who had follow-up tracing undertaken, 26 completed their treatment 
successfully (17 were contacted during the tracing and 9 were not contacted but returned 
later to treatment). As shown in Table 5, the follow-up tracing activity increased the number 
of patients successfully treated in the centre by 4%.
Table 5: Contribution of follow-up tracing activities in treatment success of tuberculosis 
patients treated in the CNHP-P, Cotonou, Benin, between January and September 2013.
All smear positive tuberculosis patients 450
Patients with a successful outcome (%a): 403 (88)
Did not miss a scheduled appointment and did not need to be traced during treatment (%b) 377 (94)
Missed a scheduled appointment, traced but never contacted face-to-face and returned to 
treatment on their free own (%b)
9 (2)
Missed a scheduled appointment, traced and contacted face-to-face and brought back to 
treatment (%b)
17 (4)
Note:
ª The percentage calculated from all patients (N=450) who had been started on treatment.
b The percentage calculated from all patients (N=403) who were successfully treated.
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DISCUSSION
This is the first study in Benin within the NTP to assess the results and impact of tracing 
activities in patients with tuberculosis who missed their SA. In Cotonou, males were more 
likely to miss a SA while interestingly those with associated HIV infection were at lower risk. 
The SAs at 3.5 months and at 5 months were those most likely to be missed. Travel to a 
destination outside the city of residence and feeling better on anti-TB treatment were the 
two main factors associated with failing to attend the SA. We finally found that the tracing of 
those who failed to attend their SA, while not always successful in the face-to-face contact 
of patients, increased the treatment success rate by 4% among patients treated in this city. 
The strength of this study is that it was done within the context of the TB programme and 
included a large number of consecutively registered patients. The main limitation is that 
we only included patients from Cotonou and the results may not be representative of the 
country as a whole. Further limitations are the lack of a control group, limited information on 
baseline characteristics of participants and potential bias on data collection. Tracing was an 
already accepted component of the national programme and data routinely collected have 
been used for this study. These limitations cited above could be addressed in the future by a 
prospective cohort study that also will include a group control.
As a chronic disease, TB requires treatment for a minimum of six months. Thus, keeping 
patients with TB on treatment and ensuring that all SA are kept is not always easy and 
remains a permanent challenge for programmes [10,11]. In routine practice, TB patients are 
usually traced if they are non-compliant with treatment or miss their appointments either 
for sputum follow-up examination or collecting medication. Our study found that less than 
10% of TB patients on treatment were non-adherent. This proportion is lower than that 
reported from other settings in sub-Saharan Africa. For example, in one review of studies 
from Uganda, Ethiopia, and Zambia, the proportion of non-adherent TB patients ranged 
from 11.3% to 29.6% [12]. In another review that included studies from Cape Town, Harare, 
Lusaka, Durban and Mbeya, overall more than one fourth of registered TB patients were non-
adherent to treatment (26%) [13]. In our study, we believe that the large majority of patients 
completed their treatment without needing any follow-up tracing because they understood 
the importance of regular, uninterrupted treatment to ensure cure of their disease, and this 
probably relates to good quality education from health care workers in the programme at 
the start of and during treatment. The most important factor in achieving this education is a 
strong willingness of health care workers to cure the patient and ensure good compliance of 
patients with scheduled appointments. This practice of persuading patients to fully comply 
with scheduled appointments is also regularly encouraged during supervisory visits, and in 
our view, this probably contributes to the low rate of loss-to-follow-up during TB treatment 
reported from the country [7]. In addition, in Cotonou, the overall good compliance with 
FOLLOW-UP AND TRACING OF TUBERCULOSIS PATIENTS WHO FAIL TO ATTEND THEIR SCHEDULED 
APPOINTMENTS IN COTONOU, BENIN: A RETROSPECTIVE COHORT STUDY
145
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
treatment is probably partly due to the assistance of patients who have already completed 
treatment, who thus share their experience and provide first-hand knowledge when it comes 
to patient support.
Despite this support, this study shows that some patients do not comply with their SA. This 
is more common in males which concurs with other reports from Africa and Asia [14,15]. In 
contrast to our study, others have found that associated HIV infection is associated with 
poor compliance with treatment [11]. We are not surprised at our finding as most patients 
with HIV-associated TB in Benin are on antiretroviral therapy, which provides structured and 
monitored care and thus would tend to improve anti-TB treatment compliance. Missing the 
SA at 5 months is a concern because this is an opportunity to collect sputum specimens and 
identify treatment failure as early as possible [16], and one of the possible solutions is for the 
programme to collect sputum specimens at home in those who have not come for follow-up. 
This study has several implications for the NTP. First, it is important that the Programme 
endorses and continues to encourage all the actions that prevent patients from being poorly 
adherent to treatment (i.e., the patients education, the health care workers’ motivation to 
providing good quality services, reminders at the different appointments, support of expert 
TB patients, food supplies and so on) and reaches and brings back to treatment those who 
are not adherent with their scheduled appointments. Second, more attention should be 
directed to male patients as they appear to be more likely to miss their SA. Third, there is a 
need to emphasize at the earlier 2 and 3 month appointments the importance of attending 
at 5 months in order for sputum smears to be checked at this time. Fourth, patients should 
be systematically asked whether they are likely to travel during treatment before the next SA, 
and if this is the case an extended supply of medications should be given to cover this period 
and advice given to redirect the patient to the nearest BMU for sputum smear examination. 
Finally, at the time of registration it is crucial to obtain a correct address, in case follow-up to 
the home is needed, and this study shows that in general this is done well in the programme 
in Cotonou.
CONCLUSION
The proportion of TB patients who failed to attend a SA in Cotonou was less than that 
found in other settings in sub-Saharan Africa. When a SA is missed, the follow-up tracing 
activities result in a small, but important, increase in treatment success. Actions performed 
to prevent patients from discontinuing treatment and to trace non-adherent patients within 
the Programme need to continue so that Benin can maintain its good programme outcomes.
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SUMMARY OF THE STUDY FINDINGS
The studies were conducted within a well performing NTP with the aim of further improving 
TB control activities in the country. The different, but interconnected, OR projects that were 
developed for this purpose, aimed to identify challenges that the National Tuberculosis 
Programme (NTP) in Benin needed to overcome so as to meet the goals and targets set out 
in the WHO End TB Strategy and the SDGs.1-3
  
The first project in Chapter 2 analysed the trend of TB over fifteen years (from 2000 to 
2014) along with the changes in epidemiological characteristics.4 The key findings were 
that the numbers with presumptive TB progressively increased and this was mirrored by an 
increase in diagnosed and notified TB cases. Reassuringly for the NTP, the majority of cases 
had new bacteriologically confirmed TB and retreatment cases (which can be an indicator 
of poor programme performance) decreased substantially. There was a seasonal pattern in 
TB cases. HIV testing rates in TB patients were excellent and one in seven of those tested 
were co-infected. Within this national spectrum, however, there was a decrease in notified 
TB cases among men and among young persons aged 15-34 years. The modelling suggested 
that TB case finding would decrease in the next five years if the current passive screening 
strategy used in the country does not change.
The next three projects in Chapters 3, 4 and 5 focused on smear-negative PTB (SNPTB),5 
Extrapulmonary TB (EPTB),6 and childhood TB.7 The key findings are summarized below. 
Overall, the proportion of patients diagnosed with SNPTB, EPTB or childhood TB among 
all TB cases was low. For instance, SNPTB accounted for less than 10% of all patients with 
pulmonary disease while EPTB and childhood TB represented 9% and 4.5% of all TB cases 
respectively. Among children, approximately 16% of those who were managed in the general 
hospital were not notified to the NTP. Confirmation of the diagnosis was rare in EPTB, only 
achieved in less than one in ten cases.
In terms of characteristics, and in comparison with patients registered with new 
smear-positive PTB, those with SNPTB or EPTB were more commonly females or co-infected 
with HIV. Older patients aged 65 years and above were more common in those with SNPTB. 
For those with SNPTB and EPTB there were significant variations between different regions of 
the country, suggesting that clinician knowledge and skills and available resources may play 
a part in the diagnosis of these condition. In children, the incidence of notified TB cases was 
paradoxically higher in those aged ≥ 5 years and the HIV prevalence was also high at 29%. 
Overall, treatment outcomes of these three groups of patient were worse compared 
with new smear-positive PTB cases. More specifically, patients with SNPTB and including 
those who were HIV-negative or HIV-positive but not on ART had higher risks of loss-to-follow 
up or death. There was a similar and unacceptable high case fatality rate among those with 
EPTB and who were co-infected with HIV, even if ART had been initiated. Surprisingly, all EPTB 
CHAPTER 9
152
patients who were lost-to-followed were from a specific region (Atlantique-Littoral region) of 
the country. 
The following two projects in Chapters 6 and 7 focused on retreatment TB 8 and drug 
resistance.9 In the first project assessing all patients in the country in 2013, retreatment TB 
patients accounted for 6% of all forms of TB, which was lower compared with the previous 
years. Retreatment TB patients were commonly found in the “Atlantique-Littoral” region, 
and were predominantly males, adults aged between 45 and 64 years and significantly more 
were co-infected with HIV. The success rate of retreatment TB patients (93%) was statistically 
comparable with new smear-positive TB patients (>88-90%), although a worse treatment 
outcome was reported in those with unknown HIV-status. Overall, about three quarters of 
the patients submitted sputum specimens for culture and DST; and of those about 10% were 
rifampicin resistant (9 patients with MDR-TB and 8 mono-resistant to rifampicin). 
In the second project, which assessed retreatment TB in the capital city only 
between 2003 and 2011, 94% underwent culture and DST and/or a line probe assay. Of those, 
two thirds had a successful DST for rifampicin and 16% had rifampicin-resistance requiring 
treatment with an MDR-TB treatment regimen. The groups at highest risk of rifampicin 
resistance were those who failed or who relapsed after a retreatment regimen. Reassuringly, 
rifampicin-resistance amongst patients living in the capital city decreased over the nine year 
period from 25% to 5% The other one third of specimens did not have a successful DST, the 
possible reasons being difficulties in specimen transportation at the start of the activity, 
negative mycobacterial cultures and inconclusive DST results. Contamination did not play a 
substantial role because contamination rates were at 2.6%.
To address the question about whether Benin should adopt the WHO 
recommendations and start failing first-line treatment TB patients on empirical MDR-TB 
regimen,10 the DST results showed that 48% of specimens were drug-susceptible, 30% had 
resistance which was not rifampicin-related or MDR-TB and the remainder had rifampicin-
resistant TB. Given that the majority of these patients did not need a MDR-TB treatment 
regimen, the WHO recommendations are not appropriate for a country like Benin.
The final project in Chapter 8 focused on patients missing one or more of their scheduled 
appointments and the added contribution or not of actively tracing these patients and 
bringing them back to care.11 The key findings were that 8% of all registered patients missed 
one or more of their scheduled appointments, with male gender being a significant risk factor 
and having HIV infection being protective. The 3.5th and 5th month appointments were those 
most likely to be missed. Principal reasons for missing appointments were travelling outside 
the capital city, Cotonou, and feeling better. In over half of the missed appointments, contact 
was made with the patient who returned to the programme to complete his treatment; and 
this improved treatment success by 4%.
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STRENGTHS AND LIMITATIONS OF THE STUDIES IN THE THESIS
The OR projects presented in this thesis had several strengths. First, all of the studies were 
conducted in a programmatic and real-life setting, compared with experimental studies in 
which there are strict inclusion and exclusion criteria. Second, data used for analysis were 
validated twice during quarterly supervisions that are routinely organized by the NTP staff; 
and this will have contributed to minimizing errors. Third, the findings of the projects and 
their implications were discussed during monthly meetings of the NTP, which helped in their 
dissemination among the decision makers. Fourth, reports of the different studies followed 
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines.12
Limitations were related to the overall operational nature of these studies, with use 
of already collected data from TB registers, laboratory registers and personal medical files. 
In addition, information on some variables that would have helped in better understanding 
some of the findings was missing because these variables were not part of the routinely 
collected data. Obtaining these additional data required additional resources (including 
financial resources), that were not available at the time of the study implementation. Despite 
these limitations, the projects reported on many challenges that are helpful for improving TB 
case management in the country.
 
HOW THE STUDY FINDINGS IN THE THESIS RELATE TO THE LITERATURE
  
In Chapter 2, there was an overall increase in TB case notifications in the country. While there 
has been an increase in TB case notifications in several sub-Saharan African countries in the 
last ten years, this is not a uniform finding and several countries in southern Africa that include 
Malawi, Zimbabwe and Swaziland have seen a decrease in absolute case numbers and case 
notification rates related to large national scale up of antiretroviral therapy (ART) amongst 
people living with HIV, with ART known to protect in these circumstances against TB.13-18 
Notification trends are country and context-specific and depend on various factors such as 
diagnostic capabilities and their coverage, associated co-morbidities such as HIV infection 
and Diabetes Mellitus (which can increase the risk of TB by a factor of three times),19,20 TB 
preventive measures such as treatment of latent TB infection and other social determinants 
of the disease. In Benin, HIV infection rates are low with a prevalence rate of 1.1% in the 
general population,21 and the proportion of TB cases with associated HIV infection is much 
lower than that reported from countries in Eastern and Southern Africa.21 Diabetes mellitus 
also does not appear to be a significant risk factor with low rates of the disease in the general 
population and amongst TB patients.22
Many African countries have reported fairly static case notifications of retreatment 
TB over the last decade or so.23 In contrast, those with good national scale up of ART, 
such as Malawi, Zimbabwe and Swaziland,13-15 have seen a decrease in recurrent TB, a not 
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unexpected finding given the strong association between recurrent TB and HIV coinfection. 
The precise reasons for the decline in retreatment TB in Benin is not known and has to be 
speculative. It most likely has nothing to do with HIV infection and may reflect the generally 
good national programme performance where attention to detail, the provision of directly 
observed treatment, uninterrupted drug supplies and regular supervision and monitoring 
ensure that guidelines are followed and treatment cure is obtained amongst new patients 
on first-line treatment.24
The seasonal variation in TB case notifications in Benin, with case numbers 
declining in winter months, has been reported from elsewhere.25-27 This finding may be due 
to poor patient access to health facilities when rains make transport and roads difficult. 
Another hypothesis is that vitamin D levels may vary in relation to the amount of sunlight, 
with Vitamin D being important for host defences against Mycobacterium Tuberculosis.28
In Chapters 3, 4 and 5, the key findings were the low numbers of SNPTB, EPTB and childhood 
TB cases notified by the programme, the specific characteristics of SNPTB and EPTB patients 
and the generally worse treatment outcomes. 
With regards to numbers, the proportion of SNPTB found in Benin was lower than 
that reported from other settings.29-31 In a recent systematic review, SNPTB accounted for 
30-60% of all forms of TB.31 According to the WHO, Benin has diagnosed fewer SNPTB cases 
in the past than expected, and the data from our study indeed confirms this. A study in 2006 
and 2007 in the largest basic management unit in Benin showed that there was a small 
proportion of patients with chronic cough who had negative sputum smears but positive 
cultures for Mycobacterium tuberculosis on Lowenstein Jensen media.32 This indicates that 
there may not be a high prevalence of true SNPTB among those who reach health centres 
for TB screening. However, the much higher proportion of patients diagnosed in health 
facilities with new smear-positive PTB does imply that there are delays in TB diagnosis in the 
country, because Acid-Fast-Bacilli positivity requires a minimum of 10,000 bacilli per millilitre 
of sputum and it takes time to develop this type of disease.33 It is well established that a 
large majority of the population presents first to traditional medicine when they develop 
symptoms of pulmonary disease.34 This is similar to the situation in other African countries 
where nearly half of PTB patients present first to traditional healers, thus delaying their 
presentation to medical care and presenting therefore with more advanced, cavitatory and 
smear-positive disease.35 
The proportion of EPTB found in Benin was also lower than that reported from 
elsewhere.36-42 In low HIV prevalence settings, EPTB patients represent approximately 15 to 
20% of all TB cases.43 In Benin, we expected more than 10% of notified cases to have EPTB 
and the low prevalence may relate to difficulties in confirming the diagnosis. According to the 
WHO recommendations, the diagnosis of EPTB should be based on at least one specimen 
with confirmed Mycobacterium tuberculosis (using microscopy examination, culture or 
rapid molecular testing), histological or strong clinical evidence consistent with active EPTB, 
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followed by a clinical decision to treat with a full course of anti-tuberculosis chemotherapy.43 
However, in Benin and in most of Sub-Saharan Africa, confirmation is difficult for several 
reasons that include: challenges in collecting appropriate specimens, lack of specialised 
physicians, microbiologists and pathologists, weak laboratory infrastructure and poor access 
to radiography and other more sophisticated imaging technologies such as ultrasound and 
CT Scan computer.
The difference found between regions in notification of these patients with SNPTB, 
and EPTB may indicate a lower availability of general practitioners and specialists in some 
settings and differences in the application of recommended algorithms and procedures, 
which include for example a course of antibiotics, chest radiography and other specific 
examinations.43-45 Involving physicians in standardised TB control activities has always been 
an important challenge for the programme, and this is an area constantly discussed and 
stressed during quarterly supervisions to basic management units around the country.
With respect to childhood TB, there is a growing interest in this specific and 
vulnerable group from both international and national communities, with roadmaps 
developed to chart the way forward in terms of better prevention, care and treatment.46,47 
The low proportion of childhood TB found in Benin has also been reported elsewhere.48-51 
Surprisingly, the incidence of notified TB cases was higher in children aged ≥ 5 years, although 
children less than 5 years of age are at greatest risk of developing active TB once infected 
with Mycobacterium tuberculosis.52-55 The predominance of TB in children aged ≥ 5 years in 
Benin may be related to misdiagnosis among under-fives for several reasons that include 
lack of training of pediatric specialists and other clinicians on using diagnostic algorithms 
for childhood TB, challenges in collecting adequate specimens and poor availability of 
tuberculin skin testing and radiographic technology. These are issues that are not confined 
to Benin but to other resource-poor African countries as well.56,57 We were surprised by the 
high rate of HIV-infection among children with TB, with nearly one third of children infected, 
that contrasted with the generally low rate reported from the general population (1.1%)21 
and amongst adult TB patients.58 The reasons are not clear and this requires further research.
For all these three groups, the recent scale up and decentralization of rapid 
molecular tests such as the Xpert MTB / RIF instruments and assays at regional level may help 
to increase confirmation of the diagnosis of these types of TB, since these assays are known 
to be more sensitive for the identification of Mycobacterium tuberculosis. 59-61
 
With regards to characteristics of patients with SNPTB or EPTB, the predominance of females 
and persons infected by HIV in comparison with new smear-positive PTB is in line with findings 
from other African countries and elsewhere. 29,31,36,39,62 The high proportion of older people 
aged 65 years and above with SNPTB raises issues about whether this is due to misdiagnosis 
of other diseases such as lung cancer, congestive cardiac failure, chronic obstructive or 
restrictive lung disease and occupational lung disease.63,64 A study in Malawi of patients 
registered with SNPTB estimated that only 78% of patients had the correct diagnosis.65 
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Unfortunately, in resource-poor countries confirmation of such diagnoses remains difficult 
and requires more sophisticated diagnostic tools such as use of induced sputum, CT scan 
infrastructure and fibre-optic bronchoscopy. Misdiagnoses may explain why patients with 
SNPTB have higher rates of unfavourable outcomes compared with new smear-positive PTB 
as these patients did not have TB at all.65-67 Addressing this issue will require improvements 
in the health system and also better use of different diagnostic algorithms.
The commonest sites for EPTB in Benin were lymph node and pleura which 
are in line with other studies.36,68 The availability of diagnostic tools plays a role, with 
gastrointestinal and renal TB being rarely diagnosed in resource-poor settings due to lack of 
appropriate radiographic facilities and trained radiologists.62,69-73 Interestingly, compared to 
other countries, there were few reported children with TB meningitis in Benin, and this has 
generally been attributed to good BCG immunization coverage.74,75
Treatment outcomes of these three groups of patient were worse than those observed among 
new smear-positive TB cases,1,58 largely due to higher rates of losses-to-follow up and deaths. 
Unfortunately, the data collected for these studies do not allow any further understanding as 
to the reasons for these adverse outcomes.
Loss-to-follow up may have several possible explanations. First, this adverse 
outcome may have been related to the issue of misdiagnosis, with not having TB and not 
improving on therapy, deciding to discontinue the medication and seeking alternative 
treatment. Second, some of these patients may have died, with this outcome not reported 
to the TB Programme. This has been found in other studies that have pro-actively assessed 
reasons for loss to follow up.76 Third, loss-to-follow up may relate to fairly rapid resolution of 
symptoms and signs and therefore a decision by the patients to stop treatment prematurely.
Unfavourable outcomes were more common in TB patients co-infected with HIV, 
particularly those who were not started on ART, and this is in line with previous studies from 
Africa.77,78 In these last few years there have been significant efforts to initiate ART in all TBHIV 
co-infected patients, in line with WHO HIV and TB guidelines.79,80 ART administered to those 
with HIV-associated TB results in excellent immunological and virological responses and a 
reduction in mortality risk of 64% - 95%.81 Timing of ART is important with the issue of when 
to start ART in relation to start of anti-TB treatment being clarified several years ago by three 
randomised controlled studies: CAMELIA, STRIDE and SAPIT.82-84 While all three trials were 
slightly different, collectively one clear message emerged, namely that early initiation of 
ART saves lives in HIV-infected patients with TB, with the benefits being particularly evident 
for those with CD4 cell counts < 50 cells/µL, many of whom may have SNPTB or EPTB. Late 
initiation of ART after having started TB treatment has been demonstrated to be associated 
with an increased risk of death.79 We believe that the persistent high rate of deaths among 
EPTB patients co-infected with HIV reported in Project 3, despite a high rate of ART uptake, 
may indeed be related to late initiation of this treatment. Such patients may have advanced 
immune suppression with CD4 counts <200 cells /µl, and therefore may be at risk for other 
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serious and potentially fatal opportunistic infections and diseases.85,86 Ensuring that care 
and prevention are available for other common opportunistic infections would help to reduce 
the death rate among co-infected TBHIV patients, and this has recently been demonstrated 
in a randomised controlled trial from four other African countries.87
In Chapters 6 and 7, and as has been discussed earlier, the decrease in retreatment TB 
patients over time probably reflects an improvement in the general treatment of new cases, 
with less chance of subsequent reactivation of the disease after treatment completion 
and thus lower relapse rates. This information is reassuring for the programme which has 
followed for decades internationally recommended procedures in providing good treatment 
for its patients.10,43,80 Elsewhere in Africa, this decrease in retreatment TB has been related 
to ART scale up where HIV-TB is a problem and has also been related to misclassification of 
previously treated TB cases.88 The predominance of retreatment cases in the “Atlantique-
Littoral” region, similar to new cases, was not surprising and can be explained by the higher 
density of population in this region. Retreatment patients were also predominantly males, 
adults aged between 45 and 64 years and were more often found to be co-infected with HIV, 
itself a risk factor for recurrent disease.79
Overall, the high levels of culture and DST for recurrent TB both in the whole 
country and the capital city compare favourably with the generally poor results found from 
other countries in Africa and Asia.89-93 A functioning system of culture and DST has a number 
of important advantages for an NTP. First, patients with Multi Drug Resistant TB (MDR-TB) can 
promptly start an MDR-TB treatment regimen without having to first experience failure to a 
standardised retreatment regimen. Second, transmission of drug resistance in the community 
is more efficiently prevented. Third, the outcomes of previously treated patients can be 
improved because patients are started promptly on an appropriate regimen. One major 
challenge encountered during implementation of the policy that recommended carrying 
out of DST before starting retreatment TB was the transportation of samples from the basic 
management units countrywide to the Mycobacterial Reference Laboratory (LRM) located 
in Cotonou for culture and DST through phenotypic methods. Of the different strategies 
that have been tested in the past, the sending of samples just after their collection through 
public transportation with reimbursement when received at the LRM seems to be the best. 
This system does not cause any delay in starting the patient’s treatment since Xpert MTB/RIF 
machines are now placed at each regional level allowing prompt diagnosis of resistance to 
rifampicin and a rapid decision about whether or not an MDR-TB treatment regimen should 
be commenced within 2 hours of the assay being started. Currently, all retreatment patients 
have information available about resistance to anti-TB drugs, through both genotypic and 
phenotypic methods.
Of all the retreatment TB cases that were tested for DST in Benin in the 2013 
study, only one tenth was found to be rifampicin resistant and required a MDR-TB treatment 
regimen. This proportion was lower in comparison with other settings.94,95 The decrease 
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over years noticed in patients requiring MDR-TB regimen  in both residents and nonresident 
cases is also reassuring. In the first group, the high number of MDR-TB cases in the first few 
years was probably due to the backlog of previously undiagnosed cases. For those who lived 
outside the country, there were many patients in the first few years who sought care in Benin 
because of the programme’s good reputation. The subsequent decline in numbers probably 
relates to better management of MDR-TB in their residence countries since 2009.
In terms of treatment outcomes, our success rate in patients in whom no resistance to 
rifampicin was detected, was higher than that reported from elsewhere.96 Compared with 
previous reports, the number and proportion of patients declared lost to follow-up with 
previous treatment and who discontinued from the retreatment regimen appears to have 
markedly decreased. 97,98  The worst outcomes reported in recurrent TB patients were in those 
with unknown HIV-status, similar to findings from other African countries.99
In Chapter 8, the proportion of patients missing one or more scheduled appointments (8%) 
was lower than that reported from elsewhere.100-102 This was probably because of the 
good quality of education given by health workers at the start of treatment and strengthened 
during the course of treatment, the motivation of health care workers to provide care for 
their patients and the assistance by peer-patients who have previously been treated for TB. 
The low contribution of the active tracing activity in improving the treatment success gives 
credence to the quality of the work carried out by these practitioners.
Men were generally less compliant to treatment than women, and this is in line 
with findings from other parts in Africa.102,103 The reasons for this were not established during 
the study but they include less opportunity for men to present to health facilities due to 
professional duties, more travel, less attention during awareness sessions and more deaths 
due to lack of attention to health care. 
It was of concern that of the missed appointments, the 5th month scheduled 
appointment was the most common. The 5th month appointment provides an early 
opportunity to detect those who are still smear-positive and obtain sputum specimens for 
culture and DST to assess whether or not MDR-TB has developed.
LESSONS LEARNED, CONTINUING GAPS AND FUTURE RESEARCH.
The first project on trends in TB in Benin provides several lessons. The high proportion 
of smear-positive pulmonary TB cases, while reassuring in terms of laboratory network 
performance, also suggests that there is a delay in the diagnosis of pulmonary TB in the 
country with patients presenting with more advanced and cavitatory disease. This calls 
for a better understanding through more qualitative research of patient delays from both 
the patient and health provider perspective and the role that traditional healers play in 
the diagnostic process in the country. There is also a need to further sensitize the general 
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population about TB and educate traditional healers on the importance of early referral of 
patients with chronic cough to health facilities for investigation.
A possible explanation for the predicted decrease in TB case notifications in 
the next five years is that the good performing programme has significantly cut down 
transmission of infection from index smear-positive cases leading to a reduction in the 
burden of TB in the country. However, this belief should be interpreted with caution. Health 
service utilization has remained low in Benin,104 especially in vulnerable groups, a passive 
case finding strategy has always been used and poverty levels remain high despite an 
increase in the last decade in the GNI. The NTP has therefore interpreted these findings to 
indicate that case detection is decreasing rather than the burden of TB is decreasing. There 
is therefore a need for a more aggressive semi-active case detection strategy, and, in line 
with recommendations from the WHO about how to implement such a strategy,105,106 this 
indeed has been adopted. With support from the GFATM, there have been pilot sessions with 
patients living near to health centres being screened for symptoms of TB and being invited 
for physical examination followed by sputum smear microscopy. Additional cases have been 
diagnosed as a result. Other pilot projects are also taking place, especially in Cotonou, to 
screen vulnerable populations such as persons infected by HIV, those with diabetes mellitus 
and pregnant women for TB. 
There are indeed gaps here in knowledge and these will require the implementation 
of prospective studies which may include: i) the burden of TB in vulnerable populations, ii) 
the most relevant strategies for screening vulnerable populations with minimal resources; 
iii) the prevalence of patients with chronic cough who consulted traditional healers in the 
country; and iv) the pathways that patients experience to reach a final diagnosis of TB. With 
the decrease in TB case notifications, a national TB prevalence study would be helpful to 
provide more robust information about the current status of the TB epidemic in Benin. A 
final study here could focus on the possible causes of seasonal variation of TB in the country. 
The next three projects on SNPTB, EPTB and childhood TB provide important lessons 
about the lower prevalence of these types of TB than anticipated and the rare bacteriological 
confirmation of disease. The management of TB in children was not perfect and was marked 
by under-diagnosis (particularly in under-fives) and/or under-reporting to the NTP. The high 
proportion of children diagnosed and treated in the city’s general hospital without having 
been notified to the NTP adds to the evidence that the true burden of childhood TB in the 
city and country is under-reported. Treatment outcomes of patients with these types of TB 
including children were worse than those for new smear-positive PTB, due to higher losses 
to follow up and more deaths. More specifically, those infected with HIV were at higher risk 
of unfavourable outcomes compared with HIV-negative patients. Although, concomitant ART 
administration with TB treatment contributes to diminish the risk of death among TB-HIV co-
infected patients, unfortunately this risk remains compared with HIV-negative patients. There 
is a need to pay more attention to those with pleural effusion and ascites because of a higher 
CHAPTER 9
160
rate of adverse outcomes compared with other types of EPTB: in Malawi, cirrhosis of the liver 
was often misdiagnosed as TB ascites107 and this may also be the case in Benin.
Some of these challenges have been already discussed at the national level. 
In general, there is a need for further advocacy to obtain better engagement of general 
practitioners in TB control and this has included several training sessions for practitioners on 
the diagnosis of all these types of TB, their treatment and prevention, as well as lectures on 
how to interpret chest X-rays. Health system improvements that include the deployment of 
additional specific diagnostic tools and their maintenance, further involvement of specialists 
and the possible request to well-off patients to pay for more sophisticated investigations 
may lead to better diagnoses of SNPTB and EPTB.
Following the study on childhood TB in Cotonou, there have been several meetings 
and training courses that involved both the NTP staff and paediatricians/other practitioners 
in charge of children across the country. The goals were to improve TB diagnosis, 
notifications and treatment outcomes among children. There has been better awareness 
about presumptive TB symptoms in childhood, the recommended algorithm for the 
diagnosis of childhood TB and the current validated therapeutic strategies. In addition, these 
meetings and trainings have provided the opportunity to discuss several issues regarding 
TB notification to the NTP. They have been followed by the writing and dissemination of 
a national guidebook for childhood TB management, and also the establishment of a 
TB register for children in paediatric services. With all of these programmatic activities 
combined with the use of more sensitive diagnostic tools such as Xpert MTB/RIF, the country 
is expecting a significant improvement in childhood TB diagnosis and management. Finally, 
a structured supervision check-list sheet is being amended, which should lead to guidelines 
and recommendations in the field being actually implemented. The progress that is planned 
and achieved will be discussed at least twice a year within a committee that includes both 
NTP staff and paediatricians. All these actions also contributed to an improvement in the 
notification of children who are managed in the general hospital.
Regarding outcomes, improved treatment success could be obtained through 
better monitoring and a reduction of both lost to follow-up and deaths among patients with 
these types of TB. Patients with SNPTB need more attention to treatment and follow-up, and 
consideration of Directly Observed Treatment as is the case with smear-positive PTB. The 
same lessons apply to those with EPTB and especially those with the worst outcomes such 
as pleural effusion and ascites.
Finally, there is room for improvement in the management and follow-up of 
TB-HIV co-infected patients, even though ART initiation and uptake is in line with what is 
recommended by WHO.79 First, since the start date of ART was not usually documented in 
TB registers, an important recommendation for the NTP would be to introduce systematic 
documentation of the ART initiation date in TB registers in all basic management units of 
the country, in order to be able to monitor and address any delays in starting HIV-treatment. 
Second, there are needs to be improvement in the management other severe opportunistic 
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diseases or complications, through for instance financial support of examinations that are 
required for confirmation of diagnosis and also the costs of treatment; and this would help 
to reduce further morbidity and mortality. These interventions cannot be addressed without 
close collaboration with the national AIDS programme and mobilization of resources. 
In terms of knowledge gaps and future research, the real reasons for losses to 
follow up among patients with SNPTB or EPTB and children diagnosed with TB are unknown 
and these should be investigated through prospective and more qualitative research studies. 
The childhood TB study was only carried out only in Cotonou, the capital city, and this needs 
to be repeated for all regions in the country. 
The two projects on retreatment TB and drug resistance provide reassuring lessons 
that the problem is not huge and that TB patients with a previous history of TB treatment 
are generally well managed, resulting in a high treatment success rate among those with 
fully susceptible bacilli. In contrast to many other countries in Africa, the system for doing 
culture and DST works well leading to sound information that the majority of retreatment 
TB patients, including those who have failed treatment, can still be successfully treated with 
first line anti-TB drugs. The data from the studies do not support the WHO recommendation 
of treating all failure cases in Benin with an empiric MDR-TB treatment regimen.10,108 Our 
studies further suggest that this WHO recommendation, that is meant to be applied in case 
of the unavailability of DST results, must be adjusted to country-specific situations. Giving 
an unnecessary, long and potentially toxic, empirical MDR-TB treatment regimen to patients 
who do not need it will increase the risk of loss-to-follow-up during treatment and the 
development of resistance to second line anti-tuberculosis drugs, which would inevitably 
foster the emergence of extensively drug resistant (XDR) TB in the community.109
There are two other important lessons from these studies. First, if resources 
ever became limited with respect to performing culture and DST, the priorities for these 
investigations would be in the following order: failures or relapses after a retreatment regimen 
patients, followed by failures to first-line treatment, followed by patients lost to follow-up 
and followed by relapses. Second, validated studies have demonstrated that if the rifampicin 
resistance prevalence exceeds 15% in any group, the positive predictive value of a rifampicin-
resistant result with Xpert MTB/RIF is more than 90%, but this declines to 32% whenever the 
prevalence drops to less than 1%.108,110,111 In these situations of low drug-resistance prevalence, 
it is recommended that Xpert MTB/RIF results for rifampicin-resistance be confirmed by 
culture and DST to avoid false positive results. According to our study findings, therefore, in 
patients who have failed or relapsed after retreatment and failed or returned after default 
(lost to follow-up) with first-line treatment, a rifampicin-resistant result with Xpert MTB/RIF 
could be accepted without any need to confirm with culture and DST.
There are two other outstanding issues that merit improvement. They relate to 
the poor outcomes of patients with unknown HIV-status who were retreated for TB and the 
failure to collect or examine the final follow-up sputum smears. Fortunately, the proportion 
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of patients with unknown HIV status is low and HIV testing uptake in Benin is high (96%-
97%).1,58 The NTP has taken note of these results and health care workers are encouraged to 
continue convincing those who have declined HIV-testing to get the test performed at some 
stage during treatment. Failure to obtain the final follow-up sputum smear examination after 
treatment completion has also been discussed with programme staff so that the proportion 
of patients who are declared cured can be increased.
There are some knowledge gaps that can be filled by further operational and mixed-
methods research. There is a need to know why the majority of patients who were retreated 
after having been lost to follow up were from a specific region (the Oueme-Plateau). Among 
those found to be rifampicin resistant, there is a need for a better understanding of their 
treatment history with a view to preventing this event happening to others. The treatment 
success rate of MDR-TB patients was good in Benin at above 85%.112 Implementation 
of a research project with the purpose of studying characteristics of those who had an 
unfavourable outcome would contribute to further improving this success.
The final project on missed scheduled appointments showed the importance of keeping 
health workers motivated and enthusiastic so that they continue to deliver high quality 
education and assistance to their patients. Male patients in particular need more attention 
because of their higher risk of treatment discontinuation compared with females. Likewise, 
more attention must be paid to the 5th month appointment which is the one most likely to 
be missed. In order to address all these issues and for the programme to be more efficient 
and reduce the proportion of patients with missed appointments, a register that provides the 
date of the next scheduled appointment was established and is now regularly completed. 
According to health workers, this register is a great help to alert them to patients who have 
failed to attend their next scheduled appointment so that they can be brought back to 
treatment and care. In addition, to overcome the challenge of not missing the 5th sputum 
smear follow up examination, one possible solution is to collect sputum specimens at home 
for those who are not available to come to the clinic for their appointments – this strategy has 
yet to be tested and is an operational research project in waiting.
Travelling outside the capital city, Cotonou, and feeling better were the principal 
reasons for missing scheduled appointments. The NTP now recommends that health workers 
systematically ask patients whether they are likely to travel before the next appointment. If 
this is so, then sufficient drugs are given to cover this period, and the patient is also given 
directions to the nearest BMU for drug supplies and sputum smear examination if this 
is necessary. The NTP also advises health workers to stress to patients the importance of 
continuing care and follow up until the end of treatment, even if patients are starting to feel 
better.  
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THE ROLE OF OPERATIONAL RESEARCH WITHIN THE BENIN NATIONAL TB 
PROGRAMME
With the new End TB targets and Sustainable Development Goals focused on ending the 
epidemic of TB, through a marked reduction in incidence and mortality and avoidance of 
catastrophic costs for the patient and family, there is a need for the development of new 
tools (diagnostics, drugs and vaccines). However, there is also a pressing need to know 
more about how to deliver these once they are developed and importantly how to deliver 
the existing tools much more efficiently than is currently the case.113 The so-called “Know-
Do” gap is large and researchers need to work much more collaboratively with national and 
non-governmental field-based staff and communities to ensure optimal delivery of health 
services for patients.
In this regard, the placement of an OR fellow in the Benin NTP has led to the 
production of much useful OR, that has provided the programme with valuable information 
that is not easily accessible just from programme reports or reviews. All these OR projects 
in this thesis have been carried out within the routine services of the Benin NTP. There are, 
however, several challenges. First, sustained funding is required to maintain this position. 
Increased levels of funding would be even better as a second OR fellow can help to build 
the critical mass which can result in even more relevant and useful OR, as has been well 
demonstrated in India.114 Second, the Benin NTP needs to undertake more mixed methods 
research, with both quantitative and qualitative research, so that it can better answer some of 
the « why » questions in addition to the « what » questions. Capacity building will be required 
to undertake this more intensive and demanding methodology. Third, it would benefit the 
country if OR was also decentralised so that programme officers at regional and district level 
who handle data on a daily basis learn to formulate questions and develop simple protocols 
that can be implemented at source. Again, this requires internal capacity building and a new 
philosophy that OR is an integral part of the NTP. This has been done elsewhere in Africa with 
success and needs to be repeated.114,115 Finally, findings from OR studies are not sufficiently 
published in peer-reviewed journals and there is a need to educate journal editors about the 
intrinsic value of OR and the importance of providing journal space for sharing knowledge 
about what works about one programme and one country to the next.116-118
IMPACT OF RESEARCH FINDINGS ON POLICY AND PRACTICE
There are some implications from the studies conducted in this thesis for policy and practice 
change and these are shown in the Table. The broad principal recommendations for the 
NTP and health sector include: better sensitization and communication in the community 
about TB and the need for early referral of those with presumptive TB to allopathic medical 
care: moving from a passive case finding strategy to a semi-active case finding strategy so 
that vulnerable groups are identified and screened for TB; expanding the use of molecular 
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technology (especially Xpert MTB/RIF) to improve bacteriological confirmation of difficult 
to diagnose groups such as those with SNPTB, EPTB and children; working closely with the 
paediatricians in the country to improve the case management of childhood TB and with 
general practitioners to improve the diagnosis and treatment of SNPTB and EPTB; working 
with the National AIDS Programme to ensure high rates of HIV testing and timely initiation of 
ART to those with HIV-TB; continuing to ensure good management of retreatment TB so as to 
avoid an epidemic of MDR-TB and XDR-TB. 
Benin has a good performing and well recognised NTP. Further improvement in challenging 
areas is not only good for the country but serves as an example to the international 
community  of what can be done to ensure as good a programme as possible and to end the 
TB epidemic by 2030.
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CONCLUSION
Overall, the OR projects developed in this thesis have helped to better understand how the 
National TB Programme in Benin is performing in the diagnosis and treatment of patients 
with TB. Over a nine year period, notified TB cases have gradually increased with some 
variations noted regarding seasonality, gender and category of TB. A best fit model, however, 
predicts that TB case finding will decrease in the future, raising an important issue for the 
programme about whether to continue with its passive case finding strategy or move to a 
semi-active case finding strategy: in fact this has already been done for vulnerable groups. 
Three OR projects focused on difficult to diagnose types of TB (SNPTB, EPTB and childhood 
TB). While the prevalence of these types was low, nevertheless important issues were 
identified about their characteristics and poor treatment outcomes and recommendations 
were made about how to improve case management. Two projects assessed an important 
category of patient, namely those with previously treated TB at high risk of drug resistance. 
The OR projects provided reassuring information that the national system of culture and DST 
worked well, the prevalence of MDR-TB was generally low and the WHO recommendation to 
give empirical MDR-TB treatment for patients failing treatment did not apply to Benin. The 
final project examined the issue of patients missing scheduled appointments and found that 
this was not common, when it did occur it was the 5th month that was usually missed and 
that active tracing made only a small contribution to improving treatment success. Practical 
measures were introduced to try and further mitigate this problem. 
While the studies were mainly focused on improving case management of TB in 
Benin, they have international importance. First, the study observations and the changes 
made to policy and practice should help the country meet the WHO END TB targets and goals 
and thus contribute to the international community’s pledge to end TB by 2030. Second, 
the study assessing whether or not to follow WHO recommendations about empiric MDR-TB 
treatment is a valuable lesson for other countries about the importance of locally generated 
evidence to answer difficult questions. Finally, the embedding of an OR fellow in the NTP 
and the conduct, completion and publication of relevant country-wide research studies is 
a lesson for the international community and countries about the importance of OR within 
a programmatic setting and to make dedicate resources available. The acceptance of this 
discipline will be essential if the new TB tools (diagnostics, medications and a vaccine) are 
developed and are going to be rapidly integrated into routine programme activities and 
make the require difference to health systems and patients.
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SUMMARY
Background: In Benin, for the past several decades, the diagnosis and treatment of 
tuberculosis have been managed within the National Tuberculosis Programme (NTP). The 
Programme operates well with a high treatment success rate among new bacteriologically 
confirmed tuberculosis cases. To improve tuberculosis case management and learn more 
about the other types of tuberculosis in order to reduce gaps and meet the 2030 SDGs, an 
Operational Research Fellow (SA) was placed within the NTP and this led to the development, 
completion and publication of several Operational Research projects focused on TB.
Aim and objectives of the thesis: To Describe TB case management in Benin, particularly in 
relation to four identified and important challenges for TB Control in the programme.
Thesis Structure: This thesis has nine chapters. Chapter 1 provides a general introduction 
and the rationale for carrying out the body of work contained in the thesis. Chapters 2 – 8 
constitute the main body of work consisting of seven inter-related but distinct operational 
research projects developed within the NTP and focused on secondary routinely collected 
data. Each project has a specific aim and objectives and each is structured into Introduction, 
Methods, Results and Discussion sections within their respective chapters. Tables and 
Figures related to each project are inserted within each chapter with references listed at the 
end. There is a list of acronyms and these are also spelt out in each chapter followed by the 
abbreviation in brackets. Chapter 9 summarises the main findings of the presented studies, 
the strengths and limitations of the work, how the study findings relate to previous literature, 
the lessons learned and the knowledge gaps and further research priorities and finally how 
the research has impacted on policy and practice with a view to improving programme 
performance.   
The presented studies: All seven studies are operational research studies in Benin using 
data generated from within the NTP. All seven studies have been published in peer-reviewed 
journals. Within the articles, the editorial conventions of the publishing journals have been 
respected. There have been minor changes to the formatting and typesetting so that they 
can fit within this thesis.
In order to set the scene and identify the current challenges for the Programme, an overall 
analysis of the trends and characteristics of patients treated for TB during these last years 
in Benin was conducted. An Operational Research project was implemented and covered a 
period of fifteen years of activities from 2000 to 2014. The findings of this study are described 
in Chapter 2. This study showed an increase in presumptive TB and case notifications, 
with the majority of cases having new pulmonary bacteriologically confirmed TB. However, 
certain categories of TB decreased – there was a decrease in retreatment TB, a decrease 
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in case notification rates in males and in young people aged 15-34 years-old. A modelling 
study forecasted a decrease in the estimated number of all notified TB cases in the next 
five years. While this may have been a true reflection of the future TB burden in Benin, the 
NTP was concerned that this forecasted decline could be due to missing cases and strongly 
advocated for additional active TB case finding strategies. With support from the Global 
Fund Against AIDS, TB and Malaria, active screening strategies have since been implemented 
amongst certain vulnerable groups such as those with diabetes mellitus, pregnant women 
and prisoners.
There is dearth of information on the management of smear-negative pulmonary 
TB (SNPTB), extra pulmonary TB (EPTB) and childhood TB. To fill the knowledge gaps, the OR 
projects successively developed in Chapters 3, 4 and 5 were carried out. The objectives of 
these studies were to determine the characteristics and treatment outcomes of patients with 
the types of TB listed above. The main findings were the low proportion of these types of TB, 
the low rate of bacteriological confirmation among those with EPTB and the large variation in 
case notification between regions. Particularly in the specific group of children, in Cotonou, 
the capital city, findings suggested there were misdiagnosis (especially in under-fives) and 
under-reporting. This last issue was supported by the report that 16% of children with TB 
managed in the general hospital were not notified to the programme. In terms of treatment, 
patients with these types of TB had higher rates of unfavourable outcomes compared with 
new smear-positive pulmonary TB, due to losses to follow up and deaths. In SNPTB, those 
who were HIV-negative or HIV-positive but not on ART had a high risk of loss-to-follow up or 
death. Likewise, a high risk of death was reported among those who were diagnosed with 
EPTB and were co-infected with HIV, even when they were treated with ART. Amongst those 
with EPTB, patients with pleural effusion or ascites had the worst outcomes. All the patients 
who were lost-to-followed up among EPTB cases were from a specific region. 
These study findings have led to recommendations for better monitoring of 
patients diagnosed with these types of TB. Following the childhood TB study, the Benin 
NTP has put in place several activities to improve the management of childhood TB in the 
country, including national meetings, the writing and dissemination of directives, training 
and the establishment of a six-monthly supervisory visits to paediatric services
The WHO has also raised awareness about the importance of better management 
of retreatment TB because of the high risk that these patients pose for the rising trend of 
drug resistance. Two Operational Research projects were implemented around retreatment 
TB and these are described in Chapters 6 and 7. The objectives were to determine the 
characteristics and treatment outcomes of retreatment TB patients; the proportion who 
underwent Culture and DST and of these the proportion who needed a MDR-TB treatment 
regimen; and to ascertain whether it was correct to treat all TB treatment failure patients with 
an empirical MDR-TB treatment regimen in line with WHO recommendations. These studies 
demonstrated that the proportion of retreatment patients was low; the proportion that 
underwent Culture and DST was high; and less than two in ten retreatment patients needed 
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a MDR-TB treatment regimen. In addition, the treatment success rate of retreatment patients 
with fully drug-susceptible bacilli was high. In the Benin setting, it was not appropriate to 
treat all treatment failure cases with an empirical MDR-TB treatment regimen and the NTP 
did not accept the WHO guidance in this regard following these findings.
In TB case management, a favourable outcome is strongly linked to good patient 
follow-up and 100% attendance at scheduled appointments. A unit was created in Cotonou 
to trace those who missed their scheduled follow-up appointments and an Operational 
Research project was implemented to assess the contribution of patient tracing activities 
towards a successful treatment outcome. This study and its findings are presented in 
Chapter 8. The main findings were that less than one in ten patients missed one of their 
scheduled appointments and the overall contribution of tracing activities towards treatment 
success was low, probably as a result of good quality education delivered by health workers 
to patients prior to and during the course of treatment. However, the study also highlighted 
some weaknesses in these TB control efforts and recommendations have been made. These 
include the need to systemically ask patients at the start and during the course of treatment 
whether they are likely to travel and to assure there is sufficient medication available during 
this period. Moreover, in order to reduce any delay in tracing initiation, which had been 
noticed in some patients, a register listing the next scheduled appointment for each patient 
was introduced. Since this register has been established, the time for initiating tracing of 
poorly adherent patients has significantly reduced.
The final Chapter 9 discusses these projects together, summarises their principal 
findings, links the findings to the previous published literature, outlines the lessons learned 
and offers recommendations for policy and practice change. 
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In conclusion, all these Operational Research Projects strongly contributed to either changes 
in policy or practice or improving knowledge in different aspects of TB in the National 
Programme. 
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SAMENVATTING
Achtergrond: In de afgelopen decennia vond de diagnose en behandeling van 
tuberculose in Benin plaats binnen het kader van het nationaal tbc-programma (NTP). Het 
programma werkt goed met een hoge succesgraad bij nieuwe bacteriologisch bevestigde 
tuberculosegevallen. Om het casemanagement te verbeteren en meer te weten te komen 
over de andere soorten tuberculose en zo de hiaten op te vullen en tegemoet te komen aan 
de Duurzame Ontwikkelingsdoelen voor 2030, kreeg een onderzoeker opdracht operationeel 
onderzoek te doen binnen het kader van het NTP. Dit leidde tot de ontwikkeling, de voltooiing 
en de publicatie van verscheidene projecten op het gebied van operationeel onderzoek 
geconcentreerd op tbc.
Doel en doelstellingen van het proefschrift: Het beschrijven van het tbc-casemanagement 
in Benin, in het bijzonder met betrekking tot vier geïdentificeerde en belangrijke uitdagingen 
voor tbc-bestrijding in het programma.
Structuur: Dit proefschrift bestaat uit negen hoofdstukken. Hoofdstuk 1 geeft een algemene 
inleiding en de beweegredenen voor het uitvoeren van het werk dat in het proefschrift is 
opgenomen. De hoofdstukken 2 - 8 vormen het belangrijkste deel van het werk dat bestaat 
uit zeven onderling samenhangende, maar afzonderlijke projecten op het gebied van 
operationeel onderzoek die binnen het NTP zijn ontwikkeld en gericht zijn op secundaire, 
routinematig verzamelde gegevens. Elk project heeft een specifiek doel en doelstellingen 
en elke projectbeschrijving omvat de hoofdstukken Inleiding, Methoden, Resultaten en 
Discussie. Tabellen en cijfers met betrekking tot elk project zijn opgenomen in elk hoofdstuk 
met verwijzingen aan het einde. Er is een lijst van acroniemen die tevens in elk hoofdstuk 
worden beschreven, gevolgd door de afkorting tussen haakjes. Hoofdstuk 9 geeft een 
samenvatting van de belangrijkste bevindingen van de gepresenteerde studies, de sterktes 
en beperkingen van het werk, hoe de onderzoeksresultaten zich verhouden tot eerdere 
literatuur, de geleerde lessen en de kennislacunes en verdere onderzoeksprioriteiten en 
ten slotte hoe het onderzoek het beleid en de praktijk heeft beïnvloed met het oog op het 
verbeteren van de prestaties van het programma.   
De gepresenteerde studies: Alle zeven studies omvatten operationeel onderzoek in Benin, 
waarbij gebruik werd gemaakt van gegevens uit het NTP. Alle zeven studies zijn gepubliceerd 
in peer-reviewed tijdschriften. Binnen de artikelen zijn de redactionele conventies van de 
uitgeversbladen gerespecteerd. Er zijn kleine wijzigingen aangebracht in de opmaak en 
typografie om ze in te kunnen passen in dit proefschrift.
Om een beeld te schetsen en de huidige uitdagingen voor het programma in kaart te brengen, 
werd een algemene analyse uitgevoerd van de trends en kenmerken van de patiënten die de 
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laatste jaren in Benin behandeld werden voor tuberculose. Er werd operationeel onderzoek 
uitgevoerd dat een periode van vijftien jaar – van 2000 tot 2014 – bestreek. De bevindingen van 
dit onderzoek worden beschreven in hoofdstuk 2. Dit onderzoek toonde een toename van het 
aantal vermoedelijke tbc- en casusmeldingen aan, waarbij het in het merendeel van de gevallen 
ging om nieuwe gevallen van biologisch bevestigde pulmonale tbc. Bepaalde categorieën tbc 
namen echter af: er was een daling van het aantal herbehandelde tbc-gevallen en een daling 
van het aantal meldingen bij mannen en jongeren in de leeftijd van 15-34 jaar. Een modelstudie 
voorspelde een daling van het geschatte aantal gemeldde gevallen van tuberculose in de 
komende vijf jaar. Hoewel dit een getrouwe afspiegeling kan zijn van de toekomstige tbc-last in 
Benin, vreesde het NTP dat deze voorspelde daling te wijten zou kunnen zijn aan ontbrekende 
gevallen en was het een sterk voorstander van aanvullende strategieën voor het vinden van 
actieve tbc-gevallen. Met steun van het Wereldfonds tegen aids, tuberculose en malaria zijn 
sindsdien actieve screeningsstrategieën uitgevoerd bij bepaalde kwetsbare groepen zoals die 
met diabetes mellitus, zwangere vrouwen en gevangenen.
Er is gebrek aan informatie over het management van sputum-uitstrijknegatieve 
pulmonale tuberculose, extrapulmonale tuberculose en tbc bij kinderen. Om de kennislacunes 
op te vullen zijn de operational research-projecten die achtereenvolgens in de hoofdstukken 
3, 4 en 5 zijn ontwikkeld, uitgevoerd. De doelstelling van deze studies was het bepalen van de 
kenmerken en behandelingsresultaten van patiënten met de hierboven genoemde typen tbc. 
De belangrijkste bevindingen waren het lage aandeel van deze soorten tbc, de lage graad van 
bacteriologische bevestiging bij patiënten met extrapulmonale tuberculose en de grote variatie 
in de meldingen van geval tot geval tussen de regio's. Met name in de specifieke groep kinderen, 
in Cotonou, de hoofdstad, suggereerden de bevindingen dat er sprake was van verkeerde 
diagnoses (vooral bij kinderen onder de vijf jaar) en onderrapportage. Deze laatste kwestie werd 
ondersteund door het rapport dat 16% van de kinderen met tbc die in het algemene ziekenhuis 
werden verzorgd, niet aan het programma waren gemeld. Wat de behandeling betreft, hadden 
patiënten met dit soort tbc een hoger percentage ongunstige resultaten in vergelijking met nieuwe 
uitstrijkpositieve pulmonale tuberculose, als gevolg van uitval en sterfgevallen. Bij sputum-
uitstrijknegatieve pulmonale tuberculose hadden degenen die hiv-negatief of hiv-positief waren, 
maar geen ART kregen, een hoog risico op uitval of overlijden. Eveneens, werd een hoog risico op 
overlijden gemeld voor patiënten die met extrapulmonale tuberculose waren gediagnosticeerd 
en gecoïnfecteerd waren met hiv, zelfs toen zij met ART werden behandeld. Onder hen hadden 
patiënten met pleura-effusie of ascites de slechtste uitkomsten. Alle patiënten die uitvielen in de 
groep met extrapulmonale tuberculose kwamen uit een specifiek gebied. 
Deze onderzoeksbevindingen hebben geleid tot aanbevelingen voor een betere 
controle op patiënten die met deze soorten tbc worden gediagnosticeerd. Na de studie 
over jeugd-tuberculose heeft het NTP in Benin verscheidene activiteiten op touw gezet om 
het management van jeugdtuberculose in het land te verbeteren, waaronder nationale 
vergaderingen, de verspreiding van richtlijnen, opleiding en de totstandbrenging van halfjaarlijkse 
controlebezoeken aan pediatrische diensten.
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De WGO heeft ook de bewustwording van het belang van een beter management van 
herbehandelde tbc vanwege het hoge risico dat deze patiënten vormen voor de stijgende trend 
van resistentie tegen geneesmiddelen. Er werden twee onderzoeksprojecten uitgevoerd rond 
herbehandelde tbc. Deze worden beschreven in hoofdstuk 6 en 7. De doelstellingen waren het 
bepalen van de kenmerken en behandelingsresultaten van patiënten herbehandeld voor tbc; 
het bepalen van het aandeel van de patiënten bij wie een kweek werd afgenomen en die getest 
werden op geneesmiddelengevoeligheid en het aandeel daarvan dat een behandelingsregime 
voor multiresistente tbc nodig hadden; en om na te gaan of het correct was om al diegenen 
waarbij de tbc-behandeling niet aansloeg te behandelen met een empirisch behandelingsregime 
voor multiresistente tbc overeenkomstig de aanbevelingen van de WGO. Deze studies toonden 
aan dat het aandeel van herbehandelde patiënten laag was; het aandeel van hen waarbij een 
kweek werd afgenomen en die werden getest op hun geneesmiddelengevoeligheid was hoog; 
en minder dan twee op de tien herbehandelde patiënten behoefden een behandelingsregime 
voor multiresistente tbc. Bovendien was het succespercentage bij herbehandelde patiënten 
met volledig geneesmiddelgevoelige bacillen hoog. In Benin konden niet al diegenen waarbij de 
tbc-behandeling niet aansloeg worden behandeld met een empirisch behandelingsregime voor 
multiresistente tbc en naar aanleiding van deze bevindingen accepteerde het NTP de richtlijnen 
van de WGO in dit opzicht niet.
Bij casemanagement in de tbc-zorg is een gunstige uitkomst sterk gekoppeld aan een 
goede monitoring van de patiënten en strikte naleving van de gemaakte afspraken. In Cotonou 
werd een eenheid opgericht om de personen op te sporen die zich niet aan de vervolgafspraken 
hielden en er is operationeel onderzoek uitgevoerd om de bijdrage van deze patiëntenopsporing 
aan een succesvol behandelingsresultaat te beoordelen. Dit onderzoek en de bevindingen 
daarvan worden gepresenteerd in hoofdstuk 8. De belangrijkste bevindingen zijn dat minder dan 
één op de tien patiënten één van hun geplande afspraken heeft gemist en dat de totale bijdrage 
van de opsporingsactiviteiten aan het succes van de behandeling gering was, waarschijnlijk als 
gevolg van de goede voorlichting die de patiënten voorafgaand aan en tijdens de behandeling 
van de gezondheidswerkers kregen. De studie heeft echter ook enkele zwakke punten in deze 
inspanningen op het gebied van tbc-bestrijding aan het licht gebracht, en er zijn aanbevelingen 
gedaan. Deze omvatten de noodzaak om patiënten aan het begin en tijdens de behandeling 
systematisch te vragen of zij op reis gaan en om ervoor te zorgen dat er tijdens deze periode 
voldoende medicatie beschikbaar is. Om de bij sommige patiënten geconstateerde vertraging bij 
het opsporen te beperken, werd bovendien een register met de volgende geplande afspraak per 
patiënt ingevoerd. Sinds de invoering van dit register is de tijd die nodig is voor het starten van de 
opsporing van patiënten die zich slecht aan de afspraken houden aanzienlijk korter geworden.
Het laatste hoofdstuk, hoofdstuk 9, bespreekt al deze projecten samen, vat hun 
belangrijkste bevindingen samen, koppelt de bevindingen aan eerder gepubliceerde literatuur, 
schetst de geleerde lessen en geeft aanbevelingen voor beleids- en praktijkveranderingen. 
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De volledige citaten van de gepubliceerde studies die deel uitmaken van dit proefschrift zijn 
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Concluderend kan worden gesteld dat al deze projecten sterk hebben bijgedragen aan 
de veranderingen in het beleid of de praktijk of aan de verbetering van de kennis over de 
verschillende aspecten van tbc in het nationale programma. 
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